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ABSTRACT
Induction therapy with Campath-IH, a humanized anti-CD52 monoclonal antibody 
depleting T and B lymphocytes, has been used in organ transplantation with the final 
goal of resetting the immune system in order to promote a tolerance-permissive 
environment and, at the same time, to reduce the need for chronic maintenance 
immunosuppression. To explore whether thisO may result from the capability of 
Campath-IH, in association with different maintenance regimens, to promote regulatory 
T cells (Treg) expansion and to assess whether this may translate into better graft 
outcomes in the long-term, 21 renal transplant patients receiving Campath-IH induction 
were randomized to low-dose SRL (n= ll) or low-dose CsA (n=10), both in addition to 
low-dose mycophenolate mofetil (MMF) as maintenance immunosuppressive therapy 
and monitored for over 30 month follow-up.
SRL-treated patients showed an important expansion of circulating 
CD4+CD25hishFOXP3+ Treg that, at one and two years after transplant, were 
significantly more abundant than in the CsA group. T cells isolated from peripheral 
blood long-term post-transplant were hyporesponsive to donor alloantigens in both 
treatment arms. In SRL-, but not CsA-treated patients, hyporesponsiveness was reversed 
by Treg depletion. T cells from CsA-treated patients were anergic to donor antigens. 
Despite higher Treg counts, SRL-treated patients had a faster GFR and RPF decline, 
more clinical proteinuria, significantly higher tubular C4d staining score and a trend to 
higher chronic allograft damage index score, compared to CsA-treated patients. There 
was no significant correlation between Treg counts and any considered outcome 
variable in the study group as a whole and within each treatment group.
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These data suggest that, after Campath-IH induction, maintenance therapy with low- 
dose SRL and MMF promotes Treg expansion, but this is not paralleled by long-term 
improved graft outcomes. Conversely, maintenance immunosuppression with low-dose 
CsA and MMF is associated with better graft function and structure than low-dose SRL 
plus MMF, possibly through the induction of T cell anergy toward donor antigens.
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AIMS
Primary
1. To compare the effect of Campath-IH, low-dose sirolimus versus Campath-IH, low- 
dose CsA, both in addition to low-dose MMF on phenotypic and functional profiles of 
peripheral blood mononuclear cells (PBMCs) in kidney transplant recipients.
2. To assess whether the increased counts of circulating CD4+CD25hlgh Treg may 
translate into better graft outcomes in the long-term.
Secondary
To compare in the two groups of kidney transplant recipients:
- Incidence of acute allograft rejection
- Time course of graft function (as serum creatinine concentration)
Time course of glomerular filtration rate and renal plasma flow (measured by 
iohexol clearance and p-amminohippurate, respectively)
Systolic and diastolic blood pressure 
Lipid profile (cholesterol, triglycerides, HDL)
24 h urinary protein excretion rate 
Patient and graft survival
- Incidence of major adverse events.
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INTRODUCTION
1. Kidney transplantation: past, present, and a possible future
An historical perspective
December 23, 1954, represents a milestone date for organ transplantation. That day, a 
surgical team under the direction of Joseph Murray, removed a kidney from a healthy 
donor and transplanted it into his identical twin, who had chronic renal failure secondary 
to glomerulonephritis [1, 2]. The organ functioned immediately, and the recipient 
survived for nine years, when his allograft failed from recurrent glomerulonephritis. The 
donor has survived for 50 years [1,2].
As more transplantations were performed between identical twins [3], approaches to 
suppressing the recipient's immune system were pursued so that transplantation might 
be extended beyond procedures involving identical twins. The knowledge in 
immunology however was still rudimentary. The first attempt to suppressing the 
rejection process, taken in the early 1950s, involved the use of sublethal total-body 
irradiation combined with cortisone. These attempts failed in most of the cases, with the 
exception of some transplantations between nonidentical twins - first at Peter Bent 
Brigham and a few weeks later in Paris [1,4]-  which provided the impetus to search for 
more effective ways to prevent rejection.
A major contribution in the control of acute rejection was provided by Robert Schwartz 
and William Dameshek, hematologists at Tufts University School of Medicine, who 
reported that 6-mercaptopurine (6-MP), which was already in clinical use for the 
treatment of acute lymphocytic leukemia, suppressed the immune response in rabbits [5, 
6]. The Wellcome Research Laboratory then synthesized several variants of 6-MP for 
screening by Joseph Murray and Roy Caine in dog kidney transplantations. Only one
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candidate drug, azathioprine, resulted in long-term survival and in only a small number 
of animals. These observations prompted a rather anxious start to the first clinical trial, 
in 1962, of chemical immunosuppression involving azathioprine [7]. In patients in 
whom azathioprine was combined with a corticosteroid, one-year rates of allograft 
survival were in the range of 40 to 50 percent, an enormous improvement over previous 
results. These clinical breakthroughs were ultimately recognized by awarding of Nobel 
Prizes to Joseph Murray (and others), for the first clinical transplantation and the first 
use of immunosuppression, and to George Hitchings and Gertrude Elion of the 
Wellcome Laboratory, for the development of drugs, including azathioprine, that affect 
nucleotide pathways [1].
The rate of successful transplantation of kidneys from cadaveric donors and familial 
HLA-matched living donors slowly increased during the 1960s and early 1970s, 
following the introduction of azathioprine with corticosteroids. Although the initial 
effect was beneficial, prolonged use of corticosteroids resulted in a high mortality rate 
due to excessive immunosuppression. Overall mortality rates also fell as programs for 
long-term dialysis improved, which made it possible to discontinue immunosuppression 
and sustain life when grafts failed [1]. In the late 1970s, cyclosporine was introduced, 
which increased the rate of one-year graft survival from 70 percent to more than 80 
percent [8]. During last decades, results of kidney transplantation have been improved 
to the point that this procedure is now considered the ideal treatment for patients with 
end stage renal disease.
Three-Signal Model o f Alloimmune Responses
10
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In 1925, Emile Holman, a surgeon at Peter Bent Brigham Hospital who performed skin 
grafts in children with extensive bums, reported that repeated grafts from maternal 
donors were rejected more rapidly than the initial grafts, which indicated donor-specific 
sensitization to the "proteins" of the donors [1]. These proteins were in the following 
decades identified as HLA antigens and the immune reaction against these alloantigens 
was thereafter named as rejection.
Alloimmune responses involve both naive and memory lymphocytes [9], including 
lymphocytes previously stimulated by viral antigens cross-reacting with HLA 
antigens[10]. In the graft and the surrounding tissues, dendritic cells of donor and host 
origin become activated and move to T-cell areas of secondary lymphoid organs. There, 
antigen-bearing dendritic cells engage alloantigen-reactive naive T cells and central 
memory T cells that recirculate between lymphoid compartments but cannot enter 
peripheral tissues [11]. Naive T cells are optimally triggered by dendritic cells in 
secondary lymphoid organs [12, 13], but antigen-experienced cells may be also 
activated by other cell types, such as graft endothelium [14].
An antigen on the surface of dendritic cells that triggers T cells with cognate T cell 
receptors constitutes "signal 1," transduced through the CD3 complex. Dendritic cells 
provide costimulation, or "signal 2," delivered when CD80 and CD86 on the surface of 
dendritic cells engage CD28 on T cells. Signals 1 and 2 activate three signal 
transduction pathways: the calcium-calcineurin pathway, the RAS-mitogen-activated 
protein (MAP) kinase pathway, and the nuclear factor- «B pathway [15]. These pathways 
activate transcription factors that trigger the expression of many new molecules, 
including interleukin-2, CD 154, and CD25. Interleukin-2 and other cytokines (e.g., 
interleukin-15) activate the mammalian target of rapamycin (mTOR) pathway to
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provide "signal 3," the trigger for cell proliferation. Lymphocyte proliferation also 
requires nucleotide synthesis. Proliferation and differentiation lead to a large number of 
effector T cells [16]. B cells are activated when antigens engage their antigen receptors, 
usually in lymphoid follicles or in extrafollicular sites, such as red pulp of spleen[17], or 
possibly in the transplant [18], producing alloantibody against donor HLA antigens. 
Thus, within days the immune response generates the agents of allograft rejection, 
effector T cells and alloantibodies.
HLA antigen presentation: direct and indirect pathways
Alloreactive T cells recognise alloantigens via two distinct pathways: direct and 
indirect. Direct recognition occurs when recipient T cells recognise intact donor MHC 
molecules complexed with peptide on donor stimulator cells. In contrast, indirect 
recognition occurs when the recipient APC process the donor-MHC molecules prior to 
presentation to recipient T cells in a self-restricted manner [19].
The first clear evidence that T cells with exclusively direct allospecificity can effect 
transplant rejection was provided by a relatively recent study. Reconstitution of SCID or 
Ragl_/_ mice with syngeneic CD4+ T cells led to rejection of MHC class II-expressing 
cardiac allografts but not MHC class Il-deficient grafts [20]. Furthermore, Ragl_/_ mice 
that were also MHC class Il-deficient rejected allogeneic cardiac transplants when 
reconstituted with CD4+ T cells. Since these mice have no CD8+ cells and lack the 
capacity for MHC class Il-restricted indirect allorecognition, these results indicate that 
direct pathway CD4+ T cells were both necessary and sufficient to mediate allograft 
rejection [20].
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Anti-donor alloreactive T cells derived from the naive fraction of the recipients’ T cell 
repertoire must be primed in lymphoid tissue. Therefore, the priming of naive direct 
pathway alloreactive T cells is likely to only occur predominantly during the first few 
weeks after transplantation, while donor-derived dendritic cells are available. Once 
those dendritic cells have died, the naive T cell repertoire of the recipient is likely to be 
less important as far as direct anti-donor responses are concerned [19]. Intriguingly, 
Lechler and Batchelor showed that injection of donor-derived dendritic cells is able to 
restore immunogenicity of rat renal grafts depleted of incompatible passenger cells [21, 
22].
The hypothesis that also indirect pathway may play a role in transplant rejection was 
first proposed by De la Rosa and Talmage in early 1980s [23]. Ten years later, 
Auchincloss et al. clearly confirmed the importance of this pathway in allogeneic 
response by using MHC deficient mice [24]. Their most compelling evidence that the 
indirect pathway is sufficient to mediate transplant rejection was the observation that 
MHC class I knock out recipient mice could reject skin grafts from MHC class II knock 
out donor mice [24]. The recipient mice lacked CD8+ cytotoxic T cells capable of 
recognising donor MHC class I molecules directly, and the CD4+ T cells in the recipient 
animals could only be stimulated by recognising donor MHC class I molecules 
indirectly, presented in the context of recipient MHC class II molecules. These findings 
were supported using a murine skin allograft model, which demonstrated that the 
indirect pathway alone was sufficient to elicit allograft destruction in the absence of 
direct allorecognition [25]. Primed cells from mice previously immunised with 
allogeneic spleen cells or skin cells were shown to proliferate in response to peptides 
derived from donor-MHC in the context of self-MHC.
13
Notably, many studies have suggested that the direct and indirect pathways of 
allorecognition engage in cross-talk, for example CD4+ T cells with indirect antidonor 
specificity can amplify direct pathway CD8+ T cell responses and direct pathway CD8+ 
T cells can also be regulated by tolerant indirect pathway CD4+ T cells [26]. Moreover, 
Lechler et al. recently described another mechanism by which alloreactive T cells are 
activated. Recipient DCs can acquire donor MHC through cell-to-cell contact and this 
acquired MHC can stimulate a T cell response, which has been called the semidirect 
pathway [27].
Effectors and Lesions o f Rejection
Effector T cells that emerge from lymphoid organs infiltrate the graft and orchestrate an 
inflammatory response, which recruit activated macrophages, B cells, and plasma cells 
that eventually induce parenchymal injury and deterioration of graft function [16]. The 
diagnostic lesions of T cell-mediated rejection reflect mononuclear cells invading the 
kidney tubules (tubulitis) and the intima of small arteries (arteritis). [28]. Injury is not 
simply lysis of target cells, since typical lesions develop in mice lacking cytotoxic T-cell 
lytic molecules, but may involve transdifferentiation of epithelial cells into 
mesenchymal cells— and cell senescence [28].
A humoral reactivity against donor antigens may also occur, eventually resulting in 
antibody-mediated acute rejection. This is diagnosed by clinical, immunologic, and 
histologic criteria, including a demonstration of complement factor C4d in peritubular 
capillaries. C4d is a fragment of the classical complement pathway component C4, 
which is activated by antigen-antibody complexes [29]. C4 is activated and 
proteolytically cleaved into C4a and C4b, exposing a reactive and short-lived thiolester
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group in C4b that binds to nearby molecules covalently. C4b is subsequently inactivated 
by cleavage into C4c and C4d, the latter fragment containing the covalent bond to the 
tissue that thereby can remain at the site of complement activation [29].
Humoral response may also be mild and not induce an acute injury. The presence of 
anti-HLA antibodies, however, has been associated with the development of chronic 
rejection [30]. Chronic rejection, clinically defined as progressive loss of renal function 
with hypertension and low-grade proteinuria, is the leading cause of late allograft 
dysfunction and accounts for renal failure in 50 to 80% of recipients who return to 
dialysis after transplantation [31]. The morphologic diagnosis can be difficult. The two 
most definitive features of chronic renal allograft rejection are the arterial intimal 
thickening with mononuclear cell infiltration and the duplication of the glomerular 
basement membrane (GBM). However, the arterial lesion preferentially affects the 
larger vessels, which are not always sampled in needle biopsies. The glomerulopathy 
can be mild or focal and by itself is not pathognomic of chronic rejection because it is 
also seen in thrombotic microangiopathy and certain chronic immune complex diseases. 
Interstitial fibrosis and tubular atrophy are similarly nonspecific findings that are 
compatible with a variety of causes, including post ischemic injury, hypertension, and 
chronic cyclosporine toxicity [31]. The inability to distinguish these conditions by 
histologic characteristics is reflected in the literature by the nonspecific term chronic 
allograft nephropathy, which has been used to encompass the end result of chronic 
injury resulting from immunologic reaction to donor alloantigens as well as from 
nonimmunologic mechanisms [32, 33]. More recently, an even more generic definition 
has been chosen for this condition by the Banff ’05 Meeting: Interstitial fibrosis and 
tubular atrophy, no evidence of any specific etiology [34].
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2. The hurdle of long-term immunosuppression and the importance of tolerance 
induction in organ transplantation
Newly developed immunosuppressive drugs have led to combination therapies that have 
significantly lowered the rates of acute rejection [16]. Moreover, induction protocols 
with various antilymphocyte antibodies also reduced the rate and intensity of acute 
rejection [35]. All immunosuppressive drugs have specific side effects and additively 
contribute to an overall state of immunosuppression, which leads to an increased risk of 
opportunistic infections and malignancies [16]. Calcineurin and mTOR inhibitors are 
also frequently associated with hypertension and impaired glucose and lipid 
metabolism, which eventually may contribute to increase the cardiovascular disease, 
which is the most common cause of premature death in transplant recipients [36]. In 
addition, the intrinsic nephrotoxic effect of immunosuppressive drugs such as 
calcineurin inhibitors promotes a progressive renal function deterioration [37]. Of note, 
also drugs previously considered devoid of any nephrotoxicity such as mammalian 
target of rapamycin (mTOR) inhibitors have been more recently demonstrated to 
negatively affect both glomerular and tubular cells [38].
This, together with the extension of donor and recipient criteria for transplantation [39, 
40], might explain why long-term graft outcomes did not change appreciably during last 
decade, in spite of a remarkable reduction of acute rejection rates in the short period. 
Indeed, results from the United Network for Organ Sharing (UNOS) database analyses 
showed that, at 1 year after transplantation, graft survival has reached levels higher than 
90% [41]. However, despite the significant decrease in overall acute rejection rates, the 
improvements in long-term graft survival in the last decade have been still limited [42].
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All these issues provide a strong rationale for developing strategies that promote 
transplantation tolerance.
Defining tolerance
There are many definitions of transplantation tolerance but, in general, it is thought as a 
condition of stable allograft function without immunosuppression. ‘True tolerance’ is 
defined as the absence of any detectable detrimental immune response in an 
immunocompetent host [43, 44]. The lack of an injurious pathogenic response to the 
alloantigen is specific, and the recipient is capable of responding to potentially 
pathogenic microorganisms and malignancies. Importantly, tolerance induction should 
not only protect the graft from acute rejection, but also from chronic low-grade immune 
response [44]. Nevertheless, the literature is revealing more and more cases of 
‘tolerated’ grafts actually displaying a histology of chronic rejection. Thus, the term 
‘operational tolerance’, based more on long term stable graft function and absence of 
exogenous immunosuppression, has been adopted: this less stringent term is often more 
applicable, particularly to the clinical setting [44].
Spontaneous tolerance in humans
Clinical cases have been reported of kidney transplant recipients whose graft function 
has been maintained indefinitely after the cessation of immunosuppression, 
demonstrating that operational tolerance can be achieved [43]. However, these 
spontaneous phenomena have typically occurred by way of drug nonadherence or 
withdrawal mandated by complications, and these conditions more commonly lead to
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rejection. Thus, transplantation tolerance in humans is a stochastic event under current 
treatment regimens, but is, in general, possible [43].
Acquired immune tolerance
Seminal studies by Billingham, Brent and Medawar, more than 50 years ago 
demonstrated that skin grafts from major histocompatibility complex disparate donor 
mice would be accepted indefinitely when recipient mice had been exposed to donor 
alloantigen in the neonatal period [45]. These findings provided the proof of the concept 
that induction of tolerance toward alloantigens is feasible and prompted research of 
tolerogenic strategies also in the adult animals and in the clinical setting.
Different strategies have been demonstrated effective for tolerance induction in rodent 
models of transplantation, as well as in pigs and in non-human primates [46-48]. 
However, tolerance can be more readily achieved in small, inbred animals compared 
with large, outbred animals, and even robust animal models seem less rigorous than 
adult humans.
The following paragraphs discuss those mechanisms which, on the basis of 
experimental studies and some preliminary clinical evidence, may contribute to the 
induction of transplant tolerance. Importantly, these mechanisms are not mutually 
exclusive and tolerance may be the result of several of these mechanisms operating 
simultaneously or sequentially.
Central tolerance
An important characteristic of alloimmune responses is the high frequency of T cells 
able to recognize and respond to alloantigens. This is at the basis of the common belief
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that it is necessary to achieve large-scale deletion of alloreactive T cells in order to 
create transplantation tolerance [47].
Central tolerance refers to the use of strategies that promote deletion of newly 
developing T cell with potential anti-donor reactivity within the thymus following 
encounter with donor derived cells [47].
- Thymic manipulation
The thymus plays an essential role in the maintenance of self-tolerance. Indeed, in spite 
of its size reduction with age, evidence exists that it remains functional throughout the 
whole adult life [49]. Intrathymic deletion of self-reactive lymphocytes from the 
immune repertoire (clonal selection) represents the central mechanism for self-tolerance 
achievement. This mechanism can be exploited in transplantation by the delivery of 
donor antigens to the thymus of adult recipients. This may lead to the central 
elimination of detrimental alloreactive T cell clones, resulting in specific tolerance to 
donor tissues. Because deletion physically eliminates cells with a certain antigen, 
specificity, it should lead to a robust form of tolerance which, once established, would 
not be easily perturbed [47]. Hence, deletion would be a desirable tolerance mechanism 
in the clinical setting. This could either be performed by direct intrathymic injection of 
donor-derived allopeptides or by peripheral infusion of donor haematopoietic cells that 
may migrate into the thymus [50].
Many studies have confirmed that intrathymic injection of donor antigen or allopeptides 
along with peripheral leukocyte depletion may promote operational donor-specific 
tolerance in rodent models [51, 52]; however, the feasibility of this approach in larger 
species is still questionable. Furthermore, after the intrathymic delivery of allopeptides,
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donor antigen persists in the thymus for only a defined period. Therefore, intrathymic 
delivery of donor antigen, in contrast to establishment of a stable mixed chimera, 
provides a transient presence of donor derived antigen and stimulation of tolerant 
mechanisms, rather than generating persistent deletion of thymocytes. Therefore, 
additional strategies are needed to control alloreactive T cells, after the intrathymic 
delivery of alloantigen, to transplant a solid organ graft in the long-term. In animals, the 
thymus itself has been transplanted in different ways to induce tolerance: as 
nonvascularized allogeneic thymic tissue, in composite organs (“thymokidney”), and as 
vascularized thymic lobe transplants [53]. These thymus-dependent strategies might 
overcome the problem of limited survival of donor cells inside the recipient thymus.
- Chimerism
Peripheral infusion of bone marrow (BM) and adult lymphocytes after a conditioning 
regimen has been attempted to induce a more stable and clinically feasible state of 
immune tolerance in organ transplantation [54]. Indeed, once infused, donor cells were 
expected to migrate into the host thymus and mediate selection of alloreactive T cell 
clones. The conditioning regimen aimed at deleting pre-existing cross-reactive T cells 
that would reject the donor BM and grafted organ, thus creating ‘space’ for the 
engraftment of infused BM cells. However, the potential toxicities for the recipient of 
initially proposed conditioning protocols made their clinical applicability difficult [55]. 
Subsequently, the infusion of high-dose donor BM with costimulatory blockade but 
without prior massive lymphodepletion in the host succeeded in inducing persistent 
chimerism in mice [56-58]. The inoculus of a larger amount of BM cells allowed 
overcoming the need of space for donor cells engraftment without the need of
20
myeloablation, while costimulatory blockade harnessed the peripheral T cell 
alloresponse.
These experimental evidences formed the basis for the recent successful approaches to 
induce tolerance in kidney transplant recipients through combined infusion of donor 
BM [59, 60].
Initial clinical success was reported by Strober using a conditioning regimen based on 
total lymphoid irradiation (TLI) [61] and has more recently been achieved in patients 
who require marrow replacement for multiple myeloma [60]. Pilot trials using 
haplodisparate donor-recipient pairs without underlying malignancy are now ongoing 
with cautiously optimistic preliminary results [43]. Thus, although practically complex, 
the induction of mixed chimerism seems to be a promising approach to tolerance.
Recently, two reports have been published on the successful induction of tolerance in 
patients receiving combined kidney and hematopoietic stem-cell transplantation. The 
recipient of a kidney from an HLA-matched brother received cyclosporine starting at the 
time of renal transplantation [59]. During the next 2 weeks, he underwent total 
lymphoid irradiation, and a course of antithymocyte globulin and prednisone and, 
therafter, he received an infusion of donor hematopoietic stem cells. Within 1 month 
after transplantation and consistently thereafter, the proportions of donor and recipient 
cells in the recipient's blood were about equal. Immunosuppressive therapy was 
discontinued 6 months after transplantation, with maintenance of good renal function 34 
months after transplantation [59]. In another report, Kawai et al. performed 
simultaneous kidney and stem-cell-enriched leukocyte transplantations from five HLA 
single-haplotype mismatched living related donors into recipients who had received a 
conditioning regimen with multiple agents [60]. One patient rejected the kidney. The
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other four patients had undefined spontaneously reversible or corticosteroid-responsive 
"capillary leak" phenomena, which presumably were rejection episodes; nevertheless, 
immunosuppressive therapy was discontinued in the four recipients 9 to 14 months after 
transplantation, without deterioration in the function of the grafts during 2.0 to 5.3 years 
of follow-up. There was no evidence of leukocyte chimerism in any patient for more 
than 21 days. Since only blood samples were studied, assessment of the presence of 
small numbers of donor leukocytes (microchimerism) outside the blood circulation was 
not possible.
These represent important results providing the proof of the concept that tolerance is a 
feasible goal also in the clinical setting. However, the complexity of the procedure and 
the important induction immunosuppression still represent major concerns about this 
strategy.
Peripheral tolerance
Not all self-antigens are expressed in the thymus, thus other mechanisms are required in 
the peripheral immune system to maintain a safe T cell repertoire in healthy individuals. 
Peripheral tolerance is the term applied to these naturally arising mechanisms that lead 
to anergy, deletion or suppression of self-reactive T cells which escaped from thymus 
deletional processes. Starting from this evidence, researchers have sought to promote 
these mechanisms to obtain peripheral tolerance to alloantigens.
Various strategies have been explored to achieve peripheral tolerance in experimental 
protocols including: 1. targeting all peripheral T cells independently from their 
specificity or activation state (depleting protocols), 2. inhibiting T cell activation by
22
blocking or modifying costimulatory signals (costimulatory blockade, manipulation of 
dendritic cells), and 3. harnessing activated T cells by CD4+CD25+ antigen-specific 
regulatory T cells (Treg) [62].
- Lymphocyte depletion
The development of monoclonal antibodies (mAbs) has prompted studies with various 
lymphocyte-depleting protocols in rodents, non-human primate models, as well as in 
clinical transplantation, in order to prevent acute rejection and possibly to promote 
tolerance [63]. In various animal models, anti-T cell antibodies, given at the time of 
transplantation (induction therapy), were used either alone or in Combination with other 
strategies that aim to limit clonal expansion of effector T cells. Cell-depleting 
approaches result in a profound reduction of circulating leucocytes capable of mounting 
an alloresponse at the time when the allograft is already susceptible to inflammatory 
damage following the ischaemia/reperfusion injury [64, 65]. Thereafter, lymphocytes 
will gradually repopulate the host weeks to months later when the innate immune 
response has resumed and the allograft is more quiescent.
Depletion strategies have been extensively studied in non-human primate transplantation 
models. In these studies, encouraging results were obtained using anti-CD3- 
immunotoxin (monoclonal anti-Rhesus CD3 antibody with a modified diphtheria toxin) 
alone [66], or in combination with deoxyspergualin (a monocyte inhibitor) [67] or 
sirolimus [68]. However in these models, despite profound peritransplant T cell 
depletion, consistent transplantation tolerance was not achieved with monotherapy as 
most treated animals eventually lost their grafts through chronic rejection [69]. 
Notwithstanding, this formed the basis for clinical attempts to minimize maintenance
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immunosuppression after the induction of lymphocyte depletion in organ transplant 
recipients. This approach was attempted in 28 kidney transplant patients receiving TLI 
and anti-thymocyte globulin as induction and low-dose steroid as the sole maintenance 
immunosuppression. In three patients, immunosuppressive therapy was successfully 
withdrawn, suggesting that lymphocyte depletion might promote tolerance also in the 
clinical setting [61]. Notably, one of these patients was still off immunosuppression up to 
12 years after transplant. However, the potential complications of TLI are not acceptable 
for routine transplantations, thus polyclonal or monoclonal antibodies were thereafter 
advocated as safer tools to obtain T cell depletion. Paragraph 3 will discuss attempts to 
transfer lymphocyte depletion in the clinical setting.
- Costimulatory blockade
Costimulation signalling is required for full T cell activation and differentiation of naive 
T cells into polarized effector T cells. In the absence of an appropriate second 
costimulatory signal, partially activated T cells either become hyporesponsive to 
specific T cell receptor signals (donor-specific anergy) or die by apoptosis [70]. Overall, 
by inhibiting T cell activation rather than eliminating all T cells as in depleting 
protocols, this strategy might more selectively target effector T cells and thus spare 
other potentially beneficial T cell subpopulations, such as those with immune regulatory 
properties [71].
The CD154:CD40 pathway is of crucial importance in effective antigen presentation. 
CD 154 (CD40L) is expressed on T cells, B cells, eosinophils, natural killer (NK) cells, 
platelets and dendritic cells, whereas CD40 is mainly expressed on dendritic cells, 
macrophages and endothelial cells and its ligation upregulates the expression of CD80
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and MHC molecules [72]. Blockade of the CD154:CD40 pathway using MR1, an anti- 
CD40L mAh [73] which, besides blocking signal 2 may also have a cytotoxic activity 
towards activated T cells [74], was able to induce a condition of tolerance in a skin 
transplant model in the mouse. Various clones of the anti-CD 154 mAh have been used 
in monotherapy in non-human primate models, resulting in long-term acceptance of 
renal, heart and islet allografts. However, allogeneic response was not fully prevented in 
these experiments, resulting in cellular infiltrates in the biopsies of long-term surviving 
allografts and eventual graft loss [75-77].
Excellent outcomes were observed first in small animal models using CTLA-4 Ig, a 
fusion protein with specificity for CD80/86 expressed on antigen presenting cells (APC)
[78]. CTLA-4 Ig was also used and was described to prolong pancreatic islet survival
[79] in non-human primates and, when used in combination with anti-CD 154, to induce 
indefinite acceptance of renal and heart allografts, while allowing prolonged skin graft 
survival [66, 80].
Blocking the CD28 ligands CD80 (B7-1) and CD86 (B7-2) has been also attemped. 
Monoclonal antibodies targeting these costimulatory molecules, when used in 
monotherapy failed to significantly prolong renal allograft survival in non-human 
primate models. However, combined blockade of CD80 and CD86 led to prolonged 
survival in models of renal transplant in non-human primates, though this did not result 
in tolerance, as rejection occurred after therapy withdrawal [74, 81]. Two fusion 
proteins, abatacept and belatacept, have been recently developed to bind the ligands for 
CD28, the B7 molecules CD80 and CD86 [82]. A recent randomized clinical trial tested 
belatacept in renal transplantation showing promising results for its use as an 
immunosuppressive agent [83]. Although designed to study its efficacy in preventing
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rejection compared with cyclosporine and not to address tolerance, this early study 
suggests that co-stimulation blockade will have a major role in future tolerance 
strategies [43].
- Regulatory T cells
In the past decade, it has been become increasingly clear that T cells capable of actively 
suppressing immune responses are at least in part responsible for the maintenance of 
peripheral tolerance toward self antigens [84]. Moreover, in both rodents and humans, 
there is an emerging consensus that immunoregulatory activity of these cells may be 
instrumental also for the induction and maintenance of tolerance toward alloantigens in 
the transplant setting [85].
The phenomenon of T cell-mediated regulation in transplantation tolerance is not new, 
but during the last years a number of interesting findings have brought it back into the 
limelight. Harnessing the capability of these suppressor cells to regulate immune 
responses to not only self molecules but also to foreign antigens may have an impact in 
the transplant setting. Indeed, the ability of these regulatory T cells (Treg) to induce 
unresponsiveness to alloantigens in vivo, in the absence of chronic immunosuppression, 
may inhibit the immune-mediated processes that lead to long-term graft failure [86]. 
Several subsets of Treg with distinct phenotypes and mechanisms of action have now 
been identified. They constitute a network of heterogeneous CD4+ [87, 88] or CD8+ [89, 
90] T cell subsets and other minor T cell populations such as nonpolymorphic CD ld- 
responsive natural killer T cells [91, 92].
In both humans and rodents the best characterized population of Treg is the subset 
coexpressing CD4 and CD25 (IL-2R a  chain) antigens. CD4+CD25+ Treg are defined as
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(‘naturally occurring’ or ‘innate’ since they arise during thymic ontogeny, selected as a 
result of relatively high-affinity interactions with self-peptide/MHC complexes [93]. In 
non-autoimmune-prone mice, elimination of CD4+CD25+ Treg, by a thymectomy 
carried out at day 3 of age, induced the onset of a polyautoimmune syndrome [87]. 
Importantly, adoptive transfer of CD4+CD25+ T cells from normal mice to 
thymectomized animals protected from autoimmunity [87].
In addition to their role in maintaining self-tolerance and preventing autoimmune 
diseases [87], CD4+CD25+ Treg play a role in preventing allograft rejection, as 
demonstrated in many animal models of transplant tolerance induction [94]. In a model 
of renal transplant tolerance by donor PBMC infusion in the rat, CD4+CD25+ Treg 
accumulating in tolerized kidney grafts were instrumental to the prevention of acute 
rejection [95].
Moreover, it has been demonstrated that CD4+CD25+ Treg with the capacity to prevent 
skin allograft rejection can be generated in mice by pre-treatment with donor alloantigen 
under the cover of non-depleting anti-CD4 therapy [96]. CD4+CD25+ Treg isolated , 
from the spleens of these tolerant mice are donor-specific and can transfer tolerance to a 
naive recipient [97]. Of great interest, evidence recently came out showing that such 
Treg are generated in the periphery from CD4+CD25' precursors in a pathway distinct to 
that by which naturally occurring CD4+CD25+ Treg develop [98].
The main mechanism of suppression by CD4+CD25+ Treg seems to be the inhibition of 
IL-2 production by responder T cells [99]. Interestingly, CD4+CD25+ Treg have been 
shown to constitutively express CTLA4 (CD 152) in both mice and humans. Fallarino et 
al. have attributed a key role to CTLA4, providing evidence that mouse CD4+CD25+ 
Treg can deactivate immunostimulatory function of APCs through CTLA4 engagement
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of B7 molecule [100]. Thus, CD4+CD25+ Treg can exert their suppressive activity either 
by a direct contact with T cells or indirectly through modulation of APC function.
Since activated effector CD4+ T cells also transiently express CD25, researchers looked 
for other phenotypic markers for identifying CD4+CD25+ Treg. That mice carrying the 
X-linked scurfy mutation in FOXP3 gene display multi-organ autoimmune disease and 
lack conventional CD4+CD25+ Treg [101, 102] have focused the attention on FOXP3 as
a. specific marker of Treg in mice. In mice, FOXP3 has been shown to be expressed 
exclusively in CD4+CD25+ Treg and is not induced upon activation of CD25‘ T cells. In 
addition, transfection with FOXP3 converts naive CD4+CD25' T cells into Treg [103]. 
Of particular interest, Walker et al. have shown that in humans activation of 
CD4+CD25' T cells results in the generation of two populations of cells, effector 
CD4+CD25+ and regulatory CD4+CD25+ T cells, with expression of FOXP3 confined to 
the regulatory cell subpopulation [104].
CD4+CD25+ T cells expressing FOXP3 are therefore a well characterized Treg 
population, whose activity may play a crucial role also in tolerance induction in clinical 
transplantation.
Other cells with immune regulatory properties have been described. Among them, a 
population expressing the CD8+CD28~ phenotype has been reported to be associated to 
lower rates of rejection and an increased likelihood of being weaned effectively from 
immunosuppression in kidney and liver transplant recipients [105]. This suggests that 
mechanisms of peripheral tolerance are redundant and that our knowledge of them is 
still extremely limited.
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3. Tolerance induction through lymphocyte depletion in the clinical setting
Despite the huge number of available strategies to induce tolerance in rodent models of 
transplantation, only few of them have been successfully transferred to nonhuman 
primates and, even fewer, to transplant patients. As discussed above, two recent reports 
showed that induction of chimerism through combined bone marrow transplantation 
may promote tolerance in humans [59, 60]. However, potential toxicity of the induction 
protocol and the complexity of the technique still make this approach hardly transferred 
to the clinical practice, at least not to significant numbers of patients.
So far, the pro-tolerogenic strategy that provided the most reproducible results in kidney 
transplant patients is lymphocyte depletion at the time of engraftment. Although this 
approach promotes true tolerance in only a minority of patients, it effectively allows the 
prevention of rejection with lower than standard amounts of chronic
immunosuppression in most of the cases [ 106].
Theoretically, lymphocyte depletion removes effector T lymphocytes from the 
circulation at the time of ischemia-reperfusion injury and allows the graft to heal, 
preventing a detrimental inflammatory response. During immune reconstitution, 
emergence of T cells with memory phenotype has been described (homeostatic 
proliferation), which might potentially represent a hurdle to the establishment of 
tolerance, due to their low threshold for activation [106]. However, use of compounds 
promoting Treg expansion during this phase might overcome this effect, thus allowing 
peripheral tolerance mechanisms to prevail.
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Homeostatic proliferation
The peripheral T cell pool is composed of a large and heterogeneous repertoire of naive 
and memory T cells capable of recognizing both foreign- and self-antigens [107]. This 
pool of lymphocytes is tightly regulated by homeostatic mechanisms that serve to 
control the numbers of T lymphocytes in circulation and the different subpopulations 
{i.e. CD4+ versus CD8+, naive versus memory). This is instrumental in ensuring that the 
organism has continued diversity of naive T cells able to respond to random antigenic 
challenges while preserving immunological memory to microbial pathogens formerly 
encountered [107].
Recent evidence suggests that the set point for homeostatic equilibrium involves an 
external mechanism of quorum sensing, which the T cell 'interprets' as a measure of 
available or free 'space'. Indeed, T cells seem to be under severe pressure to fill this 
space as evidenced by their robust expansion even in the absence of antigen soon after 
adoptive transfer into T cell-deficient syngeneic recipients: this is what is meant by 
homeostatic proliferation [108]. The same thing also happens after the induction of 
lymphocyte depletion.
The key hallmark of homeostatic proliferation is the induction of naive T cells to 
express conventional memory T cell markers and to differentiate into a memory-like 
state [109, 110]. In particular, L-selectin (CD62L) which is preferentially expressed on 
naive T cells, as it is necessary for entry into lymph nodes, is progressively lost as cells 
undergo homeostatic proliferation. In parallel with the loss in CD62L is the 
upregulation of CD44, a molecule whose expression is required for adhesion and 
entrance into peripheral tissues. Functionally, these cells are similar to memory cells as 
their requirement for CD28 costimulation is diminished, thus they have a lower
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activation threshold [111]. Furthermore, the rapidity and magnitude of effector 
responses following activation, such as cytokine production, cytolytic activity and 
proliferative capacity and kinetics, are also greatly enhanced [109, 110]. Thus, the 
emergence of these cells after lymphocyte depletion might also represent a hurdle to the 
establishment of tolerance [112].
However, during immune reconstitution in individuals with cancer who did or did not 
receive IL-2 therapy, CD4+CD25hlgh cells also underwent homeostatic peripheral 
expansion during immune reconstitution, and in lymphopenic individuals receiving IL- 
2, the Treg cell compartment was similarly markedly increased. Along this line, mouse 
studies showed that IL-2 therapy induced expansion of existent Treg cells in normal 
hosts, and IL-2-induced Treg cell expansion was further augmented by lymphopenia 
[112]. Thus, the success of tolerogenic strategies with lymphocyte depletion is closely 
related to the equilibrium between memory and regulatory T cells.
Looking fo r  the ideal maintenance immunosuppression after lymphocyte depletion: 
the effect o f  different drugs on Treg activity
Regulatory T cells have long been implicated in transplant tolerance. Thus, to promote 
tolerance after lymphocyte depletion, it would be an obvious benefit to promote the 
'outgrowth' of Tregs compared to non-regulatory T cells after T cell depletion. 
Intriguingly, recently evidence came out showing that different immunosuppressive 
compounds may exert different promoting or inhibiting effect on Tregs [113]. Finding 
the right combinations of immunosuppression after lymphocyte depletion might 
therefore identify the best maintenance regimens to use after induction with depleting 
agents.
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Of note, evidence has been provided that sirolimus and cyclosporine, the two most 
widely used immunosuppressants in organ transplantation, may exert opposite effects 
on Treg number and function. Indeed, sirolimus seems to promote the expansion of 
functional Treg, whereas cyclosporine might have an inhibitory effect [114].
In particular, cyclosporin A (CsA) is a potent inhibitor of the phosphatase, calcineurin, 
which is essential for T-cell activation. By inhibiting calcineurin, it suppresses the 
production of IL-2 and related cytokines through the prevention of downstream 
activation of the transcription factor, nuclear factor of activated T cells (NFAT) [113]. 
Few in vitro studies described the effect of CsA on Treg. Baan et al. showed that in a 
mixed leukocyte reaction, the induction of FOXP3 mRNA was inhibited by CsA [115]. 
This was confirmed by authors of other studies, who observed decreased FOXP3 
mRNA and protein [114] and a loss of the highly suppressive CD27+ Treg subset in 
cultures containing CsA [116]. The authors of these later studies report contradicting 
effects of CsA on the suppressive function of Treg, one observing no effect with human 
Treg and the other finding less suppression with mouse Treg [113].
There are now recent in vivo data that show a negative effect of CsA on Treg. Treatment 
of mice with CsA compromised not only the thymic generation of Treg but also resulted 
in a sharp reduction of Treg in peripheral immune compartments [117]. In a mouse bone 
marrow transplantation model, CsA administration inhibited Treg mediated suppression 
which was associated with reduced IL-2 production [118]. Together these data suggest 
that CsA is not beneficial for Treg, but is rather detrimental to their generation, survival 
and function.
Sirolimus exerts its effect at the level of mammalian target of rapamycin (mTOR), 
thereby preventing the progression from G l- to S-phase. There is in vitro and in vivo
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evidence that sirolimus treatment has favourable effects on Treg. In a study with mice 
by Battaglia et al., CD4+CD25+FOXP3+ Treg expanded ex vivo in the presence of 
sirolimus and prevented rejection of beta-islet transplants in vivo [119]. Sirolimus also 
induces de novo expression of FOXP3 in murine alloantigen-specific T cells dose 
dependently, which appeared to be TGF-pl dependent [120]. Because sirolimus can 
induce the expression of TGF-pl, it may be an important mechanism contributing to the 
development of antigen-specific Treg [113]. Interestingly, a recent study suggests that 
sirolimus can induce regulatory functions in conventional CD4+ T cells in culture [120]. 
Furthermore, evidence suggests that sirolimus -conditioned dendritic cells are poor 
stimulators of allogenic T cells but enrich for antigen-specific Treg, which can prolong 
cardiac graft survival in mice [121].
Altogether, the above evidence suggest that the choice of the maintenance 
immunosuppressive regimen after lymphocyte depletion may be crucial for the success 
of this pro-tolerogenic strategy.
Different strategies to induce lymphocyte depletion in kidney transplant patients
Lymphocyte depletion using polyclonal antibody therapy has long been a part of the 
transplant immunosuppressive armamentarium and is reserved for immunologically 
high-risk recipients. More recently, the use of both polyclonal and monoclonal depletion 
has been adopted to allow immunosuppression minimization or even to achieve donor- 
specific tolerance [122]. The long-term aim of this therapy is to minimize the toxicities 
we have come to expect with standard immunosuppression, which may be limiting 
long-term outcomes. This positive effect is offset by the potential toxicity of the global 
depletion of the recipient’s lymphocytes and, in some cases, monocytes and neutrophils.
33
Efforts aimed at identifying effective and well-tolerated induction protocols may 
maximize the long-term success of kidney transplantation.
Seminal studies in nonhuman primate transplantation models showed that lymphocyte 
depletion by total lymphoid irradiation (TLI) prolonged graft survival and promoted 
donor-specific hyporesponsiveness [123]. On the basis of this background, 28 kidney 
transplant patients received TLI and anti-thymocyte globulin as induction therapy and 
low-dose steroid as the sole maintenance immunosuppression. Immunosuppressive 
therapy was successfully withdrawn in three patients, which suggests that lymphocyte 
depletion might also promote tolerance in the clinical setting [61]. Of note, one of these 
patients was free of any imunosuppression for more than 12 years [61]. The potential 
complications of TLI are not acceptable for routine transplantation, however, and 
polyclonal or monoclonal antibodies were therefore advocated as safer tools for 
obtaining T-cell depletion.
In the 1970s, the polyclonal antibody Minnesota antilymphoblast globulin was 
introduced in the immunosuppressive treatment of organ transplant recipients and were 
used for more than twenty years, together with azathioprine and steroids (and, from 
1978, cyclosporine), to prevent and treat acute rejection. In spite of the increased risks 
of anaphylactic reactions and opportunistic infections, this experience highlighted the 
importance of lymphocyte depletion to improve patient and graft outcomes [123].
More recently, new formulations of polyclonal rabbit anti-thymocyte globulin have 
become available and have been progressively introduced in the induction protocols of 
most transplant centers. However, some concerns still persist in the extensive use of 
polyclonal antibodies, as they have been associated with a significant increased risk of 
opportunistic infection and lymphomas. Of note, potential immunization against non
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human immunoglobulin, might induce anaphylactic reactions and prevent repeated 
administrations. Thus, during last decade, research has been focused on humanized 
monoclonal antibodies [123].
4. Campath-IH
Campath-IH is a humanized rat monoclonal antibody (rat immunoglobulin IgG2b) 
directed against the CD52 antigen, which is expressed on all blood mononuclear cells 
and also on cells lining the male reproductive tract [124]. It is a powerful cytolytic agent 
and has been used therapeutically in bone marrow and organ transplantation, and in 
several autoimmune diseases [124]. It was first used by Sir Roy Caine [125] as 
induction therapy for renal transplantation in 1998 and it efficiently prevented acute 
rejection in 13 patients who received low-dose CsA as the sole immunosuppressant. 
Since then, many other trials employed this antibody to induce a pro-tolerogenic state 
that may allow reducing doses of maintenance immunosuppression [126].
A brief historical perspective
The first Campath-IH antibodies were created from rat hybridomas in an attempt to 
produce antibodies that would lyse lymphocytes in the presence of human complement 
[124]. All these antibodies were directed against the same antigen, now known as 
CD52. The first antibody was a rat IgM (Campath-IM) that resulted in only a transient 
lymphopenia in patients with leukaemia. Thereafter, an IgG antibody (Campath-IG) 
was developed, which was an IgG2b antibody, produced as a switch variant of IgG2a 
[124]. This antibody was profoundly lytic in the presence of human complement but 
also produced direct lysis by antibody-dependent cellular cytotoxicity. Finally, to
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prevent the development of rat globulin antibody responses in patients, the rat antibody 
was humanized (Campath-IH), the first such successful humanization of a clinically 
used monoclonal antibody [127]. Campath-IH and Campath-IG have very similar lytic 
activities, but Campath-IH has gradually replaced Campath-IG in clinical practice over 
the past 10 years. In addition, in two studies of Campath-IH antibodies used to treat 
acute rejection, 15 of 17 patients given the rat antibody Campath-IG exhibited a rat 
antiglobulin response, in contrast to none of 12 patients given the humanized antibody 
Campath-IH [128]. No anti-idiotype antibodies were detected, but it should be noted 
that repeat courses of the antibody were not given and that the patients were all 
receiving concurrent immunosuppression. In contrast, three of four patients with 
rheumatoid arthritis who received a repeat course of the antibody in the absence of other 
immunosuppression developed an anti-idiotype response [126].
The function of CD52 is currently unknown. It is a short glycoprotein consisting of a 
sequence of only 12 amino acids. It is attached to the outer layer of the cell membrane 
by a glycosyl phosphatidylinositol lipid anchor. The CD52 antigen is one of the most 
abundant antigens on the surface of lymphocytes, accounting for approximately 5% of 
the surface antigens [124]. This probably explains in part the profound and long-lasting 
lymphopenia produced after the administration of one or two doses of the antibody.
Campath-IH as induction agent in kidney transplantation
Campath-IH was first used as an induction agent by Caine et al. [125] in 1998 in 13 
renal transplant recipients who received low-dose cyclosporine alone as maintenance 
therapy. At the time of publication, patient and graft survival rates were 100% and there 
were two episodes of acute rejection, with a follow-up of 6-12 months. Azathioprine
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and prednisolone were added to one patient's immunosuppressive regimen to treat 
rejection. The 5-year results of the initial series were published along with those of 
another 20 patients who were subsequently entered in this pilot trial (total of 33 
patients) [129]. They found no significant difference in graft or patient survival or acute 
rejection rates in a retrospective contemporaneously controlled comparison with the 
findings in 66 patients who underwent kidney transplantation in the same unit during 
the same period and were treated with triple therapy (cyclosporine, azathioprine, and 
prednisolone). This led to hypothesize that Campath-IH, by reducing the need of 
maintenance immunosuppression (and related toxicity) to prevent acute rejection, might 
actually provide better outcomes in the longer term. However, seven patients in the 
control group were in a highly sensitized condition and received induction therapy with 
thymoglobulin. Thus, the higher immunological risk of patients in the control group 
might have lead to overestimate the beneficial effects of patients who received 
Campath-IH induction.
In light of the limitations of this study, Caine et al recently coordinated a randomized, 
controlled, prospective trial comparing the 12 month outcomes of 65 patients who 
received Campath-IH induction and delayed tacrolimus monotherapy versus those of 66 
patients on tacrolimus, MMF and steroids without induction. Results were very similar 
in the two groups, apart for an higher incidence of CMV infections in Campath-IH 
treated patients [ 129].
Ciancio et al. [130] designed a well planned three-arm trial with 30 patients in each arm 
in which compared induction with Thymoglobulin, Campath-IH, and daclizumab (an 
anti IL-2 receptor antagonist). All patients received maintenance immunosuppression 
with tacrolimus, mycophenolate mofetil (MMF), and steroids, but the Campath-IH
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group received half the dose of tacrolimus and no steroids after the first week. After a 
median follow-up of 15 months, there was no difference in patient or graft survival, 
acute rejection rates, or renal function, nor was there any difference in infections or 
incidence of diabetes or hyperlipidemia among the three groups. However, 80% of the 
Campath-IH patients remained steroid-free. Intriguingly, patients in the Campath-IH 
arm showed an higher expansion of Treg.
A number of nonrandomized retrospective studies with large numbers of patients have 
been reported in which Campath-IH was compared with other induction therapies in 
renal transplant recipients [126]. Knechtle et al. [131] compared induction with 
Campath-IH (n=126) to historical control groups treated with anti-CD25 antibody 
(basiliximab; n=799), Thymoglobulin (n=160), and other induction therapies, such as 
OKT3 or .antithymocyte globulin (n=156). For maintenance immunosuppression, all 
groups received a calcineurin inhibitor and MMF. Prednisone was used in all groups 
except the group that received Campath-IH. There was a marginal reduction in the 
incidence of biopsy-proven acute rejection (P=0.037) and a better graft survival 
(P=0.0159) in the Campath-IH group. Also, when looking at the subgroup of patients 
who experienced delayed graft function, there was significantly less acute rejection 
(P=0.0096) and a significant improvement in graft survival (P=.0119) in the Campath- 
IH group. There was no significant difference in patient survival nor in the incidence of 
infection and malignancy among the three groups.
Before this study, the same group [132] performed a pilot trial with Campath-IH 
induction and sirolimus monotherapy in 29 patients. Thirteen patients had an acute 
rejection, which in six cases was of the humoral type. However, the 3-year results 
showed graft and patient survival rates of 96% and 100%, respectively, with an
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excellent graft function. In another pilot study of Campath-IH induction with MMF and 
sirolimus in 22 kidney transplant recipients [133], there were eight acute rejections 
(36%) with leukopenia and possible pulmonary toxicity, leading the authors to suggest 
that initial use of a calcineurin inhibitor might be necessary with Campath-IH 
induction.
Shapiro et al. [134] compared Campath-IH induction (n=90) versus historic control 
patients treated with Thymoglobulin induction (n=101) and a non-induction therapy 
group (n=152). In the control group without induction therapy, the maintenance 
immunosuppression was tacrolimus, prednisolone, and usually a third agent (MMF or 
sirolimus). Both induction therapy groups received tacrolimus as maintenance 
monotherapy. After 3-4 months, spaced weaning of the tacrolimus was attempted in the 
induction therapy groups. There was no significant difference in overall graft or patient 
survival, but when looking at the subgroup of living-donor grafts, graft survival was 
significantly better for Campath-IH and Thymoglobulin compared with the control 
group without induction therapy (P=0.037). The acute rejection rate was similar in the 
Campath-IH and control groups, which was better than that in the Thymoglobulin 
group.
In an attempt to induce donor allograft tolerance, Campath-IH was also used as 
induction therapy alone with no maintenance therapy in seven nonsensitized recipients 
of living-donor transplant kidneys at the NIH Renal Transplant Center [135]. All seven 
patients developed early rejection within the first month, requiring initiation of 
maintenance immunosuppression, but all rejection episodes were successfully treated. 
More recently, the same authors [135] treated a further five recipients of a living-donor 
kidney with Campath-IH and a brief course of deoxyspergualin, which was added to the
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treatment regimen with the aim of preventing the early macrophage and monocyte 
infiltration observed in the patients treated earlier [136]. However, all patients exhibited 
a reversible rejection similar to the aforementioned group and rejection was preceded by 
or associated with marked increases in several chemokine transcripts. Therefore, used in 
this protocol, Campath-IH was unable to produce tolerance.
Recently, an analysis of Organ Procurement and Transplantation Network/United 
Network for Organ Sharing database compared the outcomes at 2 years of deceased 
donor kidney recipients treated with Campath-IH (n=690), thymoglobulin (n=4,930), 
interleukin-2 receptor antagonist (n=4,378), or without induction [137]. Patients on 
Campath-IH therapy experienced less acute rejection during the initial hospitalization 
comparing to the other groups, but this finding was not sustained 6 and 12 months after 
transplant, when the rejection-free survival of Campath-IH patients was significantly 
lower than the one of patients who received other induction agents or without induction. 
Despite this increased acute rejection risk, graft survival did not significantly differ 
among various patients groups. The increased incidence of late rejections in Campath- 
lH-treated patients might reflect the attempts to reduce immunosuppressive therapy 
among patients in this group. Importantly, among recipients of Campath-IH induction, 
rejection-free survival and graft survival were significantly higher when maintenance 
immunosuppression included calcineurin inhibitors.
Campath-IH safety profile in kidney transplantation
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The profound and long-lasting lymphocyte depletion induced by Campath-IH raised 
concerns about its safety profile, especially in the long-term. Notwithstanding, it is in 
general well tolerated and the severity of potential side effects is mild.
- Cytokine release syndrome
As with all antibody treatments, Campath-IH infusion may induce a cytokine release 
syndrome characterized by fever and hypotension. It is generally modest and normally 
controlled with an intravenous bolus injection of 1 g of methylprednisolone before 
administration of the antibody. Recently, however, a study showed that, in kidney- 
pancreas transplantation, subcutaneous administration of Campath-IH avoids this first- 
dose reaction while achieving a similar lymphocyte depletion to intravenous- 
administration [138]. Prevention of infusion-associated hypotension is particularly 
important in pancreas transplantation where venous thrombosis is a major problem.
- Infection
Despite the profound and long-lasting CD4 T cell depletion for 2-3 years produced by 
one or two doses of Campath-IH, there has been a surprising lack of serious infection in 
nearly all studies reported. Silveira and colleagues [139] examined a cohort of 449 
consecutive transplant recipients who received Campath-IH to determine the incidence 
of bloodstream infections, which might be expected to have an increased incidence in 
patients in a CD4-depleted state, as seen in patients with AIDS, for example. No 
increased risk was noted. Similarly, a low incidence of infection was noted in another 
small study in comparison with a historical control group [140], and indeed this has 
been a feature of all the reports described earlier.
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- Autoimmune disease
An interesting observation made in the long-term study of Watson et al. [129] was the 
occurrence of an autoimmune disorder in two patients who had received Campath-IH, 
one with autoimmune hypothyroidism and one with autoimmune hemolytic anemia. 
This is relevant bearing in mind that, of 27 patients with multiple sclerosis treated with 
Campath-IH, nine developed autoimmune hyperthyroidism [141]. Recently, also the 
case of a kidney transplant recipient who developed autoimmune thyroiditis four years 
after Campath-IH induction has been reported [142]. Thus, although rare in the setting 
of organ transplantation, increased risk of autoimmune disease should be considered 
when facing transplant patients receiving Campath-IH induction. This risk might be 
even higher considering that, in transplant patients, this adverse event might have been 
underreported.
- Coagulopathy
Campath-IH administration has been also associated both with disseminated 
intravascular coagulation (DIC) in a patient with bone marrow transplantation and with 
massive bleeding in a kidney transplant recipient. In both cases, the adverse event 
followed the first Campath-IH administration. No clear mechanism has been advocated 
to explain how CD52 antibody may affect coagulation.
Do patients with Campath-IH induction reject their grafts in spite o f the absence of  
circulating T lymphocytes?
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Unexpectedly, the aforementioned clinical experiences showed that acute rejection does 
occur in renal transplant recipients who undergo induction therapy with Campath-IH, 
despite the profound lymphocyte depletion. However, the histologic pattern may be 
different than the one observed with conventional immunosuppression. Comparing 
biopsies of renal transplant recipients with acute rejection who did or did not receive 
Campath-IH induction, Zhang et al. showed that Campath-IH induction was associated 
with acute rejections with a majority of the cells (up to 95%) being monocytes and a 
minority T lymphocytes [143]. Conversely, in renal specimens from patients who did 
not receive Campath-IH induction, monocytes were mixed with many other 
inflammatory cells including T lymphocytes, eosinophils and neutrophils [143]. This is 
consistent with the fact that Campath-IH can severely deplete peripheral T lymphocytes 
to minimal levels, whereas its effect on monocytes is much milder. These findings 
confirm those previously observed by Kirk et a l who tried to use Campath-IH alone 
[135] or followed by a deoxyspergualin [136] in two small series of kidney transplant 
recipients . All patients treated with these protocols experienced an acute rejection 
episode that required the introduction of maintenance immunosuppression. Intriguingly, 
all the rejection episodes were mainly mediated by infiltrating monocytes. The authors 
suggested that monocyte and macrophage lineage cells resistant to Campath-IH release 
cytokines in the graft, perhaps in an attempt to recruit effector T cells and, in doing so, 
they induce renal dysfunction. Importantly, all the acute rejections responded to typical 
rescue therapy. After reversal of acute rejection, the clinical scenario is most consistent 
with immunologic indifference rather than tolerance. That is to say that the healed 
allograft does not induce sufficient chemotactic signals to attract a significant
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inflammatory infiltrate, thus acute rejection can be prevented also with small amounts 
of maintenance immunosuppression.
When Campath-IH induction was followed by maintenance monotherapy with 
sirolimus, an increased incidence of acute rejections of the humoral type was observed. 
In a small prospective study, five out of 29 patients treated with this 
immunosuppressive strategy experienced an acute humoral rejection that in one case 
resulted in loss of the graft [132]. However, in the trial by Kaufman et al. [144] of 
tacrolimus and MMF, there were no episodes of acute rejection that were humoral in 
origin or macrophage-mediated. In a number of other studies, no histologic details were 
given other than a statement that rejection was graded based on Banff criteria. This 
suggests that, in the presence of a calcineurin inhibitor after induction with Campath- 
IH, humoral rejection is uncommon.
Recently, Gallon et al. [145] compared kidney graft biopsies during an acute rejection 
episode of 12 patients who received Campath-IH induction and MMF and tacrolimus as 
maintenance therapy with those of a control group of transplant patients who did not 
receive induction therapy. They confirmed previous data showing that monocyte 
infiltration is higher among patients who received Campath-IH induction, but they also 
pointed out that T cells in the rejecting grafts displayed more frequently a memory 
phenotype. As previously discussed, these cells might indeed be more resistant to 
Campath-IH, thus potentially representing a hurdle to the induction of tolerance.
5. Tools to monitor the immune response in organ transplant recipients
Monitoring immune reactivity of transplant patients is instrumental for understanding 
the mechanisms underlying tolerance and may aid in the design of strategies for the 
induction of tolerance in transplantation. Moreover, identification of immunological
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tolerance would allow the partial or complete cessation of immunosuppressants in 
selected patients, a highly attractive goal, given the morbidity and mortality associated 
with long-term administration of such therapy. However, despite the pressing need to 
develop tolerance assays, to date, no one has been shown to predict accurately the 
development or presence of donor-specific tolerance after transplantation. Many 
promising candidate assays measure the presence of anti-donor responses or 
proinflammatory responses ex vivo, usually in peripheral blood lymphocytes.
Immune monitoring assays that currently are in development can be divided broadly 
into two major categories: donor antigen specific and antigen non-specific. Donor 
antigen-specific assays measure the response of T and B cells to specific donor 
antigens, whereas antigen-nonspecific assays for the most part determine the phenotype 
of surface markers or functional state of cells with the goal of identifying a pattern that 
is associated with a particular clinical status [146].
Antigen-specific assays fo r  monitoring transplantation immunity and tolerance
Strict definitions of transplantation tolerance include impaired responses to donor 
antigens with maintenance of immune responsiveness to third-party and non-donor 
antigens. Therefore, assays that evaluate donor-specific responses of recipient 
lymphocytes are likely to be informative in transplantation. Assays of T cell reactivity 
that reflect antigen-specific responses include the mixed leukocyte reaction (MLR), the 
limiting dilution (LDA), the enzyme-linked immunospot (ELISPOT) and the trans vivo 
delayed-type hypersensitivity (DTH) assays [146].
Mixed Lymphocyte Reaction (MLR)
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Mixed lymphocyte reaction (MLR) represents one of the first assays developed to 
measure proliferative response of lymphocytes towards HLA mismatched cells. In its 
classical form, peripheral blood lymphocytes from two individuals are mixed together 
in tissue culture for several days; lymphocytes from incompatible individuals will 
stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) 
whereas those from compatible individuals will not; in the one-way MLR test, the 
lymphocytes from one of the individuals are inactivated thereby allowing only the 
untreated remaining population of cells to proliferate in response to foreign 
histocompatibility antigens [147].
In kidney transplant recipients, donor-specific hyporesponsiveness assessed by MLR at 
3 and 6 months after transplantation was associated with better graft outcome at 1 year 
[148]. A recent study in pediatric kidney transplant recipients showed that donor- 
specific hyporesponsiveness was associated with improved graft survival also at 3 years 
and with lower incidente of CAN [149]. Moreover, these data suggest that although 
downregulation of donor-specific reactivity might not be a prerequisite for stable graft 
function it could help identifying recipients who require less immunosuppression [149].
Limiting dilution assays
Limiting dilution analysis (LDA) is a method for determining the frequency of defined 
clones of lymphocytes responding to a specific antigen or with a particular effector 
function [150]. The technique consists of setting up multiple replicates of graded 
dilutions of responder cells (usually patients' unselected peripheral blood lymphocytes 
or purified populations of CD4+ or CD8+ cells) in wells containing a non-limiting 
stimulus (e.g. donor stimulator cells). The readout from a particular well is only
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considered positive if the measure chosen exceeds the mean of controls (cultures 
lacking responder cells) by a factor of three or more. The number of 'negative' wells at 
each dilution of responder cells is determined. As the concentration of the responder 
cells increases, the proportion of 'negative' wells will tend to be less; the relation 
between the number of negative cultures and the mean number of precursors can be 
plotted and a frequency obtained [151].
LDA has been effectively used to predict graft-versus-host disease (GVHD) and 
survival of bone marrow transplantation [152, 153]. In solid organ transplants, the data 
is less abundant, and conflicting data have been reported in the ability of CTLp 
measurement to predict rejection [154-156].
Enzyme-linked immunospot (ELISPOT)
ELISPOT assay is a hybrid that combines features of a MLR and an ELISA assay in 
that responder/recipient T cells are cultured with inactivated stimulator/donor or third- 
party cells in tissue culture plates that are coated with an antibody that is specific for the 
cytokine of interest (many cytokines have been studied, including IFN-y, IL-2, IL-4, IL- 
5, and IL-10). After a fairly brief culture period, the cells are washed away and the 
bound cytokine is detected, using labeled secondary antibodies and an automated plate 
reader. Each spot that is detected represents a cell that had been primed to the 
stimulating antigen(s) in vivo (effector or memory T cells). Thus, this assay measures 
the frequency of previously activated or memory T cells that respond to donor antigens 
by producing a selected cytokine rather than the total amount of cytokine that is 
produced and secreted into supernatants (as measured using an ELISA). This is an 
important advantage because cytokines are captured immediately upon secretion from
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cells, whereas cytokines that are secreted in supernatants may be subject to breakdown 
or dilution or may be used up by other cells [146].
The frequency of IFNy-producing cells detected by ELISPOT has been shown to be low 
in stable recipients of renal allografts and significantly increased in those recipients who 
experienced rejection [157]. In a follow-up study, the mean frequency of T cells primed 
to donor antigens at 6 months was shown to correlate with serum creatinine at 6 and 12 
months independently of acute cellular rejection, delayed graft function, or the 
recipient's panel-reactive antibody [158]. The frequency of donor-reactive cells, primed 
through the direct or indirect pathway, was also shown to be increased in kidney 
transplant recipients with chronic allograft nephropathy [159].
Transvivo delayed-type hypersensitivity (DTH) assay
In this assay, human peripheral blood mononuclear cells are injected with specific 
antigens into either the footpad or the pinna of immunodeficient mice, and the 
magnitude of the resultant swelling after 24 h is taken as an index of the reactivity of 
these cells to that antigen [31]. VanBuskirk AM, et al. described four transplant 
recipients in whom all immunosuppression had been discontinued [160]. Three of these 
patients, who had prolonged drug-free graft survival, were shown to have alloantigen- 
specific hyporesponsiveness in the trans vivo DTH assay. By contrast, the fourth 
patient, who had previously displayed, but lost, operational tolerance, had a strong 
alloantigen-specific trans vivo DTH response [160].
Theoretically, the trans vivo DTH may be useful as a tool for identifying tolerant 
transplant recipients. However, because of the need for mice and that the assay is 
relatively cumbersome, the utility of this assay for routine clinical immune monitoring
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is uncertain. Nevertheless, this assay also is being evaluated in larger, multicenter trials 
and may be helpful mainly as a research tool.
Non antigen-specific assays for monitoring transplantation immunity and tolerance
A number of non-antigen-specific assays that may be useful for post-transplantation 
monitoring of the recipient immune response have been described. Such assays include 
phenotyping of recipient cells, quantifying the response of recipient T cells to 
polyclonal stimulation in vitro and quantification of gene expression.
Phenotyping o f recipient immune cells
Regulatory cells have been shown to be important for controlling immune responses in 
a number of pathogenic disease processes as well as after transplantation. A clear 
relationship between the presence and activity of Treg and clinical transplant outcomes 
has not yet been clearly shown. However, the presence of Treg might theoretically 
represent a marker of immunoregulation in stable transplant patients and phenotypical 
analysis of lymphocytes isolated from transplant recipients could help to identify 
patients who may be given a lower immunosuppression.
Other markers of leukocyte activation might be useful in defining the level of immune 
reactivity, thus helping in shaping immunosuppressive therapy.
T cell responses to polyclonal, non-antigen-specific stimulation
Beside assays evaluating T cell activation in response to allogeneic donor MHC 
molecules, it is possible to quantify T cell aspecific response toward a polyclonal 
stimulus. To this purpose, different assays have been developed. One of the most
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common consists of stimulating blood lymphocytes with phytohemagglutinin in 
ELISPOT plates. The number of spots specific for a target cytokine (usually IFN-y) 
after a short culture are a measure of lymphocyte reactivity [146].
Assays to quantify gene expression
Extensive studies that have been conducted using animal transplant models have used 
PCR analysis of gene expression to show associations between the expression of certain 
genes and the nature of the recipient anti-donor immune response. Recently, the 
measurement of FOXP3 mRNA in urine was reported to correlate with the outcome of 
acute rejection after renal transplantation, with increased expression of FOXP3 
associated with a greater likelihood of reversal and improved graft survival [161].
6. In vitro alloreactivity of transplant patients
Evaluating in vitro alloreactivity of transplant patients represents a major tool for 
understanding mechanisms at the basis of alio immune response and for identifying 
potential ways to promote tolerance. To this purpose, patients with stable graft function 
focused transplant immunologists’ interest the most.
Interestingly, a large fraction of these patients show a low in vitro alloreactivity. 
Different, yet not mutually exclusive, mechanisms of donor-specific 
hyporesponsiveness have been proposed, including regulation and anergy.
The first clinical efforts to study the role and the relevance of CD4+CD25+ Treg in the 
regulation of alloimmune responses in transplant patients has only recently emerged 
[162, 163]. The frequency and functional profile of circulating CD4+CD25+ T cells have 
been evaluated in 10 lung transplant recipients with stable clinical condition and in 11
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with chronic rejection [164]. The frequency of CD4+CD25+ T cells were significantly 
higher in stable transplant patients as compared with that found in patients with chronic 
rejection. In addition, functional evaluation of these cells demonstrated their regulatory 
profile: they were hyporesponsive to conventional T cell stimuli and suppressed the 
proliferation of CD4+CD25‘ T cells [164].
To better clarify the function of CD4+CD25+ Treg in clinical transplantation, their role 
in regulating both the direct and indirect pathway has been evaluated. Salama et al. 
[162] reported on twenty-three renal transplant patients, grouped into two cohorts with 
or without an history of acute rejection. These patients were chosen on the basis of their 
low reactivity to the mismatched donor-derived HLA-DR antigen. By employing 
ELISPOT assay, the authors were able to detect significant increase in the frequency of 
IFN-y-producing cells stimulated by donor-derived mismatched HLA-DR peptides, after 
depletion of the CD25+ subset. This increase was alloantigen-specific, as the response to 
recall mumps antigen was unaffected by CD25 depletion. Notably, this frequency 
increase was associated with the history of graft rejection, and the initial status of: 
alloresponses toward the mismatched alloantigen in vitro. Conversely, Game et al. 
[165] failed to detect any changes in the direct alloreactivitiy specific to donor-type 
alloantigens after CD25 depletion. By screening twelve stable renal transplant patients, 
the authors measured the effects of CD4+CD25+ T cell depletion on alloresponses in the 
direct pathway by a Limiting Dilution Assay (LDA), as well as by ELISPOT for IFN-y. 
In 11 out of 12 patients, no significant increases were detected in the frequency of 
donor-specific T cells after depletion of the CD25+ subset. In one case, the increase 
occurred in both donor- and third party-reactive T cells. Thus, they concluded that 
CD4+CD25+ T cells are not the major regulators responsible for donor-specific direct T
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cell hyporesponsiveness. This conclusion is supportive of their previous experimental 
results showing anergy as one of the mechanisms of hyporesponsiveness of anti-donor 
T cells in the direct pathway [162]. Subsequent data confirmed that hyporesponsiveness 
toward donor antigens in organ transplant patients with stable function is, at least in 
part, sustained by Treg immune regulation of the indirect pathway [166, 167]. Still, the 
role of Treg has subsequently been reported also in the control of direct recognition 
pathway of alloantibodies [168]. Indeed, CD4+CD25+Foxp3+ T cells harvested from 
renal transplant patients are able to suppress both indirect and direct alloproliferation in 
vitro. However, a functional analysis of circulating Treg (by depleting/reconstituting 
experiments) harvested from renal transplant recipients maintained on different 
immunosuppressive regimens showed that these cells mediate donor hyporesponse only 
in a subset of patients [169].
Intriguing data are also emerging about different promoting or inhibiting effects of 
various immunosuppressive agents on Treg number and function. Indeed, chronic 
immunosuppression with CsA in renal transplant patients has been associated with 
lower levels of circulating Treg as compared with SRL immunosuppression, possibly 
due to the inhibitory effect of calcineurin inhibitors on IL-2 pathways, that are required 
for Treg proliferation [114, 170].
Another population of T cells with regulatory effects expressing the CD8+CD28~ 
phenotype was associated with lower rates of rejection and an increased likelihood of 
being weaned effectively from immunosuppression in kidney and liver transplant 
recipients [105]. FOXP3 positive CD8+CD28~ T suppressor (Ts) cells are antigen 
specific, MHC class I-restricted, and interact directly with antigen-presenting cells 
(APC). Ts render antigen presenting cells tolerogenic, inducing the downregulation of
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costimulatory molecules and upregulation of the inhibitory receptors, immunoglobulin­
like transcripts (ILT)3 and ILT4. ILT3 and ILT4 display long cytoplasmic tails 
containing immunoreceptor tyrosine-based inhibitory motifs (ITIM), which mediate 
inhibition of cell activation by recruiting tyrosine phoshatase SHP-1. The interaction 
between allospecific CD8+CD28“ cells and epithelial cells is bi-directional since 
tolerogenic ILT3+ILT4+ epithelial cells induce the in vitro differentiation of CD8+ into 
CD8+CD28“ T cells [171, 172]. So far, however, only few groups have focused on their 
role.
Beside Treg, a study by Lechler et al. in human renal transplant recipients indicated that 
T anergy plays an important role in maintaining hyporesponsiveness toward donor 
antigens [165]. They demonstrated that donor-specific hyporesponsiveness can be 
specifically reversed by ex vivo treatment of recipient CD4+ T cells with IL-2 in stable 
renal transplant patients, consistent with the hypothesis that anergy may contribute to 
the decrease in anti-donor frequencies. Conversely, the third-party frequencies were 
unaffected by IL-2 stimulation, also indicating that the increase in anti-donor frequency 
after IL-2 is unlikely to be due to nonspecific stimulatory effect of IL-2 [165].
The finding that IL-2-driven cell division can reverse hyporesponsiveness in direct 
pathway T cells may have relevance to the link between systemic infections such as 
CMV or local infections of the urinary tract and acute rejection episodes. Conceivably, 
infection of the urinary tract can result in production of IL-2 locally or in the draining 
lymph nodes, leading to reversal of the anergic state of the allospecific T cells and 
consequent acute rejection.
Effect of Campath-IH induction on alloreactivity o f transplant patients
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Lymphocyte depletion has long been pursued as a therapeutic strategy to induce 
tolerance since the earliest days of transplantation. Indeed, after depletion, the emerging 
graft-specific T cells were thought to encounter donor antigens in a healed state and to 
be purportedly reinforced to become anergic. Thus, the availability of a relatively safe 
lymphocyte depleting antibody such as Campath-IH offered the opportunity to test this 
hypothesis in the clinical setting. The clinical experience accumulated so far actually 
confirms these pro-tolerogenic properties of peri-operative lymphocyte depletion, as it 
allows prevention of acute rejection with doses of maintenance immunosuppression 
significantly lower than the ones used in conventional regimens. However, studies 
aimed at evaluating the mechanisms at the basis of these immunemodulating effects are 
still few.
It is now clear that sensitivity of various CD52 positive cells to Campath-IH depletion 
is variable, with antigen-experienced memory T cells being less susceptible to depletion 
than naive cells [173]. Consequently, differences in recipient’s allospecific immune 
repertoire at transplantation can cause relative resistance or sensitivity to depletion. 
Recently, Trzonkowski et al. found that after Campath-IH induction the recovery of 
CD8+ T cells was much faster than that of CD4+ T cells [174]. Of note, repopulating 
CD8+ T cells were mainly of immunosenescent CD28'CD8+ phenotype and were able to 
suppress CD4+ T cell proliferation. Intriguingly, the authors hypothesize that expanded 
CD28'CD8+ T cells might compete for 'immune space' with CD4+ T cells suppressing 
their proliferation and therefore delaying CD4+ T-cells recovery [174]. This delay might 
be associated with the clinical outcome as CD4+ T cells, notably CD4+ T effector 
memory cells, were shown to be associated with rejection. These findings, combined 
with those indicating that lymphopenia induces some degree of general homeostatic
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activation, suggest that the specific immune capabilities and requirements for T cell 
immunosuppression during repopulation after Campath-IH induction may vary among 
individuals as a function of their T cell repertoire maturity.
As for the functional profile of repopulating lymphocytes, Bloom et al. [175] compared 
anti-donor and third party responses of T cells isolated from patients receiving 
Campath-IH induction and sirolimus as maintenance monotherapy with those from 
patients treated with basiliximab induction and on maintenance therapy with CsA, 
MMF and steroids. Interestingly, they found that proliferative responses to donor 
antigens were equal between Campath-IH and control group, but T cells from Campath- 
IH patients displayed a greater response to third-party antigens suggesting that 
Campath-IH induction combined with sirolimus monotherapy may promote donor- 
specific hyporesponsiveness. As stated above, however, this immunosuppressive 
approach is burdened by a too high incidence of acute humoral rejections, thus the real 
meaning of donor-specific immunosuppression may in fact vary greatly among different 
patients [132].
7. Campath-IH: still unanswered questions
Most of the experience with Campath-IH in kidney transplantation comes from small, 
non randomized studies. However, the collective experience accumulated so far suggest 
that Campath-IH infusion at the time of transplantation is able to modulate the immune 
system response to the point that acute rejection can be prevented with lower than 
conventional doses of maintenance immunosuppression. Early experiences also 
demonstrated that Campath-IH induction alone is however not sufficient to prevent 
rejection without minimal doses of maintenance immunosuppression.
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The best maintenance therapy after Campath-IH induction still needs to be identified. 
Seminal experience by Caine [125] showed that maintenance immunosuppression with 
low doses of cyclosporine monotherapy are effective in preventing acute rejection and 
similar findings were subsequently reported also with tacrolimus [144]. Conversely, 
sirolimus monotherapy was associated with too high an incidence of acute rejection of 
the humoral type [132]. When mycopheonalate mofetil was associated to sirolimus, the 
incidence of acute humoral rejections dramatically declined [133]. So far, however, 
randomized prospective studies comparing different maintenance immunosuppressive 
regimens after Campath-IH induction are lacking. Moreover, it would be important to 
investigate long-term graft histology changes in patients who received Campath-IH 
induction and different low-dose maintenance immunosuppressive regimens.
Importantly, different maintenance immunosuppressive agents might also exert different 
effects on lymphocyte phenotype and function. Indeed, data suggest that cyclosporine, 
by affecting IL-2 signalling, might impair the proliferative capabilities of Treg [176], 
whereas sirolimus seems to promote their expansion [177]. On the other hand, only 
cyclosporine seems to provide enough immunosuppression to inhibit memory T 
lymphocytes, those cells that are largely spared by Campath-IH [173].
Thus, comparing the effect of different maintenance immunosuppressive regimens after 
Campath-IH induction both on the phenotypic and functional characteristics of 
peripheral lymphocytes and on clinical outcomes might be of utmost importance.
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METHODS
Patients and study design
Twenty-one patients (13 men and 8 women) with end-stage renal disease who 
underwent primary kidney transplant were enrolled under an Ethics Committee- 
approved protocol at the Ospedali Riuniti Bergamo, Italy, following written informed 
consent. Primary cadaver (n=19) and living-related (n=2) donor renal transplant 
recipients were selected based on the following criteria: age 18-70 years, current PRA 
<10%, non-HLA identical to the donor. A negative CDC crossmatch test was required 
prior to transplantation. Eligible patients were allocated to one of the following two 
study groups according to a randomization design: Group 1 (n= 11) was assigned to 
Campath-IH, low-dose sirolimus (SRL) and low dose Mycophenolate mofetil (MMF); 
group 2 (n=10) entered to a regimen with Campath-IH, low-dose Cyclosporine (CsA) 
and low-dose MMF (Figure 1). Randomization was performed at the Laboratory of 
Biostatistics of the Clinical Research Center for Rare Diseases “Aldo e Cele Dacco” o f 
the Mario Negri Institute. Patients consented to serial monitoring of their blood 
leukocyte population phenotype and function. At one year after transplantation, mean 
circulating Treg count was four-fold higher in SRL than CsA-treated cohort. Thus, we 
designed an extension phase of the study. All patients of both cohorts were maintained 
on their original treatment arm and were followed for additional 18 months (up to 
month 30 after transplantation). At 24 months after transplantation, consenting patients 
underwent a per-protocol biopsy. The final goal of this extension phase of the study was 
to assess whether patients on SRL compared to those on CsA, in addition to express 
more Treg cells, were also more effectively protected from the late structural and
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functional changes (as assessed by kidney biopsy evaluation and serial GFR 
measurements) characteristic of chronic allograft injury. All the investigators involved 
in patient care, evaluation of study outcomes - such as histology scores and kidney 
functional parameters and data handling and analyses were blinded to Treg counts.
As a further post hoc analysis, we stratified patients on the basis of Treg counts at 1 
year: those with Treg counts above (Treg+, n=10) or below (Treg’, n= ll) the median 
value. Again, we compared the outcomes in the two groups, in order to evaluate 
whether patients with higher Treg might exert a beneficial effect independently from the 
immunosuppressive therapy employed.
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Schematic representation of study design.
Twenty-one primary kidney transplant Caucasian recipients were enrolled Patients were randomly allocated 
on a 1:1 basis to either low-dose sirolimus (SRL group, n = ll)  or low-dose CsA (CsA group, n=10) added on 
to low-dose MMF and induction therapy with Campath-IEL Immunosuppressive treatments are indicated by 
arrows. At surgery, patients received 500 mg methylpredmsolone, followed by a 30 mg infusion of 
Campath-IH. Methylpredmsolone was also infused on day 1 (250 mg) and 2 (125 mg) post-transplant. Low- 
dose Sirolimus (Low SRL) was started on post-transplant day 1 (4 mg/day p.o., then adjusted to target 
trough levels o f  5-10 ngfml). Intravenous CsA (low CsA) was started soon after surgery (1-2 mg/kg^iay), on 
day 1 post-transplant tv . CsA was shifted to oral CsA (2 mg/kgftwice daily) and then adjusted to achieve 
trough blood concentrations o f 120 to 220 ng/ml in the first month post-surgery, and o f 70 to 120 ng/ml 
thereafter. In both groups, patients were also given MMF at the oral dose o f 500 mg twice daily starting on 
day 1 postoperatively (target M PA concentration: 0.5-1.5 mg/ml).
Phenotypic and functional assessments are outlined on the left. Timing o f each evaluation is marked with a 
cross.
Figure 1
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Immunosuppressive protocol
Campath-IH (Alemtuzumab, Schering Plough, Milano, Italy) was given as a single 
intravenous infusion (30 mg, over 2 hours) intraoperatively on the day of transplant 
(day 0). Thirty minutes prior to the Campath-IH infusion, the patients were 
administered 500 mg methylpredmsolone. Corticosteroids were also administered on 
day 1 (250 mg) and 2 (125 mg) post transplant. Thereafter, patients were free of 
steroids. Patients randomized to sirolimus (Rapamune, Wyeth, Rome, Italy) received 
the drug at the oral dose of 4 mg/day in a single morning administration starting on the 
day 1 after transplant. Sirolimus dosing was adjusted to target trough level of 5-10 
ng/ml range. In the CsA-based group, the drug was started i.v. (at the dose of 1-2 
mg/kg/day) just after surgery and shifted to the oral formulation (Neoral, Novartis 
Pharma, Basel, CH) on day 1 post transplant. CsA doses were adjusted to achieve 
trough blood concentration of 120 to 220 ng/ml in the first month post-surgery, and of 
70 to 120 thereafter. Patients of both groups were also given MMF (Cell Cept, Roche, 
Milan, Italy) at the oral low dose of 250 to 750 mg twice a day starting on day 1 
postoperatively according to total blood leukocyte count.
Postoperative monitoring
After kidney transplantation all patients were managed according to the standard 
protocol in use at our center. Serum creatinine levels, electrolytes, blood cell counts and 
other routine laboratory tests were monitored daily during hospital stay and up to 15 
days after discharge. These parameters were then evaluated twice a week up to 1 month 
post transplant; then every one or two weeks up to 3 months post surgery and thereafter 
at monthly intervals. These evaluations were performed by the central laboratory of the
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Azienda Ospedaliera 0 0 .  RR. Bergamo, Bergamo, Italy. Glomerular filtration rate 
(GFR) as an index of graft function, was estimated at monthly intervals by Walser 
formula [178]. Trough levels of mycophenolic acid were performed every week in the 
first month post-surgery, every 2 weeks during month 2-4, and every month thereafter. 
Trough morning blood sirolimus levels were monitored every 4-5 days in the first 
month post surgery, every 2 weeks during month 2-4, and every month thereafter by 
high-performance liquid chromatography (HPLC). Similarly, trough blood CsA levels 
were measured daily during hospitalization and then every week up to the first month 
post-transplant, every 2 weeks during month 2-4, and every month thereafter. Direct 
measurement of GFR and renal plasma flow (RPF) was performed by the plasma 
clearance of iohexol and of p-aminohippurate (PAH), respectively, every 6 months post­
transplantation. At the same time intervals, the pharmacokinetic profile of SRL and CsA 
was also evaluated by high-performance liquid chromatography (HPLC). Trough levels 
of immunosuppressive drug and GFR and RPF were evaluated at the Clinical Research 
Center Villa Camozzi, Ranica (BG), Italy.
CMV antigenemia was monitored serially [179] and intravenous gancyclovir was 
administered when positive peripheral blood leukocyte count was > 20 cells/mm3, and 
continued for at least 1 week after the count had decreased to 0 cells/mm3. In CMV 
antibody negative recipients of graft from CMV antibody positive donors, intravenous 
gancyclovir was started on day 4 post-transplant regardless of CMV antigenemia and 
continued for 14 days. All patients were given standard anti-microbial prophylaxis, 
including trimethoprim-sulfamethoxazole or inhaled pentamidine (monthly) against 
Pneumocystis carinii for 6 months post-transplant.
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At 2 years after transplantation, the two groups of patients underwent per-protocol graft 
biopsy unless medically contraindicated or if the patient refused consent. Rejection 
episodes were, diagnosed on the basis of clinical judgement by the following criteria: 
25% increase in serum creatinine concentration over the previous evaluation in the 
presence of expected drug blood/plasma trough levels, associated with renal ultrasound 
findings excluding urinary tract obstruction or other surgical complications. If clinical 
and/or laboratory signs indicated the occurrence of a rejection episode, renal biopsy was 
performed, unless medically contraindicated. If acute graft rejection was diagnosed, 
methylpredmsolone i.v. pulses were administered. With positive response to treatment, 
the patients remained on the study, but oral steroid was resumed up to a maintenance 
daily dose of 8 mg. If graft rejection was steroid-resistant or a second acute rejection 
episode did occur, the patients were withdrawn from the study and treated with other 
more conventional immunosuppressive regimens.
Graft loss was determined as the time of re-establishment of long-term dialysis therapy 
or death. Delayed graft function was defined as the requirement of at least one dialysis 
session during the first 7 days after transplantation. All patients were followed after 
renal transplant for the incidence of acute rejection, graft loss, graft function, adverse 
events that required treatment or hospitalization, death, and drug blood levels.
Graft function measurement
Serum creatinine concentration was measured using a standard laboratory technique 
(Synchron CX9 ALX Pro, Beckman-Coulter, Milan, Italy).
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Determination o f glomerular filtration rate (GFR) and renal plasma flow (RPF) by 
plasma clearance of iohexol andpara-aminohippuric acid
Plasma concentrations of iohexol and PAH were determined by high performance liquid
chromatography (HPLC) as previously reported [180] with minor modification. Plasma
samples were added 50 pi of 1 ,3 -d im eth y lu ric  acid (200 pg/ml in phosphate buffer, pH
7.4) and deproteinized by adding 750 pi 5% perchloric acid and centrifuging. Twenty
microliters of the supernatant was chromatographed using a System Karat HPLC
equipped with variable wavelength detector (Beckman, Fullerton, CA, USA) and a 250
x 4 mm column packed with Lichrosorb C-18 (Merck, Darmstadt, Germany). Iohexol
and PAH are eluted by a mixture of deionized water/acetonitrile (96:4 by volume,
adjusted to pH 2.5 with phosphoric acid), pumped at a rate of 1.5 ml/min. Internal,
calibration curves of iohexol and PAH are prepared for each set of samples.
The iohexol plasma profile determined for each patient is analyzed by a one-
compartment open model system. All data were fitted by a non-linear regression
2
iterative pharmacokinetic program (data are weighted by 1/y , where y is the observed
value) on a personal computer. The clearance of iohexol was determined using the 
measurements from the timed period 120 minutes after the injection to the last sampling
point, according to a one-compartment model (CLj) by the formula:
CLi= Dose/AUC
(where AUC is the area under the plasma concentration-time curve) and then the value 
was corrected according to Brochner-Mortensen [181], in order to estimate GFR 
(plasma clearance) by using the formula:
CL= 0.990778 x CL] - 0.001218 x CL!2.
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2
GFR value was then normalized by the body surface area (GFR/ 1.73 m ).
PAH clearance was calculated according to the formula:
RPF=Ro/CSSP AH
where Ro is the infusion rate; CSSPAH is the PAH plasma concentration at the steady 
state (i.e. mean of PAH plasma concentrations measured at 150, 160, 170, 180 minutes 
from iohexol injection)
Renal plasma flow, estimated by plasma clearance of PAH, was then normalized by
2
body surface area, and expressed as ml/min/1.73 m .
The plasma profiles were analyzed by one-compartment open model system, and 
calculated clearance of iohexol corrected according to the Brochner-Mortensen formula 
[181]. With the same HPLC analytical run, the plasma concentration of PAH was also 
measured. GFR and RPF values were expressed per 1.73 m of body surface area. 
Further details about the procedure are described in Appendix A.
Phenotypic and functional analyses of peripheral lymphocytes 
Peripheral leukocyte count and lymphocyte phenotype
Peripheral blood cells were monitored serially by flow cytometry. The absolute count of 
each leukocyte population was determined using a single platform method. Twenty pi 
of MultiTEST four-color antibodies (BD Bioscience, San Jose, CA) and 50 pi of 
peripheral blood on K3EDTA were added to bead-containing TruCount tubes. The 
following MultiTest antibodies were used: CD3/CD4/CD8/CD45 and
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CD19/CD16+56/CD3/CD45 (BD Bioscience) to determine the percentages and absolute 
counts of total T (CD3+) CD4+ (CD3+CD4+), CD8+ (CD3+CD8+), natural killer (NK) 
(CD3~CD16+CD56+), and B (CD3“CD19+) lymphocytes. Four hundred and fifty pi of 
FACS Lysing Solution was added and tubes were incubated for 20 minutes at room 
temperature. Samples were analysed using FACSCalibur cytometer and CELLQUEST 
software (BD Bioscience).
T lymphocyte subset immunophenotyping
For T lymphocyte subset immunophenotyping, frozen peripheral blood mononuclear 
cells (PBMC) obtained by Ficoll-Paque gradient centrifugation were used; PBMC were 
incubated with 20 pi of different fluorochrome conjugated murine monoclonal 
antibodies against human CD3, CD4, CD8, CD25, CD28, CD69, CD45RO antigens 
(BD Bioscience). In selected experiments labelling for CD3, CD4, CD25 and Ki-67 (BD 
Bioscience), a nuclear cell proliferation-associated antigen expressed in all active stages 
of the cells cycle, was performed. Thereafter, 200-300 pi of 1% paraformaldehyde was 
added to the cells, which were acquired immediately or stored at 4 °C in the dark for 
acquisition within 24 hours.
The labelling procedures were carried over as BD Bioscience technical data sheets. The 
samples were analyzed by four colour FACScan flow cytometer using the 
CELLQUEST Software (BD Bioscience). For each marker, blank samples with isotype 
matched control antibodies were analyzed.
FOXP3 expression
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After gating for the CD3+ cell population, CD4', CD4+CD25’, CD4+CD25low, 
CD4+CD25hlgh, CD8+CD28' T cells were isolated by cell sorting (FACSAria, BD). The 
purity of sorted cells was >99%. Total RNA was extracted from either PBMC or FACS 
sorted cells by PicoPure RNA isolation kit (Arcturus, Mountain View, CA, USA). Total 
RNA was reverse transcribed to cDNA using Superscript II Reverse Transcriptase 
(Invitrogen, Carlsbad, CA, USA). Quantitative real-time PCR was performed on a 
TaqMan ABI Prism 5700 Sequence Detection System (Applied Biosystems, Foster 
City, CA, USA) with SYBR Green PCR Core reagents. PCR reactions were performed 
in triplicate, with 1 pi c-DNA and SYBR Green PCR Core reagents in a final volume of 
25 pi. Primers were designed with Primer Express 2.0 Software (Applied Biosystems) 
and purchased from Sigma-Aldrich. To amplify human FOXP3 transcript the following 
primers were used, based on Genbank sequence AF277993: for (300nM) 5'-AGC CAT 
GGA AAC AGC ACA TTC -3'; rev (300nM) 5'- GAG CGT GGC GTA GGT GAA A- 
3'. Beta 2-microglobulin served as a housekeeping gene to assess the overall cDNA 
content. Beta 2-microglobulin primers were as follows: for (300nM) 5'-AAG TGG GAT 
CGA GAC ATG TAA GC -3'; rev (300nM) 5’-TCA TCC AAT CCA AAT GCG G - 3\ 
After an initial holding step of 2 minutes at 50°C and 10 minutes at 95°C, samples were 
cycled 40 times at 95°C for 15 seconds and 60°C for 60 seconds. Melting curve analysis 
showed a single dissociation pick either for FOXP3 or beta 2-microglobulin PCR 
products, confirming the specificity of the reactions. No amplification was found in 
control reactions without c-DNA.
Similar amplification efficiencies were demonstrated for both the target and the 
housekeeping gene by analyzing serial cDNA dilutions, showing an absolute value of 
the slope of log input cDNA amount versus A threshold cycle (Ct) (Ct target- Ct
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housekeeping gene) of <0.1. Then the AACt equation was used to compare the FOXP3 
gene expression in each sample with the expression in CD3+CD4+ cells from a pool of 
healthy subjects taken as reference (calibrator). Results were expressed as arbitrary units 
(AU) taking the expression in the calibrator as 1.
Measurement of lymphocyte alloreactivity
Peripheral blood mononuclear cell (PBMC) and spleen cell sampling
Either recipient or living donor PBMCs were isolated from heparin-treated blood. The 
blood was diluted with an equal volume of balanced salt solution and layered carefully 
over Ficoll-Paque PLUS (Pharmacia, Uppsala, Sweden) in a centrifuge tube. After 
centrifugation at room temperature (2400 rpm for 20 min, without brake), the following 
layers will be visible in the column, from top to bottom: plasma and other constituents, 
PBMC, Ficoll-Paque, and erythrocytes and granulocytes which should be present in 
pellet form. This separation allows easy harvest of PBMC using a sterile transfer pipet. 
The cells were then washed with Phosphate Buffer Saline solution (PBS) to remove the 
platelets and centrifuged (1800 rpm for 8 min). PBMC were thereafter resuspended in 
complete RPMI supplemented with L-glutamine and penicillin/streptomycin and 20 % 
heat inactivated pooled human serum type AB (Sigma, St Lous, MO). The cells were 
counted using a hemocytometer, then aliquoted and frozen in the presence of 10% 
DMSO. Subsequently, PBMC were placed in liquid nitrogen vapor.
Deceased donor spleens were cut into small fragments and filtered through a stainless 
steel screen to obtain a total spleen cell suspension. Cell suspension was then filtered 
through a 40 pm cell filter. For erythrocyte lysis, cells were treated with ACK (0.15 M 
NH4CI, lOmM KHCO3, 0.1 mM EDTA, pH 7.4) on ice for 8 minutes, then washed whit
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PBS. Splenocytes were thereafter resuspended in complete RPMI supplemented with L- 
glutamine and penicillin/streptomycin and 20 % heat inactivated pooled human serum 
type AB. The cells were counted using hemocytometer, then aliquoted and frozen in the 
presence of 10% DMSO. Subsequently, splenocytes were placed in liquid nitrogen 
vapor.
Before using in MLR and ELISPOT experiments, spleen cells were depleted of CD2+ 
cells by immunomagnetic cell isolation using Dynabeads CD2 kit (Dynal Biotech, Oslo, 
Norway).
Cryopreservation o f PBMC and splenocytes
Freshly isolated PBMC and splenocytes were resuspended at 1 x 107 viable cells/ml in 
RPMI + 20% serum AB. In each 1.5 ml cryovial were placed 750 pi of this suspension 
and then were added drop by drop other 750 pi of a solution with RPMI + 20% serum 
AB + 20% DMSO.
Cryovials were placed in a Mr. Frosty-style freezing container that has been filled with 
100% isopropanol according to the manufacturer’s instructions. The freezing container 
was thereafter put at -80°C overnight and then cryovials were transferred into liquid 
nitrogen vapor.
Thawing of PBMC and splenocytes
Cryovials were transferred from liquid nitrogen vapor to a 37°C water bath. Then, 
suspension was diluted into warm media and centrifuged at 1800 rpm for 8 minutes. 
The supernatant was decanted, and the tube was gently flicked with a finger to break up 
the pellet. Then, cell were resuspended in 3-5 ml of RPMI + 20% human serum. Cell
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number and viability by Trypan blue staining were assessed thereafter.
Mixed lymphocyte reaction (MLR)
For MLR, lxlO5 recipient PBMC (in 100 pL) were added in triplicate wells in a round- 
bottomed 96-well plate. Irradiated (4000 RAD) stimulator cells (100,000) isolated from 
the donors (either PBMC from living donors or CD2-depleted spleen cells from 
cadaveric donors), from third-party subjects (either PBMC or CD2-depleted spleen 
cells) or from the recipient (PBMC, self control combination) were added to the wells. 
Third-party controls were chosen, to the extent possible, so that the number of 
mismatches for HLA was the same as that between the donor and recipient. Aliquots of 
responder PBMC were also incubated with medium alone (negative controls). The 
plates were then incubated for 6 days at 37°C, 5% CO2 and were pulsed with 1 pCi [3H] 
thymidine during the last 16 h. Thereafter, cells were harvested using an automated 
harvester. [3H] thymidine incorporation by T cells was used as a parameter of cell 
proliferation and measured by a beta-counter. The mean counts per minute (cpm) were 
determined and the stimulation index (SI) was calculated by the ratio of the cpm 
obtained in the presence of allogeneic combinations (donor or third party) to the cpm in 
the control wells (self combination).
Enzyme-linked immunosorbent spot (ELISPOT) assays
ELISPOT assays were performed using BD ELISPOT Human IFNy reagents. 
Responder PBMCs from the recipient were placed in 96-well ELISPOT plates 
(Millipore, Billerica, MA) pre-coated with capture anti-IFN-y at the concentration of 
300,000 per well. Irradiated (4000 RAD) stimulator cells (300,000) from the donors
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(either PBMC from living donors or CD2-depleted spleen cells from cadaver donors), 
from third-party subjects (either PBMC or CD2-depleted spleen cells) or from the 
recipient (PBMC, self control combination) were added to the wells and the plates were 
incubated overnight at 37°C, 5% CO2. Aliquots of responder PBMC were also 
incubated with medium alone (negative controls) or in the presence of 10 pg/mL 
phytohemagglutinin (PHA, positive controls). Each combination was run in triplicate 
wells. The assays were then carried out according to the manufacturer’s instructions. 
The resulting spots were counted on a computer-assisted Immunospot image analyzer 
(Aelvis Elispot Scanner system). Results are the mean value of IFN-y spots/300,000 
recipient PBMC stimulated with donor or third party cells after subtracting IFN- y spots 
in negative controls (usually 2 or less).
Renal transplant per-protocol biopsy 
Renal biopsy procedure
Patients were admitted to our Transplant Center the day before the procedure. Those on 
antiplatelet or anticoagulant therapy were asked to interrupt this therapy one week 
before the day planned for the procedure. Coagulation profiles and platelet counts were 
evaluated at the admittance and those patients showing abnormalities did not undergo 
the biopsy. Also patients with bleeding time higher than 10 minutes did not underwent 
the procedure. All patients were informed about the potential risks of the procedure and 
signed an informed consent approved by the Ethical Committee of our Hospital.
The biopsies were all performed by the staff radiologists with automated biopsy gun 
under sonographic guide. The Biopty gun, a sterilized spring-loaded instrument, was 
fitted with an 18-gauge needle, and the tip of the needle was placed just inside the renal
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capsule of the lower pole of the transplanted kidney. Real-time sonographic guidance 
was used to determine placement. The needle excursion of 2.3 cm after firing was taken 
into account during needle positioning. After the biopsy, the tissue cylinder was 
inspected under the reflected light microscope. The biopsy was repeated if this check 
failed to reveal glomeruli in the tissue cylinder. Generally, a single biopsy was enough.
Kidney biopsy processing
The kidney samples of patients were left in Dubosq-Brazil fixative for four hours. After 
the fixation step, the samples were dehydrated in growing concentrations of ethanol (50, 
70, 90, 100 % for five minutes each). Then, after one hour in toluene, the samples were 
collected into the small stainless steel base molds (Electron Microscopy Sciences, 
Rome, Italy), completely immersed into the paraffin and left for two hours at 60 °C. At 
this temperature the paraffin is in the liquid state and it can infiltrate the tissue. After the 
two hours, the samples were embedded in paraffin using special plastic rings and left at 
room temperature to permit the solidification of the paraffin. Finally, the kidney, 
samples included into the blocks of paraffin were cut by microtome (LKB, Bromma, 
Historange Microtome) or stored at room temperature.
Staining protocol
Dubosq-Brazil fixed, paraffin embedded kidney sections (3 pm) were deparaffmized, 
rehydrated and incubated for 30 minutes with 0.3% H2O2 in methanol to quench 
endogenous peroxidase. Tissues were treated with proteinase-K (20 pg/ml, Sigma- 
Aldrich, Milan, Italy) for 10 minutes at 37°C, followed by microwave (twice for 5 min 
in citrate buffer 10 mM, pH 6 at operating frequency of 2450 MHz and 600-W power
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output) and citrate buffer (15 min) incubations for antigen retrieval. A polyclonal 
antibody against human C4d (C4dpAb, Biomedica, Vienna, Austria) was diluted 1:50 
and added overnight at 4°C. Subsequent steps included incubations with the secondary 
antibody (biotinylated goat anti-rabbit IgG, Vector Laboratories), avidin-biotin 
peroxidase complex (ABC) solution, and finally the development with 
diaminobenzidine. The sections were then counterstained with Harris hematoxylin 
(Biooptica, Milan, Italy). A set of biopsies comprising samples from each patient group 
was processed and developed simultaneously. Negative controls were obtained by 
omitting the primary antibody on a second section present on all the slides.
Histology injury scoring
Chronic allograft injury was diagnosed where diffuse tubular atrophy or diffuse 
interstitial fibrosis were documented alone or in association with interstitial 
inflammation, arteriosclerotic lesions, or glomerulopathy [34, 182, 183].
Semiquantitative analysis of changes was performed according to chronic allograft 
damage index (CADI) [184], by an investigator who was blinded to the clinical status of 
the patients. The CADI score is the sum score of six histology parameters, including (a) 
interstitial inflammation and (b) fibrosis, (c) tubular atrophy, (d) mesangial matrix 
increase and (e) sclerosis of the glomeruli, and (f) intimal proliferation of the blood 
vessels. Each individual parameter was scored from 0 to 3. Evaluation and scoring of 
C4d expression was also done. The signal intensity at glomerular and tubulo-interstitial 
level was graded on a scale of 0 to 3 (0, no staining; 1, weak staining; 2, staining of 
moderate intensity; 3, strong staining).
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For quantification of histology changes in each biopsy, at least three stained slides were 
used: one with hematoxylin-eosin, one with Masson’s trichrome, and one with periodic 
acid-Schiff staining.
Monitoring of immunosuppressive drug levels 
Mycophenolate mofetil
Trough levels of mycophenolic acid were assayed every week in the first month post­
surgery, every 2 weeks during month 2-4, and every month thereafter.
Total and free MPA plasma concentrations were measured by HPLC, introducing some 
modifications to already published methods [185]. MPAG was estimated as MPA after 
hydrolysis mediated by p-glucuronidase.
Sirolimus
Sirolimus levels were monitored every 4-5 days in the first month post surgery, every 2 
weeks during month 2-4, and every month thereafter by high-performance liquid 
chromatography (HPLC). For the preparation of in-house QCs and calibration 
standards, different pools of whole blood samples from 15 healthy volunteers was used. 
In addition, subsequent to signing of an informed consent form, EDTA anticoagulated 
whole blood samples were obtained from 30 kidney, heart and liver transplant recipients 
not given SRL.
Standard samples of SRL (purity ranging from 97 to 98%, according to different 
batches) and 32-O-desmethoxyrapamycin (internal standard, IS) were generous gifts 
from Wyeth-Ayerst Research Laboratories (Princeton, NJ) and furnished with adequate 
information on drug source, lot number, expiration date and certificate of analysis.
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Cyclosporine
Trough blood CsA levels were measured daily during hospitalization and then every 
weeks up to the first month post-transplant, every 2 weeks during month 2-4, and every 
month thereafter. CsA was measured by HPLC with UV detection, using the method 
from Kahn et al [186], with some modifications, as described in the “Solution and 
Instruments” section.
Sample size and statistical analyses 
Sample size
This is mainly an immunological, clinical research project, so no assumption was made 
on the power of our present study to detect differences in PBMC phenotypic and 
functional characteristics and in clinical outcome variables between the two groups of 
transplant patients who received, after Campath-IH induction, maintenance therapy 
with either low-dose SRL or CsA both combined with low-dose MMF. The rationale for 
this approach was that this was a pilot, explorative study and that outcome data might 
have provided the background for designing future adequately powered trials to 
definitely assess the role of different immunosuppressive strategies on the number and 
in vitro function of Treg and the impact of these cells on clinical outcomes of kidney 
transplant patients.
Statistical analyses
Baseline characteristics of patients were compared by % test or by t test as appropriate. 
SRL and CsA groups were compared for factors that might affect the outcome, 
including recipient gender, age at transplant, cold ischemia time, DGF and the degree of
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Human Leukocyte Antigen (HLA) mismatch. Biopsy data were analyzed by the 
nonparametric Kruskal-Wallis test for multiple comparisons.
Clinical and biochemical parameters at different time points post transplantation were 
compared by means of analysis of covariance (ANCOVA) including the corresponding 
value at 6 months in the model. Patient and graft survival were compared by the log 
rank test. The GFR and RPF slopes were calculated on the basis of values measured at 
6, 12, and 18 months after transplant. The statistical significance level was defined as p 
<0.05. Calculations were performed using SAS v.9 and MedCalc (Gent, Belgium) 
software.
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SOLUTIONS AND INSTRUMENTS
PBMC isolation and storage 
Ficoll
Ficoll-Paque™ PLUS is a sterile, ready to use density gradient medium for purifying 
lymphocytes in high yield and purity from small or large volumes of human peripheral 
blood, using a simple and rapid centrifugation procedure.
Ficoll-Paque PLUS is an aqueous solution of density 1.077 + 0.001 g/ml containing 5.7 
g Ficoll 400 and 9 g sodium diatrizoate with 0.0231 g calcium disodium 
ethylenediamintetraacetic acid in every 100 ml. Ficoll 400 is a synthetic high molecular 
weight (Mw 400 000) polymer of sucrose and epichlorohydrin which is readily soluble 
in water. The molecules of Ficoll 400 are highly branched, approximately spherical and 
compactly coiled with a Stokes’ radius of a about 10 nm. Ficoll 400 has a low intrinsic 
viscosity (17 ml/g) compared with linear polysaccharides of the same molecular weight 
(cf. dextran Mw 400 000: /h/ 49 ml/g) and solutions of Ficoll 400 have low osmotic 
pressures.
Phosphate buffered saline (PBS)
Phosphate buffer saline (PBS) is a buffer solution containing sodium chloride, sodium 
phosphate and potassium phosphate that helps to maintain a constant pH. It is isotonic 
and non-toxic to cells. We started from a 10X Concentrate without Ca and Mg (GIBCO) 
that, when diluted to a IX concentration, yielded a phosphate buffered saline solution 
with a phosphate buffer concentration of 0.01 M and a sodium chloride concentration of 
0.154 M. The solution pH was 7.4.
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RPMI medium
RPMI medium with L-glutamine (Sigma-Aldricht) plus 20% human serum was used as 
cell medium.
Human serum
For PBMC and splenocyte cultures, human serum (Sigma Aldricht) from a pool of AB 
males was used instead of fetal calf serum to minimize the potential ractivity of the 
cells. Serum was obtained by a pool of healthy donors. Each donor was tested for and 
found non-reactive for Hepatitis B& C and non-reactive for Human Immunodeficiency 
Virus (HIV) antibody by ELISA. Serum was added at a 20% concentration into RPMI 
solution. Before use, the complement serum was inactivated by heating for 56°C for 30 
minutes.
Dynabeads CD2 kit
The Dynabeads CD2 kit (Dynal Biotech, Oslo, Norway) is intended for magnetic 
isolation or depletion of CD2+ cells. Dynabeads are mixed with the sample in a tube. 
The Dynabeads will bind to the target cells during a short incubation, and then the bead- 
bound cells are separated by a magnet. Dynabeads CD2 are provided in phosphate 
buffer saline (PBS), pH 7.4, containing 0.1% bovine serum (BSA) and 0.02% sodium
o
azide. Dynabead concentration is 4 x 10 /ml.
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Dimethyl sulfoxide (DMSO)
DMSO is a solvent used as a cryoprotectant. Added to cell media, it prevents the cells 
dying as they are frozen. Cells were suspended in standard media plus serum and 10% 
DMSO, put in a Freezing container to -80°C and then, 24 hours later, placed into liquid 
nitrogen vapor.
5100 Cryo 1°C Freezing Container, "Mr. Frosty ”
This device provides the critical, repeatable -l°C/minute cooling rate required for 
successful cell cryopreservation and recovery. It requires 100% isopropyl alcohol and 
mechanical freezer. Cells were frozen with this freezing container to -80°C and then 
were placed into liquid nitrogen vapor.
PBMC phenotyping 
TruCount Tubes
Each TruCOUNTTube contains a lyophilized pellet that dissolves during sample 
preparation, releasing a known number of counts of lymphocyte subsets. By gating the 
bead population during analysis, it is possible to calculate subset absolute counts.
FACS Lysing Solution
FACS Lysing Solution (Becton Dickinson), 10X concentrate, is provided as 100 mL of 
a proprietary buffered solution containing <15% formaldehyde and <50% diethylene 
glycol. Before use, the solution is diluted 1:10 with deionized water. The prepared 
solution is stable for 1 month when stored at room temperature.
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Monoclonal antibodies
Murine monoclonal antibodies against human antigens were used. For leukocyte subset 
counting the Multitest antibodies (BD Bioscience) CD3/CD4/CD8/CD45 and 
CD 19/CD 16+56/CD3/CD45 were used. The following florochromes were used for 
different T cell subset antigens: CD3 PerCP, CD4 FITC (or APC-Cy7, according to the 
different combinations of the other antibodies), CD8 PE (or APC-Cy7), CD25 PE, 
CD28PE, CD69 FITC, CD45RO PE, Ki-67 FITC (used after cell permeabilization). 
Isotype mouse IgGi,1c (FITC, APC-Cy7, PerCP, or PE) and IgG2aPE were used as 
controls.
All the antibodies were purchased from BD Bioscience.
BD FACS Aria
The BD FACSAria flow cytometer is an automated multicolor flow cytometry system 
that performs both cell phenotype analysis and sorting.
BD CellQuest software
BD CellQuest software allows to acquire and analyze data from flow cytometer on a 
Macintosh® computer. Working in the CellQuest Experiment window, it is possible to 
create several types of plots, including multicolor contour plots and overlaid histograms, 
and generate statistics for dot plots, histograms, density plots, and contour plots. We 
used this software both for analyzing data on the phenotypic profile of PBMC and to 
sort them.
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FOXP3 expression 
PicoPure RNA isolation kit
The PicoPure RNA Isolation Kit (Arcturus, Mountain View, CA, USA) was developed 
to efficiently isolate total RNA from a small number of cells. The isolation protocol 
consists of extracting cellular RNA, then loading the extract onto the MiraCol™ 
Purification Column to bind the RNA. After washing away impurities, the RNA elutes 
in only 10 pi of buffer, ready for use.
Total Reagents and Supplies in kit:
- Conditioning Buffer
- Extraction Buffer
- 70% Ethanol
- Wash Buffer
- RNA purification columns with collection tubes
- Microcentrifuge tubes
Superscript II Reverse Transcriptase
Superscript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) is an engineered 
version of M-MLV RT with reduced RNase H activity and increased thermal stability. 
The enzyme is purified to near homogeneity from E. coli containing the modified pol 
gene of Moloney Murine Leukemia Virus. The enzyme can be used to synthesize first- 
strand cDNA at higher temperatures than conventional M-MLV RT, providing 
increased specificity, higher yields of cDNA, and more full-length product. It can 
generate cDNA up to 12.3 kb.
Components of the kit:
80
- Superscript™ II RT
- 5X First-Strand Buffer (250 mM Tris-HCl, pH 8.3 at room temperature, 375 mM
KC1; 15 mM MgCl2)
- 0.1 MDTT
SYBR® Green PCR Core Reagents kit
Includes AmpliTaq Gold® DNA Polymerase, AmpErase® UNG, dNTP Mix with 
dUTP, SYBR® Green PCR Buffer and mM MgC12 Solution to perform real time PCR 
analysis. Direct detection of PCR product is monitored by measuring the increase in 
fluorescence caused by the binding of SYBR Green dye to double-stranded (ds) DNA.
TaqMan ABI Prism 5700 Sequence Detection System
TaqMan ABI Prism 5700 Sequence Detection System (Applied Biosystems, Foster 
City, CA, USA) is a real-time PCR machine which enables detection and quantification 
of PCR products in real-time using either SYBR green reagents or Taqman probes. It is 
possible to monitor PCR reactions cycle by cycle enabling quantification and rapid 
analysis of many different targets.
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PBMC functional assays
MLR
Tritiated thymidine
One jiCi titriated thymidine (Amersham) was added to the MLR cultures 16 h before 
harvesting. It was used under the standard safety rules for work with radioactive 
compounds.
ELISPOT
ELISPOT kit
The enzyme-linked immunospot (ELISPOT) assay is a powerful tool for detecting and 
enumerating individual cells that secrete a particular protein in vitro. Based on the 
sandwich enzyme-linked immunosorbent assay (ELISA), the ELISPOT assay derives its 
specificity and sensitivity by employing high affinity capture and detection antibodies 
and enzyme-amplification. The sensitivity of the assay lends itself to measurement of 
even very low frequencies of analyte-producing cells (eg, 1/300,000).
The ELISPOT kit (BD) included:
- 2 Pre-coated ELISPOT plates
- Biotinylated Detection Antibody
- Enzyme Conjugate (Streptavidin-HRP)
- Assay Diluent
- Wash Concentrate (20x)
- P B S ( l O x )
- AECSubstrate Buffer
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- AECChromogen
Aelvis Elispot Scanner system
The A.EL.VIS (Automated ELispot Video-analysis System) ELISPOT analyser is an 
automated instrument for the analysis of ELSPOT data. When scanning a 96 well 
membrane or foil the plate image is transferred to the connected PC using intelligent 
image analysis algorithms to separate the single wells. The extracted well images are 
individually stored and subsequently analysed by EliAnalyse software. The software is 
theoretically divided in two parts. Firstly the acquisition mode enables definition of data 
storage, secondly the analysis mode.
Processing of biopsy samples 
Fixative for light microscopy
The fixative used for light microscopy, Dubosq-Brazil, was prepared adding 150 ml of 
ethanol at 80 % (diluted in water) to 60 ml of formaldehyde at 40 % (commercially 
available at this percentage by Carlo Erba Reagenti) and to 15 ml of acetic acid glacial 
(Carlo Erba Reagenti). Finally, 1 g of picric acid (Carlo Erba Reagenti, Milan, Italy) 
was added to the solution.
Solutions for Hematoxylin-eosin staining
Haematoxylin:
- Haematoxylin 6.0 g
- Alluminium Sulphate 4.2 g
- Citric Acid 1.4 g
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Sodium Iodate 0.6 g
- Ethylene Glycol 269 ml
- Distilled Water 680ml 
Eosin:
- Eosin Yellowish 1.0 g 
Distilled Water 100 ml
Scott's tap water:
In a beaker containing 1L distilled water, 20g sodium bicarbonate and 3.5g 
magnesium sulphate were added and mixed thoroughly to dissolve the salts. 
Using a filter funnel, the solution was transferred into a labelled bottle.
Solutions for Masson’s trichrome staining
Bourn’s Solution:
- Picric Acid, saturated aqueous solution 75.0 ml
- Formaldehyde, 37-40% 25.0 ml
- Glacial acetic acid 5.0 ml 
Weigert’s Iron Hematoxylin:
Solution A
- Hematoxylin 10.0 g
- Alcohol, 95% 1,000.0 ml 
Solution B
- Ferric chloride, 29% aqueous solution 20.0 ml
- Distilled water 475.0 ml
- Glacial acetic acid 5.0 ml
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Working Solution
- A mix of equal parts of solutions A and B 
Biebrich Scarlet-Acid Fuchsin Solution
- Biebrich scarlet, 1% aqueous solution 360.0 ml
- Acid fuchsin, 1% aqueous solution 40.0 ml
- Glacial acetic acid 4.0 ml 
Phosphomolybdic-Phosphotungstic Acid Solution
- Phosphomolybdic acid 25.0 g
- Phosphotungstic acid 25.0 g
- Distilled water 2,000.0 ml 
Aniline Blue Solution
- Aniline Blue 25.0 g
- Glacial acetic acid 20.0 ml 
1% Acetic Acid Solution
- Glacial acetic acid 1.0 ml
- Distilled water 99.0 ml
Solutions for periodic acid-Schiff staining
0.5% Periodic Acid Solution:
Periodic acid 0.5 g 
Distilled water 100 ml 
Schiff Reagent
Mayer’s Hematoxylin Solution
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Monitoring of immunosuppressive drug levels 
Mycophenolic acid (MPA)
Human plasma, chemicals and materials
Calibration standards and QCs were prepared using pools of plasma samples from 15 
healthy volunteers and from 20 kidney and liver transplant recipients not given MMF or 
EC-MPS (used to test potential concomitant medications).
Standards of MPA and MPAG were initially donated by Roche Pharmaceuticals (Palo 
Alto, CA). After 2002, MPA was bought from Sigma (St Louis, MO), together with p- 
toluic acid (PTA, used as internal standard). All the batches of MPA have a purity > 
98% and were provided with the certificate of analysis. Acetonitrile, methanol were 
HPLC grade and were purchased by BDH (UK), all other chemicals were from Sigma. 
HPLC quality deionized water was prepared using Milli Q50 (Millipore, Bedford, MA). 
Bond-Elut C l8, 200 mg, 3 ml cartridges were obtained from Varian (Leini, Italy).
Stock solutions, calibrators, and quality control standards
Stock solutions, containing 10, 100 mg/L of MPA and 50 mg/L PTA were prepared in 
methanol and stored at 4°C until use. Aliquots of the stock MPA solutions were diluted 
with drug free plasma to give 6 calibrators (0.1, 1, 5, 10, 20 and 40 MPA mg/L). Two 
in-house QCs were prepared in drug-free plasma with a final concentration of 2 and 20 
mg/L MPA. Calibrators and QCs were stored at -20°C until use.
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Sample preparation
Over 95% of MPA is bound to albumin, whereas only a limited amount of the drug is 
distributed within blood cells [187]. Therefore, plasma is the matrix of choice for the 
assessment of MPA levels in the blood.
Five hundred microliters of plasma was mixed with 1.5 mL of water, 50 pL of internal 
standard and 750 pL of 0.1 N HC1. The mixture was applied to a C l8 solid phase 
extraction column pre-conditioned with 2 mL of methanol followed by 2 mL of water. 
The column was dried and then eluted with 1 mL of methanol/0.1 N acetate buffer 
(80:20 v/v) pH 4. Samples were collected in HPLC vials.
HPLC apparatus and conditions
A System Gold HPLC equipped with a model 166 UV detector set at 254 nm and a 
model 507 autosampler (Beckman, Fullerton, CA) were used. The autosampler was kept 
at room temperature, and a 50 pL aliquot sample was injected. The separation was 
carried out at room temperature using a C l8 column, 250 x 4.6 mm, 5 pm (Hypersil 
BDS, Hewelett Packard, Ge). A guard column (LiChrosper 100 RP-18, 5 pm) was 
placed just before the column. The mobile phase for elution of the column was 45% 
acetonitrile and 55% aqueous phosphoric acid (0.05%), at flow rate of 0.8 mL/min. Data 
were collected and processed using a 32 Karact software for HPLC system (Beckman, 
Fullerton, CA).
Assay validation
Method performance was determined in accordance with the FDA Guidance for 
Bioanalytical Methods Validation for Human Studies.
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Sirolimus
Stock solutions, calibrators and quality control standards
Stock solutions containing 50 and 100 pg/mL were appropriately prepared in methanol 
for SRL and IS, respectively. SRL working solutions of 100, 500, and 2000 ng/mL were 
prepared in 50/50 methanol/water, and for IS a working solution of 1000 ng/mL was 
prepared in methanol. All the solutions were stored at -20 °C.
Taking into account the therapeutic range of SRL trough levels, calibrator samples were 
prepared mixing appropriate volumes of SRL from stock working solutions to EDTA 
anticoagulated human whole blood from healthy volunteers to achieve different 
concentrations from 2.5 to 60 ng/mL (2.5, 5, 10, 15, 20, 40, and 60 ng/mL). Calibrators 
were prepared by diluting each spiking solution to 10 ml with K3EDTA control human 
whole blood in 10 ml volumetric flasks. The flasks were stopper and shaken to mix. 
Pools are measured into 1 mL aliquots in polypropylene tubes and frozen at -20°C until 
use. Three in-house QCs, representing the low, medium and high concentrations, were 
prepared in drug-free whole blood with a final concentration of 3, 10 and 30 ng/mL 
SRL. Calibration, QCs and reference standards were aliquoted and stored at -20°C until 
use.
Sample preparation
SRL is extensively distributed in red blood cells, independently of concentration and 
temperature [188], so we decided to use whole blood as the preferred matrix for method 
validation.
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One millilitre volume of whole blood sample was pipetted into disposable 
polypropylene tubes and supplemented with 50 pL of IS solution (1000 ng/mL). The 
tubes were vortex-mixed for 40 seconds; 1.5 mL of zinc sulphate solution was first 
added followed by a 1.5 mL acetone. The tubes were vortex-mixed for a further 50-60 
seconds and centrifuged at 3000 g for 5 minutes at room temperature. The clear 
supernatant was poured into another polypropylene tube, diluted with 2 mL distilled 
water, mixed and loaded onto a Bond-Elut cartridge (preconditioned with 1 mL 
acetonitrile followed by 1 mL methanol and finally by 1 mL distilled water) placed on a 
Vac Elut 20 Manifold (Varian). The Bond-Elut cartridges were washed with 1.5 mL of 
70% methanol/30% water. In each step the solvent was allowed to drop out from the 
cartridge. Then 500 pL hexane was added and the column was allowed to go dry under 
vacuum. SRL and IS were eluted in polypropylene tubes with 1 mL acetonitrile. In all 
steps the flow rate did not exceed 1 mL/min. The eluate was taken to dryness either 
under a gentle nitrogen stream in a water bath at 37 °C or in a model RC 10.09 
centrifugal evaporator (Jouan, Saint-Herblain, France) and the residue was dissolved in 
0.15 mL of water-methanol-acetonitrile (40/30/30) and transferred in a polypropylene 
vial. Internal calibration curves for SRL were prepared for each set of samples. At least 
60 samples (including controls and calibration curve) can be extracted in 4 h and 
processed by HPLC in less than 20 h.
HPLC apparatus and conditions
A System Gold HPLC equipped with a model 166 UV detector set at 278 nm and a 
model 508 autosampler (Beckman, Fullerton, CA) with the sample tray kept at 4 °C, 
were used. A 90 pL aliquot of sample was injected onto reversed-phase C l8, 5 pm,
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guard column (Alltima, 7.5 x 4.6 mm, Alltech, Sedriano, Milan, Italy) connected to a 75 
x 4.6 mm column packed with Ultrasphere C8, 3 pm (Beckman) heated at 50 °C by a 
Model 880 oven (Spark-Holland, Emmen, The Netherlands) and was eluted by a 
mixture of distilled water/methanol/acetonitrile (34/30/36) pumped at a rate of 1 
ml/min. Due to the high percentage of the organic phase that may dry off, resulting in 
increased retention time, the mobile phase was prepared every one or two days before 
analysis, filtered and degassed under vacuum using a polycarbonate 0.4-pm membrane. 
An in-line filter (0.5 pm) was placed between the autosampler and the column. Data 
were collected and processed using a 32 Karat software (Beckman, Fullerton, CA).
Method Validation
Method performance was determined in accordance with the FDA Guidance for 
Bioanalytical Methods Validation for Human Studies, as described above.
For the Proficiency Test initially 78 blinded samples, packaged as 5 batches of samples 
each, were analyzed. In addition, ongoing proficiency was tested by analyzing 3 blinded 
samples from the Reference Laboratory every month.
Cyclosporine
Human whole blood, chemicals and materials
Calibration standards, QCs and blanks were prepared using pools of whole blood 
samples from healthy volunteers (n=15) and from kidney (n=10) and liver (n=10) 
transplant recipients not given CsA.
CsA and cyclosporine D (IS) were kindly supplied by Novartis Pharma (Basel, CH), 
with a declared purity of 100%. Methanol and acetonitrile (BDH, UK) were of HPLC
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grade. All other solvents were of analytical grade (Sigma, St Louis, MO). Deionized 
water was prepared using a Milli Q50 system (Millipore, Bedford, MA).
Stock solutions, calibrators and QCs
Stock solutions containing 100 mg/L of CsA and IS, as well as working solutions (10 
mg/L for CsA and 20 mg/L for IS) were prepared in methanol. For calibration of the 
analytical system appropriate volumes of CsA from stocked working solutions were 
added to 1 mL EDTA anticoagulated human whole blood to achieve 7 different CsA 
concentrations (20, 50, 100, 200, 500, 1000 and 2000 ng/mL). QCs were prepared 
spiking known volumes of CsA from working solutions to drug free whole blood in 
order to obtain three concentrations (30, 300, 900 ng/mL CsA). CsA solutions, 
calibrators and QCs were stored at -20°C.
Sample preparation
To one mL of peripheral vein blood samples we added IS (50 pL), hydrochloric acid
0.2N (1 mL), and heptane (1 mL). The mixture was vortexed for 10 sec to lyse the 
blood cells. Subsequently we added diethyl ether (8 mL) and each tube was tightly 
capped. Extraction of CsA was effected on a reciprocal shaker. The organic phase was 
clarified by centrifugation for 15 min at 3000 RPM. The ether layer was decanted into a 
clear glass tube and washed with sodium hydroxide 0.1 N (lmL). Following a second 
centrifugation for 10 min, the ether layer was transferred into a clean glass tube and 
evaporated to dryness under a gentle nitrogen stream in a water bath at 37°C. The 
residue was redissolved in 200 pL of the mobile phase and washed by vortexing for 30
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sec with heptane (1 mL). The sample was finally centrifuged (10 min at 3000 RPM) and 
the lower aqueous layer transferred in a polypropylene vial.
HPLC apparatus and conditions
A system Gold HPLC with a UV detector set at 214 nm and a model 580 autosampler 
(Beckman, Fullerton, CA) was used. A 50 pL of aqueous layer was injected into a C-8 
HPLC column (150 x 4.6 mm, 5 pm, Beckman) heated at 72°C by a LC oven 101 
(Perkin Helmer, Milan). Isocratic liquid chromatography separation was carried out 
using a mobile phase of water/methanol/acetonitrile (27/32/41) at a flow rate of 1 
mL/min. Data were collected and processed using a 32 Karact software (Beckman).
Method Validation
Method performance was determined in accordance with the FDA Guidance for 
Bioanalytical Methods Validation for Human Studies, as described above.
Since July 2003, this method is enrolled in the Cyclosporine international Proficiency 
Testing Scheme. Ongoing proficiency is tested by analyzing 3 blinded samples from the 
Reference Laboratory every month.
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RESULTS (I Part)
1. Phenotypic and functional profiles of peripheral blood mononuclear cells 
(PBMCs) in kidney transplant patients who received Campath-IH induction and 
low-dose SRL or low-dose CsA, both in addition to low-dose MMF in a steroid-free 
regimen.
Introduction
The best maintenance therapy to combine with Campath-IH induction is unknown and 
the immune regulatory mechanisms that allow prevention of acute rejection with lower 
than conventional doses of maintenance immunosuppression after Campath-IH 
induction are still unclear. Notably, different maintenance immunosuppressive regimens 
might differently affect phenotype and function of peripheral lymphocytes.
Thus, in the first part of the study, we aimed to define the phenotypic and functional 
profile of peripheral lymphocytes from kidney transplant patients given Campath-IH;; 
induction and low doses of SRL or CsA, both combined with low doses of 
mycophenolate mofetil as maintenance immunosuppression.
Specific aims
Specific aims of the first part of the project were:
i) To assess the depleting effect of a single 30 mg dose of campath-lH on 
peripheral leukocytes in kidney transplant recipients;
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ii) to study the impact of SRL and CsA, each combined with MMF on the
recovery of different leukocyte subsets in kidney transplant patients after 
Campath-IH induction;
iii) to evaluate whether the two immunosuppressive regimens differently
affected Treg number and function after Campath-IH induction;
iv) to measure T cells alloreactivity in kidney transplant patients who received
Campath-IH induction and maintenance immunosuppression with low-dose 
MMF and low-dose SRL or CsA;
v) to evaluate whether potentially reduced alloreactivity against donor antigens
depends on the presence of Treg or on anergy.
Results
Demographic and baseline clinical characteristics o f patients included in the study
Table 1 shows donors’ and recipients’ baseline characteristics, cold and warm ischemia 
time, and HLA -A, B and DR mismatches of patients included in the study and 
randomized to maintenance therapy with SRL or CsA therapy. All patients received 
kidney transplant from deceased donors, except for two of those on CsA whose donors 
were living-related. Donors’ age, weight, and gender distribution were very similar 
between the two groups. Cold ischemia time for grafts from deceased donors ranged 
from 14 to 18 hours, whereas warm ischemia time was around 30 minutes in both 
groups. Recipients’ age, weight, and gender distribution were similar as well between 
the two groups and between donors and recipients of the same randomization arm. The 
number of donor-recipient HLA mismatches was virtually identical between SRL 
(4.0±1.4) and CsA patients (4.0±1.2), ranging from 1 to 5. Major causes of renal failure
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were IgA nephropathy (n = 6), pyelonephritis (n = 3), and polycystic kidney disease (n 
= 3). For 6 patients the diagnosis of end-stage renal disease was unknown. None of the 
patient in either group was diabetic (Table 1).
Effect o f Campath-IH induction on peripheral leukocytes: extent o f depletion and 
time-course o f recovery in the two groups o f kidney transplant recipients
Depletion o f  circulating leukocytes after Campath-IH induction 
We first studied the effect of Campath-IH depletion on leukocyte subset counts and 
phenotype in the two cohorts of patients. Using flow cytometry analysis, absolute 
numbers of total CD3CD19+ B cells, CD3'CD16+CD56+ NK cells, monocytes (figure 
2a), of total CD3+ T cells and of CD3+CD4+ (CD4+) and CD3+CD8+ (CD8+) subsets 
(figure 2b) were calculated for healthy subjects and patients at baseline and at 14 days 
after Campath-IH induction. For the same subjects absolute numbers of monocytes 
were obtained from a complete blood count done on the same day (figure 2a). Baseline 
values of total B cells, NK cells, monocytes and T cells and CD4+ and CD8+ T cell 
subsets of patients in the two groups were not different from those observed in healthy 
control subjects (n= ll; mean age 36 years; range: 32-55), suggesting that the uremic 
milieu does not alter the composition of circulating PBMC. All the patients included in 
the study were indeed on chronic hemodialysis from at least 6 months. After Campath- 
IH induction, B, NK, and T cells in kidney transplant patients were almost completely 
depleted, consistently with data showing that CD52 is expressed by all these cell 
populations. On the contrary, depleting effect of Campath-IH on monocytes was much 
less evident. This phenomenon has been already reported by other authors, and may be 
due to the reduced expression of CD52 by these cells. (Fig. 2a-b).
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When we evaluated more in detail the phenotype of CD4+ T cells spared by Campath- 
IH induction, we found that the proportion of CD45RO+ cells 14 days after transplant 
was significantly higher than the one observed in the study patients at baseline, as well 
as in healthy individuals. CD45RO is the main hallmark of memory T cells and finding 
that the relative number of cells expressing this marker increased after Campath-IH 
induction suggests that these cells were more resistant than naive ones (expressing 
CD45RA) to its depleting effect (Fig. 2c). Of note, Campath-IH depletion was not 
affected by the type of maintenance immunosuppressive therapy. The number of 
circulating lymphocytes at 7 and 14 days after induction was indeed virtually identical 
in the two groups.
Time-course o f repopulating lymphocytes after Campath-IH induction in the two 
treatment groups
Absolute numbers of repopulating total leukocytes, CD3-CD19+ B cells, CD3- 
CD16+CD56+ NK cells, monocytes, CD3+ T cells and CD3+CD4+ and CD3+CD8+ T 
cell subsets in the peripheral blood of patients from baseline to 24 months after 
transplantation were obtained by FACS analysis.
The number of total circulating leukocytes declined remarkably during the first two 
weeks after Campath-IH induction, and remained persistently lower than basal levels in 
both groups of patients up to 2 years after transplant (Fig 3a). At around 6 months after 
Campath-IH infusion, B cells returned to pre-transplant values (Fig. 3b). Recovery was 
faster for NK cells that reached baseline values in 2-3 months after transplant (Fig 3c). 
Depleting effect of Campath-IH on monocytes was transient, as at one month after 
transplant these cells returned to values recorded at baseline (Fig 3d). Maintenance
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therapy with SRL or CsA had no effect on the time of B cell, NK cell and monocyte 
recovery, although monocytes in SRL patients tended to repopulate more slowly than in 
patients on CsA (Fig. 3b-d).
Differently from other leukocyte subpopulations, recovery of total T cells was very 
slow, so that in the SRL group their levels at 24 months after transplant were about one 
third of the baseline values (Fig 4a). T cells in CsA patients recovered faster, but they 
required about one year to reach baseline values. In both SRL and CsA-treated patients, 
the rate of recovery of CD4+ T cells over time was low, to the point that, at month 24 
post-transplantation, these cells were approximately one-third of baseline values (Fig. 
4b). On the contrary, CD8+ T cells had a significantly different time-course in the two 
treatment groups. In the SRL patients, at two years after transplant, the number of 
circulating CD8+ T cells was still only a half of the baseline value. Conversely, CD8+ T 
cells in CsA patients fully recovered at month 4 and, at one and two years post 
transplant, their values were twice the baseline ones (Fig. 4c). This resulted into a 
reduced CD4+/CD8+ T cell ratio in the CsA group that was significantly lower than, 
preoperatively up to month 24 after transplant (Fig. 4d).
Effect o f Campath-IH induction and different maintenance immunosuppression 
regimens on circulating Treg
Campath-IH depleting effect on circulating Treg
Among CD4+ T cells, those exerting immune regulatory effects are mainly confined in 
the CD25+ population. However, as CD4+CD25+ T cells include also effector/memory 
T cells (Tef), additional markers are needed for the identification of Treg. Recently, 
evidence came out that the levels of CD25 expression by CD4 Treg and
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effector/memory CD4+ T cells is actually different and may be used to discriminate 
these two cell populations. In particular, CD4+ T cells showing high levels of CD25 
have regulatory properties, whereas those whose CD25 expression is low display the 
characteristics of effector/memory T cells. Resting CD4+ T lymphocytes are CD25 
negative [189]. On the basis of this evidence, we used the levels of CD25 marker 
expression to differentiate CD4+CD25hlgh Treg, CD4+CD25low effector/memory T cells, 
and CD4+CD25‘ resting T cells. Using flow-based frequency enumeration and absolute 
CD3+CD4+ cell counts obtained on the same day, absolute numbers of 
CD3+CD4+CD25\ CD3+CD4+CD25low and CD3+CD4+CD25high cells were calculated in 
healthy subjects, and in patients at baseline and at 14 days after Campath-IH infusion. 
The percentage of all these CD4+ T cell subpopulations were similar between healthy 
subjects and patients at baseline, which further confirms that chronic renal failure does 
not significantly affect the phenotypic profile of peripheral lymphocytes. Importantly, 
early after Campath-IH infusion, there was a profound and unselective depletion of 
CD4+CD25hlgh, CD4+CD25low, and CD4+CD25’subsets in all transplant patients, as 
shown in figure 5a. Within the CD4+ T cell compartment, the percentage of CD25hlgh at 
14 days post transplant was comparable to baseline values, confirming that Campath-IH 
did not spare this cell subset (Fig. 5b). No difference was recorded between the SRL 
and the CsA groups in the days immediately after Campath-IH infusion.
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SRL- but not CsA-based maintenance immunosuppression is associated with in vivo 
expansion o f  CD4+CD25hlgh cells following Campath-IH
As a further step, we aimed to assess whether different maintenance immunouppression 
might have affected recovery of different CD4+ T cell subpopulations after Campath-IH 
induction. Among the CD4+ T cell pool, the percentages of CD25* and CD25low 
remained relatively stable during the whole follow-up period in both treatment groups. 
Notably, in patients on SRL, we found a transient decrease in CD4+CD25' percentages 
and a significant mirror increase in CD4+CD25low cell percentages at 1 month after 
transplant (Fig. 6a-b), which returned to baseline thereafter. When we looked at the 
absolute numbers of CD4+CD25' and CD4+CD25low, however, both SRL and CsA 
patients showed a marked depletion of these cell populations after Campath-IH 
induction that only recovered at two years after transplant. Indeed, at this time point * 
after transplant, CD4+CD25’ cells were less than one fifth and less than one third of 
baseline values in SRL and CsA patients, respectively, whereas CD4+CD25low were still 
lower than one fourth in the SRL group and around the average of values recorded- 
before Campath-IH administration in the CsA group (Fig. 6e).
From month 1 post-transplant, the percentage of CD25hlgh cell subset within total 
CD3+CD4+ T cells progressively increased over baseline in SRL-treated patients (Fig. 
6c), reaching values significantly higher than pre-transplant from month 4 to 24 
postoperatively. Conversely, in the CsA group, the trend of CD4+CD25hlgh cell 
percentage to increase was milder, so that values significantly higher than pre-transplant 
were recorded only at month 6 (Fig. 6c). From month 2 up to month 24 after transplant, 
the percentage of CD4+CD25hlgh cells was significantly higher in the SRL group than in 
the CsA group. The same picture was found when we evaluated the absolute numbers of
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circulating of CD4+CD25hlgh cells. Indeed, although the total absolute number of CD4+ 
T cells was significantly lower at two years after transplant than before in both 
treatment groups, circulating CD4+CD25hlgh cells tended to increase, especially in SRL 
patients (Fig. 6e).
The Treg/Tef ratios were significantly higher (P<0.05) in the SRL than in the CsA 
group from months 2 to 24 (Fig. 6d).
Thereafter, we wondered whether Treg enrichment during lymphocyte recovery was 
due to an increased proliferation. To address this point, we evaluated the expression of 
Ki-67, a nuclear protein associated with cell proliferation, in CD4+CD25hlgh T cells at 
baseline and at 3-5 months post-transplant, the time of their maximal expansion. 
Baseline levels of CD4+CD25hlghKi-67+ T cell were similar between the two patient 
groups and between patients and healthy subjects, as well as CD4+CD25lowKi-67+ and 
CD4+CD25'Ki-67+ cell percentages (Fig 7). At 3-5 months after transplant, the 
percentages of CD4+CD25hlghKi-67+ T cell were significantly higher (P<0.05) than at 
baseline in both treatment groups, but in SRL patients they reached levels significantly 
higher (P<0.05) than in the CsA group. Of note, also CD4+CD25lowKi-67+ and 
CD4+CD25'Ki-67+ cells were found to increase after transplant, but their relative levels 
were remarkably lower than the ones found in Treg and their values were virtually 
identical between SRL and CsA patients (Fig 7).
The above findings are in line with an homeostatic expansion of all CD4+CD25+ T cell 
populations after Campath-IH induction and either maintenance immunosuppressive 
therapy. Intriguingly, however, SRL maintenance therapy selectively favoured the 
expansion of Treg.
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Expanding CD4+ CD25hlgh cells express the Treg hallmark FOXP3 
The previous results document that Campath-lH-induced T cell depletion favours the 
emergence of CD4+CD25hlgh T cells in subjects receiving SRL-maintenance therapy. 
However, CD25 can not be regarded as a specific hallmark of Treg since, as stated 
above, also effector/memory T cells express this molecule on their surface. To certainly 
exclude that our CD4+CD25hlgh Treg were not recently activated CD4+ T cells, we 
evaluated their expression levels of CD69, a marker of T cell activation. FACS analysis 
showed that the large majority (99.0%, range: 98.5-99.5%) of CD4+CD25hlgh cells from 
patients in both treatment groups at 2 baseline were CD69', excluding that they were 
activated cells.
To ascertain whether the high levels of CD25 expression in regenerating CD4+ cells 
upon Campath-IH induction reflected a regulatory phenotype, we evaluated the mRNA 
expression level of FOXP3, a gene that encodes a transcription factor required for Treg 
development and function and that is now considered the specific marker of Treg. 
FOXP3 expression was assessed by quantitative real time PCR in CD3+CD4* 
subpopulations of peripheral cells taken at 24 months post-transplant and data were 
compared with FOXP3 expression in cells from the patients at baseline and from 
healthy individuals. Using electronically sorted CD4+CD25hlgh, CD4+CD25low, and 
CD4+CD25' cell subsets, we found the highest levels of FOXP3 expression in the 
CD25hlgh subset both in patients and in healthy individuals, with intermediate and low 
levels of FOXP3 expression in the CD25low and CD25' subsets, respectively (Fig. 8a). 
No difference was observed between patients at baseline in the two randomization arms, 
nor between patients and healthy subjects, as a further proof that chronic renal failure 
does not alter the phenotypic profile of these cell populations, at least in the peripheral
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blood. At 24 months post-transplant, we found that CD4+CD25hlgh cells from SRL 
patients had significantly higher (PO.05) levels of FOXP3 expression as compared 
with baseline and with patients on GsA at the same time point after transplant (Fig. 8a). 
Moreover, in order to quantify Treg in the total CD3+CD4+ cell population, we further 
evaluated FOXP3 expression in positively selected CD3+CD4+ T cells. Again, FOXP3 
expression was virtually identical between healthy subjects and patients at baseline. 
Conversely, cells isolated 24 months post-transplant from SRL-treated patients had 
significantly higher (P<0.05) FOXP3 expression compared to CD3+CD4+ cells from the 
same patients at baseline or from healthy individuals (Fig. 8b), which is consistent with 
both CD4+CD25hlgh T cell expansion observed through flow cytometry and increased 
FOXP3 expression in this cell subset. Notably, in CD3+CD4+ T cells of SRL-treated 
patients, FOXP3 expression was higher than in the CsA group (P<0.05) at the same 
time after transplant (Fig 8b). We found no evidence in any group of significant FOXP3 
expression in CD4‘ cells (FOXP3 expression less than 0.01 AU).
Altogether these results indicate that, following lymphocyte depletion by Campath-IH 
induction, SRL but not CsA increased the pool of FOXP3 expressing CD4+CD25hlgh 
cells.
CsA- but not SRL-based maintenance immunosuppression is associated with in vivo 
expansion o f CD8+CD2S' cells following Campath-IH
Beside CD4+CD25hlgh cells, a distinct population of antigen-primed T cells, 
characterized by their CD8+CD28~FOXP3+ phenotype (Ts) and lack of cytotoxic 
activity, has been shown to display regulatory functions in human transplant recipients 
and in a murine autoimmune disease model.
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Importantly, the high levels of donor-specific Ts cells have been found in the circulation 
of organ transplant patients whose immunosuppressive therapy has been successfully 
reduced without an increased risk of acute rejection [105]. On the basis of this evidence, 
we evaluated whether Campath-IH induction might have promoted expansion of 
CD8+CD28“ cells and whether the two low-dose maintenance immunosuppressive 
regimens might have differently affected this phenomenon.
As shown in figure 9, the percentage of CD8+CD28" cells among CD8+ T cells slightly 
increased from baseline values in the SRL group but, at 2 years after transplant, they 
were not significantly different from pre-transplant. Conversely, patients on CsA 
showed a significant increase in the percentage of CD8+ cells negative for the CD28 
marker, to the point that at 2 years after transplant almost all CD8+ were also CD28\
Expanding CD8 CD28' T cells do not express the Treg hallmark FOXP3
As a further step, we wondered whether CD8+CD28' T cells isolated from our cohort of 
patients were also expressing the Treg hallmark FOXP3 gene, in line with the 
CD8+CD28' T suppressor cells described by Cortesini et al. [89, 105]. To this purpose, 
we evaluated FOXP3 gene expression levels in CD8+CD28' T cells from 3 patients 
randomized to CsA treatment at one year after transplant, using CD8+CD28' T cells 
from 3 healthy subjects as controls. CD8+CD28‘ T cells were electronically sorted from 
PBMC, and FOXP3 mRNA levels were evaluated thereafter by Real Time PCR. 
Unexpectedly, we did not find any expression of FOXP3 gene in CD8+CD28* T cell 
neither in patients nor in healthy subjects. Thus, we argued the CD8+CD28' T cells that 
we found expanded after Campath-IH induction in CsA treated patients was different
103
from the ones described by Cortesini et al. [89, 105]. Thus, we focused subsequent 
experiments on the better characterized population of CD4+CD25+FOXP3+ Treg.
Functional evaluations of Treg cells
T cell alloreactivity in the two treatment groups
Treg are anergic T cells that respond poorly to allogeneic stimuli and are also capable of 
inhibiting the alloreactive response of effector T cells [87]. Thus, functional assays were 
performed to address whether the emergence of Treg, generated upon Campath-IH 
induced lymphopenia, was associated with host T cell hyporesponsiveness against 
donor antigens. To ascertain the proliferative response of T cells to donor and third- 
party alloantigens, we used the one way mixed lymphocyte reaction (MLR). In this 
assay, PBMC of patients were mixed with donor and third party irradiated splenocytes 
or PBMC (according to the deceased or living type of donor, respectively). The rate of 
T cell proliferation was assessed by uptake of tritiated thymidine. Moreover, to evaluate 
the frequency of previously activated/memory T cells, we employed the ELISPOT for 
IFN-y following overnight exposure to alloantigens. This test allows to determine the 
number of previously activated/memory T cell clones by visualization of the IFN-y 
product of individual cells.
Samples were taken pre-transplant and at two different time intervals after T cells had 
repopulated the peripheral blood at adequate amount, i.e. at month 12 and 24 post­
transplant.
In SRL-treated patients, the anti-donor T-cell proliferative response and the frequencies 
of IFN-y producing donor-reactive cells were significantly (P<0.05) reduced at both 
post-transplant points as compared to pre-transplant values (Fig lOa-b). Post-transplant
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anti-third party alloreactivity was significantly lower than pre-transplant as well 
(P<0.05) (Fig lOa-b). These results could not be attributed to incomplete recovery of T 
cell count or to a state of general immunosuppression caused by maintenance therapy, 
since T cells isolated at the same time points responded normally to a polyclonal T-cell 
stimulus with phytohemagglutinin (PHA, Fig. 10b). In CsA-treated patients, T cells 
studied at the same time points showed donor-specific hyporesponsiveness assayed with 
MLR and ELISPOT compared to pre-transplant (Fig lOa-b) and T-cell response to PHA 
was normal (Fig 10b).
CD4+CD25hlgh T cells from SRL-treated patients suppress T cell alloreactivity ex vivo 
To clarify the role of Treg in suppressed anti-donor alloreactivity, ELISPOT assays i
were repeated on PBMC isolated at 24 months post-transplant following CD4+CD25hlgh t-
cell depletion by sorting. Indeed, in case the reduced immune response against b
alloantigens relied on active suppression by Treg, their depletion would result in an i
increased T cell activation. This was exactly what we found in PBMC from SRL -i
patients. Indeed, as shown in Fig 10a, depletion of CD4+CD25hlgh cells in this group of 
patients was associated with a statistically significant increase (P<0.05) in the frequency 
of IFN-y producing effector/memory cells to both donor and third-party antigens. The 
suppression ratios, defined as frequency after depletion minus frequency before 
depletion divided by frequency after depletion, were comparable for both anti-donor 
(0.43±0.06) and anti-third party (0.45±0.06) response. To further confirm that the 
CD4+CD25hlgh subset in SRL-treated patients had regulatory activity and to exclude any 
possible overlapping inhibitory effect of the concomitant immunosuppressive therapy 
on the function of effector T cells, CD4+CD25hlgh-depleted PBMC obtained from the
105
SRL patients before surgery were mixed with CD4+CD25hlgh cells sorted from blood 
samples of the same patients at 24 months post-transplant. As expected, depletion of 
naturally occurring CD4+CD25hlgh Treg resulted in an increased response of baseline 
PBMC. However, addition of CD4+CD25hlgh Treg isolated from the same patients at 24 
months after transplant restore the pre-depletion levels of response against both donor 
and third-party antigens (Fig. 1 lc). Of note, the amount of added Treg did correspond to 
the percentage of circulating CD4+CD25hlgh cells in patients pre-transplant, which 
supports a potential clinical significance of the above findings.
On the other hand, in patients on maintenance CsA therapy, CD4+CD25hlgh cell 
depletion had no effect on the frequencies of anti-donor IFN-y producing T cells taken 
at 24 months post-transplant (Fig. lib ), suggesting that Treg did not play a significant 
role in the hyporesponsiveness to donor alloantigens in CsA-treated patients. Thus, we 
wondered whether the reduced response against donor antigens in the PBMC of these 
patients relied on an alternative mechanism, such as cell anergy. To address this 
hypothesis, we added progressively increasing concentrations of IL-2 to PMBC isolated 
from CsA patients at 24 months post transplant and exposed to donor or third-party 
alloantigens in the ELIPOT assay. Indeed, IL-2 is able to restore cell activity in anergic 
cells. As shown in figure lid , higher concentrations of IL-2 were indeed able to 
increase the IFN-y frequencies against donor antigens to reach anti-third party values 
(Fig. lid). Thus, anergy rather than regulation seemed to contribute to donor-specific 
hyporesponsiveness in CsA-treated patients.
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Tables and figures
Table 1. Baseline patients’ characteristics according to the randomization 
arm.
SRL
(n= 11)
CsA
(n=10)
Donors
Age (years) 47.5 ± 16.0 42.3 ± 13.2
Gender (M/F) 7/4 5/5
Weight (Kg) 79.5 ± 10.0 72.0 ±13.5
Type o f donor
Cadaveric 11 8
Living 0 2
Cold ischemia time (h) 16.7 ±2.3 14.6 ±3.7
Warm ischemia time (min) 31.3 ±7.7 27.1 ±5.3
Recipients
Age (years) 53.2 ±8.9 47.0 ±16.5
Gender (M/F) 6 /5 7 /3
Weight (Kg) 71.2 ± 10.1 74.3 ± 16.9
Mismatches
A 1.6 ±0.5 1.2 ± 0.6
B 1.6 ±0.7 1.4 ±0.7
DR 1.2 ± 0.6 1.0 ± 0.8
Cause o f  renal failure
Polycystic kidney disease 1 2
Membranous nephropathy 1 0
IgA nephropathy 3 3
Interstitial inflammation 1 0
Pyelonephritis 3 0
Glomerulonephritis 1 0
Unknown 1 5
Data are mean ± SD.
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Effect o f Campath-IH (C1H), on circulating leukocyte subsets in renal transplant patients Using flow 
cytometry analysis, absolute numbers o f total CD3"CD 19* B cells, CD3-CD16+CD56+ NX cells, monocytes 
(a), o f total CD3* T cells and o f  CD3*CD4+ (CD4+) and CD3+CD8* (CDS*) subsets (b) were calculated for 
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or cyclosporine A, CsA, maintenance therapies combined with mycophenolate mofetil, MMF, were 
cumulated since no difference was recorded between the two groups at this time), (c) Percent o f memory 
CD45RO* cells within the CD3*CD4+ subset from healthy subjects, patients at baseline and at 14 days after 
Campath-IH induction (cumulative data from the SRL and the CsA group).
Figure 2
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Time course of circulating leukocyte subsets in renal transplant patients after Campath-IH (C1H) 
induction
Kinetics o f absolute numbers o f repopulatmg total leukocytes (a), CD3'C D !9* B cells (b), monocytes (c), 
and CD3"CD16+CD56+ NK cells (d), CD 3* T  cells in the peripheral blood of Campath-lH-treated renal 
transplant patients from baseline (pre-transplant, time 0) to 24 months after transplantation.
Data from recipients o f SRL plus MMF maintenance therapy are pink circles (n = ll,  n=10 at 24 months), 
data from recipients o f CsA plus MM F are blue squares (hf=10). Data are mean ±  s.e.m. *P<0.05 vs. pre- 
transplant (time 0), §P<Q.05 vs. SRL-treated group at the same time point
Figure 3
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induction
Kinetics o f absolute numbers of repopulatmg total CB3*(a), CD3*CD4+ (b), CD3+CD®+ (c) T  cells, and 
CD4+/CD8+ ratio in the peripheral blood of Campath-lH-treated renal transplant patients from baseline 
(pre-transplant, time 0) to 24 months after transplantation
Data from recipients o f SRL plus MMF maintenance therapy are pink circles (nt=ll, a=10 at 24 months), 
data from recipients o f CsA plus MMF are blue squares (hf40)„ Data are mean ±  s..e..m *P<0.05 vs.. pre- 
transplant (time 0), §P<0.05 vs. SRL-treated group at the same time point
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Effect of Campath-IH on different CD3+ CD4+ CD25+ T cell populations
(a) Usmg flow-based frequency enumeration and absolute CD3*CD4+ cell counts obtained on the same day, 
absolute numbers o f CD3*CD4+CD 25\ CD3+CB4+CD25low and CD3+CD4+CD25high cells were calculated in 
healthy subjects (n = ll) , in patients at baseline (n=21) and at 14 days post transplant (after Campath-IH, 
n=21). Cam path-IH  profoundly depleted all CD3+CD4+CD 25\ CD3+CD4+CD25fcw and CD3t CD4+CD25hi^  
cell subsets, (b) Percent of CD25iQgit within the CD3+CD4+ subset from healthy subjects (n=l 1), patients at 
baseline (n=21), at 14 days (n=21, data from the SRL and the CsA groups were cumulated since no 
difference was recorded between the two groups at this time) and at 12 months (data from the SRL, n = ll ,  
and the CsA, n=10 groups, are presented separately) after transplantation and Campath-IH (C1H-induction). 
Data are mean ±  s.e.m. °P<0.05 vs healthy subjects, patient baseline and CsA
(c) Representative FACS plots of CD25 expression on CD3+CD4+ cells from healthy subjects, patients at 
baseline, at 14 days post-transplant (post-CIH) and in patients on either SRL or CsA therapy studied at 12 
months post-transplant. CD3*CD4+ cells were designated CD25' if CD25 expression fell within the 
background staining observed using an isotype control, CD25iogil if  CD25 expression exceeded that seen in 
the CD4* population, and CD25'*DW if  CD25 expression fell between these regions.
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Using the gating shown in panel Figure 5 (panel c), post-transplant longitudinal analysis of the percent o f 
CD3+CD4+ that were CD25' (a), CB2& ™  (b) or d ) 2 5 iagi‘ (c) are shown. Panel d shows the ratio between 
CD3*CD4+ CD25i“si' and CD3*CD4+ CD25i™', whereas in panel e are shown data on absolute numbers of 
CD3+CD4*CD25\ CD3+CD4+CD25]o’fL and CD3*CD4+CD25h«*1 atbaselme and at 24 months after Campath- 
IH  infusion
Data from recipients o f SRL plus MMF maintenance therapy are pink circles (n=l 1, df=10 at 24 months), 
data from recipients o f CsA plus MMF are blue squares (n=10). Data are mean ±  s.e.m. *P<0 05 vs. pre­
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FOXP3 expression in cells from renal transplant patients following Campath-IH induction, (a) FGXP3 
mRNA is predominantly expressed in CD3+CD4+CD25iugl1 cells in all groups studied, with significantly 
higher FOXP3 in CD4+CD25lagh versus CD4+CD25' and CD4+CD25klw samples both m patients and in 
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CD3+CD4+ cells in healthy subjects (n = ll) , in patients at baseline (hf=21) and at 24 months after 
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(C1H) induction
The percentage of CD3+CD8+ cells negative for CD28, respectively, at different time points after transplant. 
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Functional assays on repopulating T cells following Campath-LH induction in renal transplant 
patients.
(a) Proliferative responses (expressed as stimulation index, SI) to donor (closed bars) and third-party 
(hatched bars) antigens in 6 days mixed lymphocyte reaction (MLR) o f T cells from transplant patients 
receiving SRL (n=6 pink colour) or CsA (n=6 blue colour) for whom donor cells were available. Each 
subject was studied at baselme and at 12 and 24 months post-transplant, (b) Frequency of previously 
activated/memory T  cells by ELISPOT for IFN -y follo wing overnight exposure to donor (closed bars) and 
third-party (hatched bars) alloantigens. The frequencies of IFN-y specific T  cells were plotted as 
spots/300,000 PBMC from transplant patients receiving SRL (qf=6 pink colour) or CsA (n=6 blue colour). 
Each subject was studied at baseline and at 12 and 24 months post-transplant. The responses to 
phytohemagglutinin (PHA, 10 pg/ml), used as positive controls are shown as circles.
Figure 10
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Functional evaluation of CD4+CD251“^ ‘ Treg in SRL patients and response to IL-2 in the CsA group
(a-b) Effect of CD4+CD25ldgh depletion by FACS sorting on the frequencies o f IFN-y producing cells. The 
number o f spots/300,000 PBM C measured before (-) and after (+) CD4+CD25*“gh depletion m PBMC from 
renal transplant patients studied 24 months after surgery are shown. C D 4*C D 25t°&1 depletion increased the 
frequencies o f anti-donor (closed bars) and anti-third party (hatched) IFN-y producing cells in the SRL (pink 
bars, n=6) but not in the CsA group (blue bars, n=6) (c) Addition (+) o f autologous CD4+CD25tugh to 
CD4+CD25kigk-depieted (+) PBMC isolated at baseline, reduced the frequencies o f anti-donor (closed bars) 
and anti-third party (hatched bars) IFN -y producing T  cells. CD4+CD25lt]seit cells were isolated by sorting 
from SRL patients at 24 months after transplantation (n=3) and 5,000 cells were added to 300,COO pre­
transplant CD4+CD25high-depleted PBM C from the same subjects.
(d) IL-2 reverted donor-specific hypo-responsiveness in CsA-treated patients. The frequencies of IFN-y 
producing cells in response to donor (closed bars) and to third-party antigens (hatched bars) in PBMC from 
CsA-treated patients studied 24 months post-transplant (n=3) were evaluate in the absence (0) or in the 
presenc e o f 10 or 50 U/mL o f  IL-2.
Data are mean ±s.e.m  *P<0.05 vs. pre-Tx. °P<0.05 vs. pre-depletion (-), #P<0.05 vs. CD25high-depleted 
PBMC (+/-).
Figure 11
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Discussion
In this part of the project, we showed that Campath-IH induction was associated with a 
profound and long-lasting lymphocyte depletion in kidney transplant patients and that 
phenotypic and functional characteristics of repopulating cells were affected by 
different maintenance immunosuppressive regimens. In particular, SRL -  but not CsA - 
therapy was associated with the expansion of functionally active CD4+CD25hlghFOXP3+ 
Treg. Importantly, however, all Campath-IH treated patients displayed a reduced 
alloreactivity against donor antigens at 2 years after transplant independently from 
maintenance immunosuppressive regimen.
Effect o f Campath-IH induction on peripheral leukocytes: extent o f depletion and 
time-course o f recovery in kidney transplant recipients on low-dose SRL or CsA, both 
combined with low-dose MMF as maintenance immunosuppression
In our series of 21 kidney transplant recipients, a single 30 mg infusion of Campath-IH 
was well tolerated and induced a profound and long-lasting depletion of T lymphocytes 
and, to a lower extent, of B cells, NK, and monocytes. The milder depleting effect on 
the latter subsets was in line with other reports and possibly relies on the lower 
expression levels of the CD52 antigen by these cell populations.
The ideal dose of Campath-IH as induction therapy in renal transplantation has still not 
yet been identified. Previous studies used higher doses or repeated administrations of 
the antibody, with the attempt of inducing more sustained lymphocyte depletion [126]. 
However, here we clearly showed that a single 30 mg infusion of Campath-IH is 
enough to deplete lymphocytes for around 9-12 months in kidney transplant patients,
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suggesting that this regimen should be preferred to other ones employing higher doses, 
in order to reduce potential adverse events and saving costs.
Intriguingly, the depleting effect of Campath-IH on T cells was preferentially targeted 
toward the naive population, suggesting that the memory cell counterpart may have a 
higher resistance to the antibody. Indeed, at 14 days after treatment, the proportion of T 
cells showing the CD45RO memory marker was significantly higher than at baseline. 
The obvious reason why different leukocyte subsets were differentially susceptible to 
Campath-IH might rely on the expression levels of CD52 receptor. Indeed, it has been 
clearly shown a correlation between high levels of expression of CD52 on T cells, in 
particular naive T cells, and the intensity of depletion achieved when Campath-IH was 
administered [190].
This is consistent with Pearl’s data [173], who found that in renal transplant recipients 
who received induction with Campath-lH/deoxyspergualin and no maintenance 
immunosuppression, T cells repopulating after depletion were predominantly activated 
memory-like T cells, which expanded in the first month after transplantation. These 
memory-like T cells, which are prone to activate an immune response, were the 
prevalent T cell population in the blood and in the allograft during rejection episodes 
[173], that uniformly occurred in all five patients included in that study. Conversely, in 
our trial, maintenance immunosuppression with MMF combined with either SRL or 
CsA was probably instrumental to limit the immune response of memory T cells after 
Campath-IH induction. Indeed, MMF has been shown to inhibit memory cell 
proliferation both in vitro in human mixed lymphocyte cultures [191] and in vivo in F5 
TCR transgenic mice exposed to the TCR specific NP68 peptide [192].
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Maintenance immunosuppression with either SRL or CsA did not affect the 
repopulation of B, NK cells and monocytes after Campath-IH induction, which was 
completed within 6 months after transplant in both treatment groups. In both groups, 
CD4+ T lymphocytes had a slow and incomplete recovery, whereas CD8+ T cell 
reappearance in the periphery occurred significantly slower in SRL than in CsA 
patients. In SRL patients, indeed, CD8+ number at two years after transplant was still 
only a half of the baseline value. Conversely, CD8+ T cells in CsA patients fully 
recovered at month 4 and at one and two years post transplant their values were twice 
the baseline ones. This resulted in a prolonged inversion of the CD4+/CD8+ ratio, which 
remained significantly lower than at baseline up to two years after transplant in the CsA 
group.
The phenomenon of CD4+/CD8+ inversion has been already described in patients 
undergoing lymphocyte depletion with polyclonal [193, 194] antibodies followed by 
CNI-based therapies. Little is known about the process of T-cell regeneration and 
lymphocyte lifespan in vivo [195]. Apart from the persistent depletion of the CD4+ cells, 
a disproportionate regeneration in the CD8+ cell subset may occur. This is in line with 
findings showing that T-cell differentiation in the adult is primarily extrathymic and 
seems to be predominantly CD8+ [196]. Interestingly, a recent paper showed that, even 
after Campath-IH induction, recovery of CD8+ T cells was much faster than that of 
CD4+ T cells in patients given MMF and tacrolimus as maintenance 
immunosuppression [174]. Moreover, most of these cells were CD8+CD28‘, in line with 
our findings in CsA treated patients. Importantly, CD8+CD28' cells have been described 
as immunosenescent CD8+ T cells, i.e. terminally differentiated and non-proliferating 
cells, that, upon reaching the limit number of cell division, do not die but rather survive
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as expanded T clones. Expanded CD8+CD28' T cells may compete for the immune 
space with CD4+ T cells, suppressing their proliferation and therefore delaying CD4+ T 
cell-recovery after Campath-IH induction.
Effect of Campath-IH induction and different maintenance immunosuppressive 
regimens on circulating Treg
Polyclonal and monoclonal anti-T cell antibodies have been used as an integral part of 
tolerance induction in experimental transplantation and clinical trials [122]. Their 
immunosuppressive activity has been though to result primarily from profound T cell 
depletion from the circulating pool via complement-dependent lysis or Fas/Fas ligand- 
mediated apoptosis [197], although emerging evidence suggests that expansion of Treg 
may have a role [198]. Following ALS-induced lymphopenia in C57/BL6 mice [199], 
the reduction of CD4+CD25+ T cells number was smaller than that of CD4+CD25’ cell 
subset, which raised the idea that Treg may be resistant to ALS-mediated depletion. At 
variance with ALS, Campath-IH does not selectively spare Treg since it induced a . 
profound and unselective depletion of CD4+CD25-, CD4+CD25low and CD4+CD25hlgh 
subsets in all renal transplant patients included in the present study. These results are 
consistent with previous findings that all CD4+ T-cell subsets, including CD4+CD25+, 
express at similar densities on their cell surface the CD52 target antigen of Campath-IH 
and addition of Campath-IH to human blood in vitro caused depletion of CD4+CD25hlgh 
cells [200].
After Campath-IH induced depletion, however, Treg repopulation significantly differed 
between patients receiving SRL or CsA as maintenance immunosuppression. Indeed, 
the percentage of CD25hlgh cell subsets progressively increased over baseline in SRL-
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treated patients, reaching values significantly higher than pre-transplant from month 4 
to 24 postoperatively. Conversely, the percentage of CD25hlgh cells among CD4+ T cells 
in the CsA group had only a transient increase at 6 months post-transplant, and 
remained substantially unchanged thereafter compared with pre-transplant values. 
Intriguingly, CD4+CD25hlgh expansion in SRL patients was anticipated by a spike of 
CD4+CD25low activated T cells at month 1 after transplant. Theoretically, this immune 
activation might have created a favourable milieu to promote Treg expansion as a 
counterbalancing mechanism to turn off the inflammatory response. However, this is 
just a speculative hypothesis.
Our findings are in line with the already reported increase of CD4+CD25+ T cells in 
peripheral lymphoid organs from rats treated with SRL. Moreover, Battaglia et al. 
recently described that CD4+CD25+FOXP3+ Treg expanded ex vivo in the presence of 
SRL and prevented rejection of [beta]-islet transplants in vivo [177]. SRL also induces 
de novo expression of FOXP3 in murine alloantigen-specific T cells dose dependently, 
which appeared to be TGF-pi dependent [201]. Because SRL can induce the expression 
of TGF-pi, it may be an important mechanism contributing to the development of 
antigen-specific Treg [202]. Interestingly, a recent study suggests that SRL can induce 
regulatory functions in conventional CD4+ T cells in culture [113]. Furthermore, 
evidence suggests that SRL-conditioned dendritic cells are poor stimulators of allogenic 
T cells but enrich for antigen-specific Treg, which can prolong cardiac graft survival in 
mice [203].
CD4+CD25hlgh T cell expansion in our patients on SRL therapy may result from two 
mutually nonexclusive and possibly complementary mechanisms. First, Campath-IH- 
induced lymphopenia may promote the selective homeostatic proliferation of naturally
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occurring CD4+CD25hlgh cells. This phenomenon has been reported in IL-2-treated 
genetically lymphopenic Rag'A mice upon adoptive transfer of CD4+CD25+ cells, 
whereas exogenous CD4+CD25' cells proliferated poorly [204]. Second, Campath-IH- 
induced lymphopenia may stimulate the expansion of CD4+CD25‘ cells followed by 
their conversion into CD4+CD25hlgh cells, as observed in other studies in 
immunodeficient [205] mice. Interchange between CD4+CD25‘ and CD4+CD25+ 
phenotype has been also observed in immunocompetent wild type mice following T cell 
depletion with ALS [206] and in ALS-stimulated human PBMC in vitro [198]. Finding 
a selective increased expression of the proliferation marker Ki-67 in CD4+CD25hlgh cells 
from renal transplant patients after Campath-IH, would support the first hypothesis. 
However, on the basis of these data, we can not exclude that proliferating 
CD4+CD25hlgh cells derived from the conversion of CD4+CD25' into CD4+CD25+ cells. 
Moreover, other studies are needed to asses if an increase in number of naive Treg, i.e. 
an increase in thymic output, could have contributed to the observed accumulation of 
CD4+CD25high in SRL -treated patients.
According to our findings, a recent paper by Knechtle’s group [175] reported that 
CD4+CD25+FOXP3+ regulatory T cells increased in kidney transplant patients after 
immunodepletion with Campath-IH and maintenance therapy with SRL. Interestingly, 
these Authors suggested that peripheral expansion of Treg may not fully explain their 
increase, thus they argued that also de novo generation/expansion from CD4+CD25' T 
cells may be involved.
On the other hand, lack of development of CD4+CD25hlgh Treg with CsA could be 
explained by the fact that IL-2 - whose generation is inhibited by CsA - promotes 
acquisition of CD25 molecules [118] and is a surviving factor for Treg in vitro [118]
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and in vivo [207]. This interpretation is in line with data showing that IL-2 therapy 
given during immune reconstitution to pediatric patients with sarcoma increases the 
frequency and absolute numbers of Treg compared with patients who did not receive 
IL-2 [204]. Finding that CsA, by inhibiting calcineurin phosphatase-dependent NF-AT 
translocation into the nucleus [208], suppresses FOXP3 promoter activity, mRNA and 
protein expression in T cells [208], is also consistent with the present in vivo data.
Our data are in line with those of a recent study showing that kidney transplant patients 
receiving CNI maintenance treatment had a significantly lower percentage of peripheral 
CD4+CD25hlgh T cells compared with patients receiving SRL [114]. Recently, evidence 
has been provided that conversion of kidney transplant recipients from tacrolimus/MMF 
to SRL monotherapy, significantly increased the percentage and absolute number of 
circulating CD4+CD25hlghFOXP3+ Treg [113]. These data support the concept that SRL 
promotes Treg expansion, which in our cohort resulted into a significantly higher 
Treg/Teff ratios than in the CsA group during the whole follow-up period.
Importantly, we carefully characterized the phenotype of circulating Treg using all the 
most important markers. Indeed, they did not express the CD69 activation marker and 
expressed high levels of FOXP3. Notably, the expression levels of FOXP3 in 
CD4+CD25hlgh T cells from SRL treated patients were significantly higher than those 
found in the CsA group, and this might be associated with a higher immune regulatory 
effect. Moreover, as we will discuss in the next paragraph, these cells were capable to 
suppress the alloreactive immune response of autologous effector CD4+CD25'/low T 
cells against donor antigens in co-cultures.
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Functional evaluations o f circulating lymphocytes
As a final step, we evaluated the functional characteristics of circulating lymphocytes, 
with a particular attention to CD4+CD25hlghFOXP3+ Treg. In vitro assessment of 
lymphocyte alloreactivity has been claimed as a potential tool to shape 
immunosuppressive therapy and to predict the risk of acute rejection. Moreover, it 
might allow understanding how Campath-IH induction efficiently prevents acute 
rejection with lower than conventional doses of maintenance immunosuppression.
Our experiments on T cell alloreactivity focused on the direct pathway of 
allorecognition. Alloreactive T cells recognize HLA-mismatched tissue via two 
different pathways: in the direct pathway, responder T cells recognize intact foreign 
MHC-peptide complexes on the surface of donor antigen-presenting cells (APC), [26]. 
In the indirect pathway, T cells recognize donor allopeptides on self-MHC molecules 
after having been processed and presented by recipient APC. During the past few years, 
the relevance of both pathways of antigen allorecognition for long-term graft outcome 
has controversially been discussed. Priming by the direct pathway has classically; been 
associated with the early posttransplantation period and especially with acute rejection, 
because professional donor APC are present during the first months only. In contrast, 
priming by the indirect pathway was suggested to play a main role in the long term; 
therefore, indirectly primed T cells were considered key mediators for chronic immune- 
mediated graft injury [26]. However, recent studies suggest that both pathways may 
persist and be of relevance for interstitial fibrosis and tubular atrophy. Notably, Herrera 
et al. demonstrated how recipient dendritic cells, when co-cultured with allogeneic 
dendritic cells or endothelial cells, can acquire substantial levels of allogeneic MHC- 
peptide complexes and subsequently prime T cells by both allorecognition pathways
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[209]. Hence, early directly primed T cells could be maintained and reactivated by graft 
cell populations such as graft endothelial cells but also by recipient dendritic cells at 
later time points. A very recent study evaluating the impact of both direct and indirect 
reactivity against donor antigens has recently shown that direct hyporesponsiveness 
against donor antigens was the only variable significantly correlated with graft function 
at multivariate analysis [159]. Thus, our evaluation. of the direct alloreactivity was 
expected to provide a strong instrument to assess immune activation against HLA 
antigens.
In our trial, the post-transplant T cell proliferative response against donor antigens and 
the frequencies of IFN-y producing donor-reactive lymphocytes were significantly 
reduced as compared to pre-transplant values in both patient groups included. 
Importantly, this could not be attributed to incomplete recovery of T cell count, or to a 
state of general immunosuppression due to maintenance therapy, since T cells isolated 
at the same time points responded normally to a polyclonal T cell stimulus with 
phytohemagglutinin. A reduced immune reactivity against donor antigens, in the setting 
of an otherwise preserved immune response is a hallmark of tolerance [46]. Thus, the 
present finding provides the evidence that after Campath-IH induction, kidney 
transplant recipient may develop signs of tolerance. Although hyporesponsiveness 
toward donor antigens might have been affected by ongoing immunosuppression, it 
suggests that grafts from Campath-IH treated patients might be protected from chronic 
immune injury, which may improve their long-term outcomes.
We also evaluated reactivity of PBMC toward third party (TP) cells, harvested from 
subjects who had a number of mismatches for HLA similar to the one between the 
donor and recipient. Intriguingly, SRL patients showed a reduced response also against
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these cells, whereas those on CsA had a substantially unaltered reactivity as compared 
with baseline. This phenomenon might reflect the alloantigen cross-reactivity of TCR 
from expanding Treg in SRL patients [210], or alternatively, a phenomenon of 
bystander regulation [211].
Our results are in line with the ones by Trzonkoski et al. [174] showing that, in 
Campath-IH treated patients receiving MMF and the tacrolimus as maintenance 
immunosuppression, the response to donor alloantigens was suppressed, whereas the 
one toward mismatched third-party alloantigens recovered partially with the time after 
transplantation.
As a final step, we asked which mechanisms were at the basis of the different in vitro 
immune responses in the two treatment groups. To this purpose, we depleted 
CD4+CD25hlgh taken at 24 months after surgery from total PBMC, to assess the impact 
of these cells in the overall immune response. In SRL patients, depletion of these cells 
resulted into a significant relapse of alloreactivity against both donor and third party 
antigens, suggesting that these cells were actually crucial in maintaining 
hyporesponsiveness toward donor alloantigens. Moreover, the addition of Treg taken at 
24 months after transplant to baseline PBMC resulted in a hyporesponse against donor 
antigens, further confirming the immune regulatory function of these cells.
Conversely, depletion of Treg did not affect response against donor or TP antigens from 
CsA patients. This was not an unexpected finding, as the proportion of Treg after 
transplantation did not significantly change as compared to baseline in the CsA group. 
On the other hand, increasing concentrations of IL-2 were associated with progressively 
higher proliferative responses of PBMC against both donors and TP antigens. 
Importantly, after IL-2 pulsing, the number of spot against donor cells equalled that
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observed against TP antigens. This is consistent with an anergic state of circulating 
leukocytes against donor antigens in CsA treated patients.
Anergy is another mechanism of immunological tolerance which, however, might be 
theoretically less powerful and stable than regulation [212]. Indeed, high levels of IL-2, 
such as those that may be associated with immune system activation during infections, 
may break this tolerance status. Importantly, in transplant patients receiving calcineurin 
inhibitors, maintenance of the anergic state seems directly dependent on IL-2 pathway 
inhibition [212]. Thus, restore of normal IL-2 levels after CsA tapering/withdrawal 
might eventually be associated with breakdown of the tolerance state.
A still unanswered question of our study is whether expansion of CD8+CD28' T cells in 
the CsA group might have played a role in the donor-specific hyporesponsiveness of 
PBMC isolated from these patients. CD8+CD28' T cells have been described as a 
population with regulatory properties, which directly interacts with antigen-presenting 
cells rendering them tolerogenic by inducing the downregulation of costimulatory 
molecules and upregulation of the inhibitory receptors immunoglobulin-like transcripts 
(ILT)3 and ILT4 [89]. Importantly, this population has been found positive for the 
FOXP3 regulation marker. According with this evidence, we tested whether the 
CD8+CD28' T cells isolated from our CsA treated patients showed an increased 
expression of this gene. As these cells showed no expression of FOXP3, we argued that 
they were not responsible for immune regulation. However, this cannot be definitely 
excluded and would require ad hoc experiments to formally assess this hypothesis. 
Indeed, a recent paper showed that in renal transplant recipients given Campath-IH as 
induction and MMF plus tacrolimus as maintenance immunosuppression, CD8+CD28- 
T cells were the main repopulating population [174], which displayed the capability to
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suppress the proliferation of CD4+ T cells. In this paper, however, no data on FOXP3 
expression in CD8+CD28- T cells have been provided.
Thus, the first part of the study clearly described the phenotype and functional 
characteristics of lymphocytes emerging after Campath-IH induction in renal transplant 
patients receiving maintenance immunosuppression with either SRL or CsA, both 
combined with MMF. In the second part, we aimed at assessing the clinical counterpart 
of the different lymphocytic phenotype and functional profile in the two treatment 
groups.
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RESULTS (II Part)
2. Long-term clinical outcomes in renal transplant patients receiving Campath-IH 
induction and low-dose SRL or CsA, both combined with low-dose MMF, as 
maintenance therapy: does the number of circulating Treg matter?
Introduction
In the previous part of the study we showed that the CD52 targeted monoclonal 
antibody Campath-IH, via lymphocyte depletion, allowed a subset of 
CD4+CD25hlghFOXP3+cells with regulatory activity to emerge, provided that 
maintenance immunosuppression with sirolimus (SRL), but not the calcineurin-inhibitor 
cyclosporine (CsA), added on to low-dose mycophenolate mofetil (MMF) is used as 
background steroid-free maintenance therapy. These findings indicate that Campath-IH 
and the combination of low-dose SRL and MMF would create the ideal environment for 
T-cell regulation to occur. Increased Treg would favor graft acceptance, and lowering 
the immune response of the host against the allograft might translate into a reduced 
incidence of acute rejection in the short-term and, possibly, of chronic rejection in the 
long period.
An immune modulatory role of CD4+CD25+ Treg in the setting of transplantation was 
first provided by in a rat bone marrow transplantation model involving the adoptive 
transfer of transplantation tolerance [213]. Since then, there has been a growing body of 
data in the literature indicating that CD4+CD25+ Treg maintain dominant transplantation 
tolerance, and CD4+CD25+ T cells from an animal tolerised to an allograft by many 
immunosuppressive regimens could transfer donor-specific transplant tolerance to a
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naive animal [78]. Importantly, CD4+CD25+ Treg could be found inside the tolerised 
graft, and these cells can have both direct and indirect allospecificity for donor antigens 
[78].
However, despite significant advances in understanding the development, function, and 
therapeutic efficacy of Treg in certain well-defined rodent models of organ 
transplantation, the relevance of Treg in the clinical setting remains unclear. Recent data 
showed that in kidney biopsies of transplant recipients with borderline acute changes 
the Treg/T cytotoxicity cell infiltrating ratio was higher than in biopsies with acute 
rejection [214]. Others have reported in patients with no history of acute rejection, ex 
vivo regulation of the host immune response toward the mismatched HLA-DR 
allopeptides by peripheral blood Treg [157]. Thus, although far from conclusive, these 
findings would suggest that Treg may limit episodes of acute rejection also in humans. 
Moreover, the presence of Treg in per protocol biopsies of renal transplant recipients 
has been reported to discriminate harmless from injurious infiltrates, evidenced by 
independently predicting better graft function 2 and 3 yr after transplantation [159].
On the other hand, a recent study in 83 renal transplant biopsies, found that Foxp3 
mRNA was higher in grafts with rejection than in grafts without signs of rejection [215] 
and Foxp3 did not correlate with favorable graft outcomes, even when the analysis was 
restricted to biopsies with rejection.
To assess whether Treg may indeed protect from the development and progression of 
chronic allograft injury, we compared long-term changes in graft structure and function 
- as assessed by serial GFR and proteinuria evaluations and per protocol graft biopsies - 
in the two cohorts of renal transplant recipients originally randomized to SRL or CsA- 
based therapy that eventually did or did not show an increase in circulating Treg cells.
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Specific aims
In the second part of the study, we aimed to assess whether the impact of diverse 
maintenance immunosuppressive regimens on peripheral lymphocyte phenotype and 
function and on Treg expansion translated into different clinical outcomes in kidney 
transplant recipients given Campath-IH as induction therapy.
More in detail, specific aims of this second part of the project were:
i) To compare graft survival and function (evaluated as serum creatinine, 
measured GFR and RPF, and 24h/proteinuria) during the follow-up period 
between kidney transplant patients who received induction therapy with 
Campath-IH and maintenance immunosuppression with low-dose SRL or 
CsA, both combined with low-dose MMF;
ii) to compare the histology score at the kidney graft per-protocol biopsy at 2 
years after transplant between patients in the two randomization arms;
iii) to compare blood pressure levels and metabolic parameters in the two 
treatment groups;
iv) to compare the incidence of acute rejection episodes in the two low-dose 
maintenance immunosuppression after Campath-IH induction;
v) to assess the safety profile of Campath-IH induction associated with low- 
dose SRL or CsA, both combined with low-dose MMF as maintenance 
immunosuppression;
vi) to evaluate whether a relationship exists between the levels of circulating 
Treg at 2 years and graft function or histology changes in the per-protocol 
biopsy performed at the same time after transplantation.
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Results
Graft survival and function
One patient in the SRL group died at 18 months due to sepsis and one additional 
patient, with post-DGF severe renal insufficiency, lost his graft 25 months post 
transplant. No patient on CsA died or lost the graft throughout the observation period. 
From the transplant day up to month 2 post-transplant, mean serum creatinine levels 
similarly decreased in both groups (Figure 12). Then, they progressively increased in 
SRL-treated patients, while remained relatively stable in those on CsA (Figure 12). 
Nevertheless, there was no significant difference in serum creatinine concentrations 
between the two cohorts at any time-point after transplant. Thereafter, we evaluated the 
slopes over time of both GFR and RFP that had been measured every 6 months. 
According with the trend of serum creatinine levels, GFR decline from month 6 post­
transplant to study end tended to be faster on SRL than on CsA (SRL -2.92±0.33, CsA - 
0.28±0.44 ml/min/1.73 m per year) (Figure 13). Notably, the renal function decline for 
CsA patients was even lower than the one reported for healthy subjects after 40 years of 
age, i.e. -1 ml/min/1.73 m per year. Time dependent changes in RPF showed a similar 
trend (SRL -10.80±5.45, CsA -1.86±3.09 ml/min/1.73 m2 per year) (Figure 13). At 
month 6 post-transplant, SRL patients had a significantly higher GFR compared to CsA 
ones. However, differences in GFR values between cohorts at subsequent visits were 
never significant, as well as differences in RPF that never achieved the statistical 
significance at any considered time point after transplant (Table 2).
During the observation period, 6 of the 11 SRL patients compared to 4 of the 10 CsA 
patients developed proteinuria persistently higher than 0.5 g/24h. At 24 months post 
transplant, urinary protein excretion rate in SRL and CsA group was 0.93±1.03 and
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0.77±0.92 g/24 h, respectively. No significant difference in 24-h proteinuria was 
observed between the two cohorts at any considered follow-up evaluation (Figure 14).
Histology
Seven patients in the SRL and 6 in the CsA groups consented to per-protocol biopsy at 
2 years post-transplant.
All samples from SRL patients showed mild to moderate tubular atrophy, interstitial 
fibrosis with focal interstitial inflammation and arteriosclerosis consistent with chronic 
allograft injury (Figure 15 and Table 3). In five cases light microscopy also showed 
mild increase in mesangial cells and matrix (Figure 15) and in one additional sample, 
(V.G.) mild increases in mesangial cells and matrix, focal marginated glomerular 
intercapillary leukocytes, mild endothelial cell proliferation and incipient segmental 
sclerosis in one glomerulus were suggestive of a transplant glomerulitis. Since this 
pattern was associated with a high SRL trough level (14.6 ng/ml), significant renal 
function deterioration and proteinuria, a SRL-related glomerulopathy was diagnosed, 
and the patient was changed to CsA maintenance immunosuppression, though 
proteinuria remained persistently elevated.
Only 3 of the 6 samples from CsA-treated patients showed moderate to severe 
interstitial fibrosis. Mild to moderate glomerular abnormalities were also seen in 4 
patients, mainly characterized by mesangial hypercellularity (Figure 15) and, in one 
case, mild increase in mesangial matrix. In this patient, recurrent IgA nephropathy was 
diagnosed after immunofluorescence analysis of biopsy specimens.
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Thereafter, we scored histology lesions according with CADI grading and, as shown in 
Table 3, we found that mean CADI score was numerically, although not significantly, 
higher in SRL- than in CsA-treated patients.
C4d glomerular staining was similar between the two study groups, whereas tubular 
staining was significantly higher (P<0.01) in the SRL- than in the CsA- group (Table 3).
Other laboratory and clinical outcomes and safety profile
On follow-up, blood pressure control and lipid profile were similar in the two cohorts, 
although patients on SRL tended to have higher levels of triglycerides and total 
cholesterol (Table 4). Three patients, one on SRL and two on CsA had acute rejection 
episodes at 14, 9 and 210 days post-transplant, respectively, that fully recovered with 
intravenous methylprednisolone. Of note, in one rejecting patient CsA blood levels were 
below the recommended target (Table 5). Three SRL and two CsA patients developed 
DGF, defined as dialysis requirement within the first week after transplant.
Fever of unknown origin, potentially associated with lymphocytolysis after CampathrH 
induction, occurred in both treatment arms, but was significantly more frequent in CsA 
patients (3 vs. 7 patients in the SRL vs. CsA group, respectively. P<0.05). Four 
cytomegalovirus reactivations, without clinical disease, arose in 4 patients on CsA and 
recovered with gancyclovir therapy. Two herpes zoster virus reactivations were 
observed in two patients on SRL and recovered with acyclovir therapy. Four bacteria 
pneumonia were diagnosed in 3 SRL- and 1 CsA- treated patient. There were also 2 E. 
coli septic episodes per group (most likely originating from the urinary tract) and 1 
acute cholangitis in the SRL group. All the above bacteria infections recovered with
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antimicrobial therapy. One patient per group was hospitalized because of congestive 
heart failure and 1 on SRL because of an acute coronary event (Table 5).
Thus, after Campath-IH induction, the safety/efficacy profile of a maintenance regimen 
including either low-dose SRL or low-dose CsA, both combined with low-dose MMF 
was similar. Indeed, the increased Treg pool associated with SRL therapy did not 
significantly affect either the risk of rejection, or the risk of infections.
Immunosuppressive drug monitoring
As shown in Table 6, mean SRL and CsA trough levels were within the target range 
(trough blood concentrations of 5-10 ng/ml for SRL and from 120 to 220 ng/ml in the 
first month post-transplant, and from 70 to 120 ng/ml thereafter for CsA) throughout the 
whole follow-up period. The mean blood levels of SRL were very stable, whereas those 
of CsA tended to progressive decrease during the follow-up period. Indeed the CsA 
dosing was progressively lowered with the attempt to use the minimal dose required to 
prevent acute rejection. Of note, the areas under the time-concentration curves (AUC) at 
different time points show that exposure of these patients to study drugs was lower than 
the one usually followed in standard immunosuppressive regimens.
Three SRL- and 7 CsA- treated patients with fever attributed to alemtuzumab (n=7) or 
MMF dose reduction because of diarrhea or CMV-associated leukopenia (n = 3), 
transiently received low-dose corticosteroids in addition to their current maintenance 
immunosuppressive therapy.
Peripheral blood Treg cell counts
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As reported in the previous chapter of this thesis, pre-transplant T lymphocyte counts 
were similar in the two groups. From month 2 post-transplant, following the profound T 
cell depletion induced by alemtuzumab, CD3+CD4+ T cells slowly recovered in both 
cohorts but remained low over baseline up to 24 months after transplantation (Figure 
4b).
The proportion of circulating CD4+ cells that comprised CD25hlgh cells (Treg cells) were 
comparable in both groups pre-transplant (Figure 6c). From month 1 post 
transplantation, the percentage of CD25hlgh cell subset in total CD3+CD4+ T 
lymphocytes progressively increased in SRL group, whereas in CsA-treated patients the 
tendency of the CD4+CD25hlgh cell percentage to increase was milder. Thus, at month 
12 post transplant, the percentage of Treg in patients given SRL were approximately 
four-fold and, at 24 months, twice higher the values than in those on CsA (Figure 6c).
We evaluated the presence of any potential relationship between the percentage of 
circulating Treg at 1 year and clinical outcomes. There was no significant correlation 
between percentage of Treg in total CD3+CD4+ T lymphocytes at 24 months posL. 
transplant and CADI scores, GFR decline and 24-h proteinuria at last visit in the study 
group as a whole, as well as in each cohort considered independently.
Post hoc analysis o f  patient outcomes according to the levels o f circulating Treg
In a post-hoc analysis, we stratified patients according to the Treg counts at 2 years of 
follow-up above (n=10) or under (n=l 1) the median value. Among patients with higher 
Treg, 8 were on SRL and 2 on CsA therapy, whereas 3 patients on SRL and 8 on CsA 
therapy had lower Treg levels (Table 7). Gender distribution, donor and recipient age at 
transplant, cold and warm ischemia time, HLA -A , B and DR mismatches, and the total
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number of HLA mismatches (Treg+: 4.2±1.1; Treg': 3.9±1.6) were similar in the two 
cohorts.
No significant difference in serum creatinine levels was observed between the two 
cohorts at any considered follow up evaluation (Figure 16). As shown in Table 8, there 
was a not statistically significant trend toward higher histology injury among Treg+ 
patients. The incidence of adverse events between the two cohorts was similar (Table 
9). Three patients, 1 in the Treg+ and 2 in the Treg' had acute rejection episodes at 14, 9 
and 210 days post-transplant, respectively, that fully recovered with intravenous 
methylprednisolone.
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Tables and figures
Table 2. GFR and RPF throughout the follow-up period in the two treatment
Months 0 6 12 18 24 30
Measured GFR (ml/min/1.73 m2)
SRL 64.9±10.9* 65.6±16.1 59.8±17.1 61.8±17.0 58.6±15.2
CsA 49.6±14.4 53.5±13.4 52.7±17.2 56.3±18.7 49.1±16.7
RPF (ml/min/1.73 m2)
SRL 543.2±209.1 516.5±199.9 382.0±91.5 438.1 ±64.5 415.1±158.0
CsA 426.3±101.3 416.4±132.4 406.4±129.2 405.6±125.4 336.4±127.1
Data are mean+SD. *P<0.05
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Table 3. Histology score in the per-protocol biopsies at 2 years after transplant.
Patients CADI Tubular C4d Glomerular C4d
SRL
1. VG 5 1.5 1.0
2. FG 8 1.5 1.8
3. PC 2 2.0 1.8
4. ZB 5 1.0 0.5
5. GG 9 0.5 0.4 .
6. CR 6 0.5 0.5
7. TG 4 0.7 0.2
Mean 5.6 1.1* 0.9
Median 5.0 1.0 0.5
CsA
1. RS 5 0.5 0.3
2. TA 2 0 0.3
3. GM 1 0 0.5
4. NF 5 ■ 0.5 0.5
5. CM 9 0 0.7
6. GG 0 0 2.3
Mean 3.7 0.2 0.8
Median 3.5 0 0.5
*P<0.01 vs. CsA
Table 4. Arterial blood pressure and systemic biochemical parameters
throughout the follow-up period in the two treatment groups.
Months post- 0 6 12 18 24 30
SBP (mmHg)
SRL 136±17 142±17 146±8 136±15 146±9 150±16
CsA 143±20 132±16 145±18 154±18 147±17 152±11
DBP (mmHg)
SRL 77±12 78±10 85±11 79±17 85±8 85±11
CsA 86±9 79±6 94±11 92±4 92±9 91±13
Total cholesterol (mg/dL)
SRL 236±46 248±56 243±5 8 235±36 240±34 237±45
CsA 225±46 223±45 209±32 210.4±18 217±22 208±35
HDL cholesterol (mg/dL)
SRL 66±22 57±16 49±9 57±13 53±11 60±16
CsA 48±18 46±14 55±15 45±14 51±11 49±12
Triglycerides (mg/dL)
SRL 174±89 151±85 173±134 141±77 138±52 155±93
CsA 212±89 183±89 148±64 152±65 172±78 154±79
Data are mean+SD.
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Table 5. Patients with adverse events in the two treatment arms.
SRL
(n=ll)
CsA
(n=10)
Delayed graft function 3 2
Acute rejection 1 2
Viral infection
CMV 0 4
HZV 2 0
Bacterial infection
Pneumonia 3 1
Urinary T ract' 2 0
Sepsis 1 1
Acute colangitis 1 0
Congestive Heart Failure 1 1
Ischemic coronary disease 1 0
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Table 6. Immunosuppressive drug dosing, trough levels, and AUC throughout the 
studv neriod in the two treatment arms.
SRL
T im e S R L  d o s e S R L  tr o u g h S R L  A U C o-24
P o s t - T x (mg/day) (ng/mL) (ng*h/mL)
Month 1 4.3 ±1.3 7.8 ±3 .2
Month 3 4.4 ± 1.9 8.6 ± 2 .7
Month 6 3.9 ± 1.5 9.1 ±3 .7 3 0 7 ± 100
Month 12 4.0 ± 0 .9 9.3 ±2.3 332 ± 73
Month 18 3.6 ±1.1 10.9 ±5.3 306 ± 52
Month 24 3.4 ± 1 .0 11.0 ±4.1 318 ± 6 2
Month 30 3.7 ± 1 .7 8.5 ±1 .4 290 ± 78
CsA
T im e C s A  d o s e C s A  Co C s A  A U C o -12
P o s t - T x (mg/day) (ng/mL (ng*h/mL)
Month 1 308 ± 72 164 ± 6 9
Month 3 238 ± 60 102 ± 22
Month 6 225 ± 49 120 ± 3 2 3328 ± 757
Month 12 195 ± 6 2 87 ± 3 2 2817 ±570
Month 18 194 ± 7 9 92 ± 2 7 2712 ±626
Month 24 164 ± 6 4 79 ± 261,2 2404 ± 7 6 5 2,
Month 30 143 ± 611 75 ± 421,3 2169 ± 8 0 6 3
Data are mean+SD. 1p<0.01 vs month 1; 2p<0.05 vs month 6; 3p<0.01 vs month 6
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Table 7. Donor and recipient parameters according to Treg counts at one year 
after transplant. Treg+ and Treg' are patients with levels of Treg higher or lower 
than the median value, respectively.
Treg+
(n=10)
Treg' 
(n— 11)
Donors
Age (years) 50.7 ±11.4 . 39.8 ± 15.7
Gender (M/F) 5/5 7/4
Weight (Kg) 76.0 ± 11.8 76.3 ± 12.8
Type o f donor
Cadaveric 10 9
Living 0 2
Cold ischemia time (h) 16.8 ±2.4 15.0 ±3.8
Warm ischemia time (min) 30.1 ±6.0 28.1 ±7.8
Recipients
Age (years) 53.2 ±8.9 47.0 ±16.5
Gender (M/F) 6 /5 7 /3
Weight (Kg) 75.8 ± 12.4 69.8 ± 14.3
Therapy
SRL 8* 3
CsA 2* 8
Mismatches
A 1.5 ±0.5 1.4 ±0.7
B 1.5 ±0.7 1.5 ±0.7
DR 1.2 ±0.6 1.0 ±0.8
Data are mean ± SD or median (range). *p<0.01 vs Treg'
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Table 8. Histology score (CADI) and C4d expression in graft biopsies from 
renal transplant recipients according to Treg count.
Patients CADI Tubular C4d Glomerular C4d
Treg
1. VG 5 1.5 1.0
2. PC 2 2.0 1.8
3. ZB 5 1.0 0.5
4. GG 9 0.5 0.4
5. CR 6 0.5 0.5
6. TG 4 0.7 0.2
Mean 5.2 7.0 0.7
Median 5.0 0.9 0.5
Treg'
1. RS 5 0.5 0.3
2. TA 2 0 0.3
3. GM 1 0 0.5
4. NF 5 0.5 0.5
5. CM 9 0 0.7
6. GG 0 0 2.3
7. FG 8 1.5 1.8
Mean 4 J 0.4 0.9
Median 5.0 0 0.5
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Table 9. Patients with adverse events according to randomization to Treg 
counts.
Treg+
(n=10)
Treg 
(n= 11)
Delayed graft function 3 2
Acute rejection 1 2
Viral infection
CMV 0 4
HZV 2 0
Bacterial infection
Pneumonia 3 1
Urinary Tract 1 1
Sepsis 1 1
Acute colangitis 1 0
Congestive Heart Failure 1 1
Ischemic coronary disease 1 0
Data are number (%).
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Graft histology
Representative photomicrographs o f  renal histology (A  and C) and C4d staining (B and D) m biopsies taken 
2 years post-transplant from patients receiving SRL (A and B) or CsA (C and D). Original magnification, 
x200 (A-C), and x400 (B-D).
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Discussion
In the second part of the study, we found that increased number of circulating Treg after 
Campath-IH induction and SRL maintenance therapy did not confer appreciable 
protection against development and progression of chronic allograft injury in renal 
transplant recipients. Actually, patients on SRL - who had higher circulating Treg 
compared to those on CsA - tended to have more severe histology changes consistent 
with chronic allograft rejection, faster GFR decline and some excess of persistent 
proteinuria.
Serum creatinine levels were relatively stable in both treatment groups during the whole 
follow-up period, although patients on SRL therapy had a slight trend toward a 
progressive increase. The lack of any significant difference in serum creatinine levels 
between the two treatment groups at any time-point after transplant might be at least 
partially explained by the small number of patients included in the study and to the 
relatively poor specificity of serum creatinine as a parameter for graft function [216]. 
Thus, to better evaluate graft function and its changes over time, we performed repeated 
(every 6 months after transplant) direct measurements of GFR and RPF by iohexol and 
PAH clearance, respectively. These are gold standard techniques that allow a precise 
and accurate evaluation of renal function [217]. Slopes of GFR changes over time 
showed that SRL patients had a significantly faster renal function decline as compared 
with CsA patients. Of note, yearly reduction of GFR in the CsA group was even lower 
than the physiological decline in healthy subjects after 40 years of age, i.e. 1 
ml/min/1.73 m2 [218]. A similar picture was found evaluating the RPF slopes, whose 
decline was remarkably although not significantly faster in the SRL than in the CsA 
group. In line with the above results, proteinuria higher than 0.5 mg/24h was slightly
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more frequent among SRL than CsA patients. Importantly, these findings might 
translate into significantly different outcomes in the longer term. Indeed, both an high 
rate of GRF decline [219] and the onset of proteinuria [220] represent strong predictors 
of poor graft survival and function in the longer term.
The trend to worse renal function in the SRL group was associated with more severe 
histology changes at the per-protocol biopsies performed at 2 years after transplant. In 
particular, grafts from SRL patients showed more important tubulo-interstitial fibrosis, 
interstitial inflammation and arteriosclerosis than CsA treated ones. Also glomerular 
abnormalities were more severe in the SRL group. This translated into numerically 
higher CADI score for SRL as compared with CsA patients. Importantly, tubular 
staining for C4d was significantly more intense for SRL patients. C4d deposition in the 
peritubular capillaries of the graft has been correlated with the lesions of transplant 
glomerulopathy and with circulating alloantibodies [221]. As in our patients, the 
functional counterpart of these histology findings is often represented by the onset of 
proteinuria (generally of a low grade) and progressive renal dysfunction. In a: 
retrospective study on 80 patients with histological diagnosis of chronic allograft 
nephropathy, those who had Cd4 positive staining in peritubular capillaries developed 
more frequently anti-HLA antibodies and had a significantly lower death-censored graft 
survival at 4 years as compared with those with negative staining (50% vs. 87%, 
P=0.002) [221]. Whether Cd4+ staining was associated with anti-HLA antibodies and 
their potential impact on graft outcomes in our series of Campath-IH patients has not 
been evaluated. Notwithstanding, the present functional and histology data suggest that 
maintenance therapy with low-dose SRL and MMF may provide a less effective graft
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protection than low-dose CsA plus MMF in renal transplant patients receiving induction 
with Campath-IH.
Finding that graft function and structure were better preserved in CsA treated patients 
was however unexpected, especially considering the renal toxicity of calcineurin 
inhibitors. Indeed, renal biopsy studies among nonrenal organ recipients with chronic 
kidney disease have shown that calcineurin inhibitor-related injury is a common finding 
[222]. Histopathologic findings include interstitial fibrosis with a "striped" appearance, 
nodular arteriolar hyalinosis, and, later, tubular atrophy with glomerulosclerosis and 
arteriosclerosis [37]. Hence, calcineurin inhibitor avoidance has been claimed as a 
strategy to improve the outcomes of the graft [223]. In our series, however, per-protocol 
biopsies from CsA treated-patients showed no sign of calcineurin inhibitor toxicity, 
possibly as a consequence of the small used doses of calcineurin inhibitor. Notably, 
CsA doses slightly declined over time and this might at least partially account for the 
improved RPF and GFR. Indeed, CsA exerts a vasoconstrictor effect, which may impair 
renal function. Thus, a progressive reduction of CsA over time might have improved 
glomerular hemodynamics and function.
Conversely, blood levels of SRL remained substantially stable over the whole follow-up 
period. Though initially considered devoid of any nephrotoxic effect, recent reports 
have been published showing that SRL might actually have renal toxicity. Indeed, a 
considerable number of de novo kidney transplant recipients on SRL-based 
immunosuppression [117, 224, 225] and of patients converted from calcineurin 
inhibitors or azathioprine to SRL due to cutaneous squamous cell carcinoma or chronic 
allograft dysfunction [226, 227], have been reported to develop proteinuria and 
glomerulopathy, both of which may predict lower allograft survival [220]. SRL toxicity
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might therefore account for worse graft outcomes of patients in this treatment arm. This, 
however, seems extremely unlikely, since treatment was titrated to SRL blood levels (5 
to 10 ng/ml) that are consistently lower compared to those associated with chronic 
nephrotoxicity (10 to 18 ng/ml) [224, 226]. Thus, other factors must be taken into 
consideration.
Finding that more severe structural and functional changes were associated with a 
significantly more intense C4d staining of the graft tissue, lend support to the possibility 
that the worse outcome of SRL-treated patients could be explained also by immune 
mechanisms resulting in more severe chronic allograft rejection. This would imply that 
in SRL-treated patients increased Treg cell count did not confer appreciable protection 
from the development of chronic alloimmune response. At variance, a specific Treg 
independent, protective effect of low-dose CsA against graft injury could explain the 
good long-term outcome of CsA-treated patients [228].
Finding that the increased percentage of Treg in SRL patients did not translate into an 
improved renal function was however unpredicted. Indeed, a large body of evidence is 
available that CD4+CD25hlgh Treg cells have potent immune regulatory effect in vitro 
[229, 230] and studies in experimental models of organ transplantation convincingly 
showed a protective effect of these cells against acute rejection in vivo. Anecdotal ex 
vivo findings in two kidney transplant patients have also suggested that Treg may play a 
role in preventing alloantigen epitope shifting, which is implicated in the ongoing 
immune activation contributing to chronic rejection [162]. Moreover, data from kidney 
transplant patients showed that the presence of Treg was associated with better 
outcomes, including a reduced risk of acute rejection [231] and better renal function in 
the long-term [167]. However, most of these results were obtained from patients on
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different immunosuppressive regimens, at different time points after transplant, and not 
prospectically followed-up. In our series, the incidence of acute rejection was extremely 
low in both treatment groups, thus it does not allow to clearly state whether higher Treg 
levels might have played any role in the prevention of acute alloimmune response. 
However, progressive renal function worsening, combined with histology signs of 
humoral chronic rejection suggest that Treg did not provide any clear advantage in 
chronic graft protection.
The lack of any protective effect of Treg on the graft was confirmed by the absence of 
any significant correlation between the percentage of circulating Treg at 12 months and 
CADI histology score, GFR decline, and proteinuria levels at the last visit in the study 
group as a whole, as well as in each cohort considered independently. To further 
confirm this finding, we stratified patients according to the relative value of circulating 
Treg at one year after transplant above or under the median value. Again, outcomes of 
patients with higher circulating Treg levels were not better that the ones found in 
patients with lower levels.
Why SRL-treated patients were not protected from chronic allograft rejection despite 
the enhanced expression of Treg remains matter of speculation. One possibility is that 
the number of circulating Treg, although increased in the SRL group as compared to 
pre-transplant values, did not reach the threshold level to properly suppress the complex 
pathways of T effector cells, and thus to limit chronic graft injury. In murine models of 
spontaneous autoimmunity or genetically engineered mice, the Treg cells function 
normally but the T effector cells are resistant to Treg-mediated suppression when the 
phosphatidylinositol 3-kinase (PI3K)-Akt pathway is hyperactivated [232-234]. 
Costimulatory receptors and T cell receptor (TCR)-stimulation activate the PI3K-Akt
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pathway in T lymphocytes which promote various cell responses associated with cell 
division including the inactivation of cell cycle inhibitors, and the induction of cyclin 
and cytokine gene expression [235]. These are early events in T cell activation that are 
not suppressed by SRL, which actually inhibits the downstream target protein kinase 
mammalian target of rapamycin (mTOR) [236]. A complementary explanation is that 
the local cytokine inflammatory milieu may inhibit the Treg immunomodulating 
activity in the graft. In support of this possibility is the evidence that in an experimental 
model of autoimmune encephalomyelitis, autoantigen-specific natural Treg accumulate 
in the central nervous system, but fail to effectively control the autoimmune reaction 
due to their exposure to locally released inflammatory cytokines, including IL-6 [237]. 
Notably, IL-6 renders naive T cells resistant to suppression and enables the initiation of 
an immune response also in the presence of Treg [238]. In the context of the graft, 
alloreactive T cells themselves may be the source of IL-6 [239]. Moreover, in an 
inflammatory milieu, Treg may release TGF-p which, combined with IL-6, might 
promote the expansion of Thl7 cells [240], a relatively new T cell subpopulation 
possibly involved in the rejection of the graft. This might explain why the potent in 
vitro activity of circulating Treg does not translate into an effective prevention the 
immune response inside the graft. Conversely, Treg activity might eventually result into 
an injurious effect through the induction of Thl7 expansion. Evidence is also available 
that cells capable of rejecting the graft definitely remain after Campath-IH therapy 
[145]. In particular, post-depletion T cells are predominantly effector/memory T cells 
that expand in the first month after renal transplantation [173]. As shown in the previous 
chapter of results, also in our patients most residual T cells after Campath-IH actually 
expressed the CD45RO+ memory-like marker. Like in the autoimmune experimental
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models, reactivity of these T effector/memory cells might overwhelm the beneficial 
immune regulation of Treg [94]. Thus, in SRL-treated transplanted patients T effector 
cells, continuously activated by alloantigens and by intragraft inflammatory cytokines, 
could be less sensitive to regulatory T cell suppression.
A critical step in the pathogenesis of interstitial fibrosis in chronic allograft injury is 
epithelial-to-mesenchymal transition (EMT), whereby renal tubular epithelial cells 
change phenotypically and functionally into myofibroblasts [241]. The factor most 
capable of inducing and completing EMT is transforming growth factor-P (TGF-p) 
[242]. A possible candidate for TGF-p production during persistent inflammation (as it 
occurs in kidney transplantation) is the Treg cell which expresses the aE(CD103)p7- 
integrin allowing adhesion to epithelial cell E-cadherin [212, 243]. Importantly, the 
expression of CD 103 is also associated with the presentation of membrane-bound TGF- 
P [244]. On this line is the recent evidence that CD103+ T cells are bound to biliary duct 
epithelium in patients with primary biliary cirrhosis [245]. Thus, as alternative but not 
exclusive explanation of the present findings, Treg recruited into the graft might indeed 
activate tubular epithelial cells to trans-differentiate into myofibroblasts and ultimately 
promote interstitial fibrosis.
Beside efficacy parameters, in our study we also evaluated the safety profile of the two 
maintenance immunosuppressive regimens. Importantly, Campath-IH infusion was 
very well tolerated in all the patients. Adverse events were relatively mild and similarly 
distributed between the two groups, suggesting that different Treg counts did not affect 
either the risk of acute rejection or the susceptibility to opportunistic infections.
Blood pressure control and lipid profile were similar in the two cohorts, although SRL 
patients tended to have higher levels of tryglicerides and total cholesterol. Negative
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effect of SRL on lipid metabolism is well known [246]. Indeed, SRL has been shown to 
increase apoB-100, apo C-II, apo C-III, and hepatic VLDL cholesterol production and 
to decrease heparin-induced LPL activity [247]. Thus, SRL appears to increase 
production of trygliceride-rich lipoproteins and prevents their breakdown.
Our present findings must be taken with caution since, because of the limited sample 
size and the reduced statistical power, the possibility of random effects cannot be 
definitely excluded. This may also explain why comparative analyses failed to detect 
significant differences in main functional and structural outcomes between the two 
treatment groups.
However, finding that all considered outcome parameters - histology score, GFR, 
proteinuria and C4d expression - consistently failed to show any trend to improved 
long-term outcome in SRL-treated patients with increased Treg count, provides a 
reasonable evidence of the robustness of our data.
Our data may have potentially important implications both for clinical management of 
kidney transplant patients receiving Campath-IH induction and for future research, on 
Treg in the clinical transplant setting. This was the first study formally comparing two 
different low-dose maintenance immunosuppressive regimens after Campath-IH 
induction. Although the number of patients included in the study was relatively small, 
our data suggest that low-dose CsA combined with MMF conferred a similar protection 
against acute rejection than low-dose SRL, but was associated with a trend toward 
better graft function and lower histology injury at the 2 year per-protocol biopsy. 
Importantly, the use of low doses of CsA was not associated with any sign of 
calcineurin inhibitor toxicity. Conversely, immunosuppressive therapy with SRL was 
associated with a trend toward faster renal function decline and worse graft hystology.
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Regardless of the mechanisms involved -  SRL nephrotoxicity and/or uncontrolled 
immune response our present results suggest that maintenance therapy with low-dose 
CsA and MMF might provide better outcomes than low-dose SRL and MMF in renal 
transplant patients receiving Campath-IH induction. Importantly, the presence of 
increased proportion of Treg among circulating lymphocytes in SRL patients did not 
provide any significant benefit on graft outcome, indicating that the role of these cells in 
the clinical transplant setting might be less evident than that suggested by experimental 
evidences in animal models.
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FINAL DISCUSSION AND CONCLUSIONS
In the present study, we showed that a single 30 mg infusion of Campath-IH was able 
to induce a profound and long-lasting depletion of peripheral lymphocytes in renal 
transplant recipients on maintenance immunosuppression with low-dose of SRL or CsA, 
both combined with low-dose MMF. The two low-dose immunosuppressive regimens 
provided an effective protection against acute rejection and a good safety profile. 
Importantly, SRL and CsA were associated with different phenotypic and functional 
patterns of circulating lymphocytes. In particular, SRL promoted the expansion of 
functionally active CD4+CD25+FOXP3+ Treg, whereas CsA therapy was associated 
with increased numbers of CD8+CD28’FOXP3' T cells, whose functional characteristics 
are however still unclear. In vitro functional evaluation of peripheral lymphocytes, 
harvested at 1 and 2 years from transplant, showed decreased reactivity against donor 
cells in both treatment groups. On the other hand, anti third party response was 
suppressed in SRL and almost intact in CsA patients as compared with pre-transplant 
levels.
In the long-term, higher percentage of circulating Treg among SRL patients did not 
translate into improved clinical outcomes. Conversely, patients on CsA tended to have 
better graft function and lower histology injury in the per protocol graft biopsies 
performed at 2 years after transplant.
At the best of our knowledge, this was the first randomized, controlled, prospective trial 
comparing the immune characteristics and clinical outcomes of two different low-dose 
maintenance regimens of kidney transplant patients undergoing lymphocyte depletion 
through Campath-IH induction.
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Lymphocyte depletion has long been recognized as a mean of preventing allograft 
rejection and has been pursued as a therapeutic strategy since the earliest days of 
transplantation [197]. Initially used to control immune response in patients at increased 
risk of acute rejection, it was subsequently proposed as a tool to minimize maintenance 
immunosuppression in patients at standard risk [122, 248]. Indeed, experience in non­
human primate models of transplantation suggested that it might promote tolerance 
toward alloantigens [106].
With this background in mind, Campath-IH has been used in different organ transplants 
[126]. So far, however, clinical experience with Campath-IH has been largely limited to 
uncontrolled pilot trials and single-center experiences [249]. At the time our study was 
designed, the presumed dominant mechanistic effect was a reduction in T-cell precursor 
frequency limiting T-cell activation during the period of recovery from ischemic injury 
[136]. More recently, evidence came out showing that the pro-tolerogenic effect of 
Campath-IH may at least partially depend on the promotion of Treg expansion [175]. 
However, different maintenance immunosuppressive regimens may differently affect 
lymphocyte number and function, thus inducing or inhibiting Treg expansion and/or 
immune activity [114]. This might account for different outcomes reported with 
different maintenance immunosuppressive regimens after Campath-IH.
Thus, comparing different outcomes and immune fingerprints associated with different 
maintenance immunosuppressive regimens after Campath-IH induction might be of 
major importance to define the best maintenance immunosuppressive strategy and 
understand immune mechanisms potentially useful to design new pro-tolerogenic 
clinical protocols.
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In the present study, we randomized recipients of a first single kidney transplant 
undergoing Campath-IH induction to maintenance therapy with low-dose SRL or CsA, 
both combined with low-dose of MMF.
Our working hypothesis was that SRL therapy would promote the expansion of 
CD4+CD25+FOXP3+ T cells [177] and, considering their potential effect in controlling 
the immune response [250], we supposed that they might improve graft outcomes by 
preventing alloimmune injury. The present results, however, challenged our initial 
assumption. Indeed, although SRL therapy was associated with Treg expansion, this did 
not translate into any clinical advantage. Though because of the small number of 
patients included, the study might have had insufficent power to detect all but a large 
effect, our results do not support the idea that higher numbers of circulating Treg 
improve graft outcomes. Indeed, in spite of increased Tregs, SRL patients had a trend to 
even worse renal function and structure at 2 year per-protocol biopsy.
Our present results suggest that in the clinical setting the role of Treg might in fact be 
less important than in animal models of transplantation. Indeed a large body of evidence 
consistently showed that Tregs can induce and maintain immune tolerance and have the 
capacity to facilitate antigen-specific long-term graft survival successfully in animals 
receiving allogeneic organ transplants [229, 251]. Thus, the development of approaches 
to generate alloantigen reactive Tregs has been thought as an effective tool to induce 
tolerance in the clinical setting. Early clinical observations of Treg in human 
transplantation include reports of positive correlation between graft survival and 
circulating Treg in lung [252], liver [253] and kidney [254] allograft patients. CD4+ 
Treg have also been reported in patients who developed spontaneous tolerance to liver 
[255] or kidney [256] allografts and in peripheral blood of human liver transplant
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recipients weaned from immunosuppression [257]. A clear relationship between the 
levels of circulating Treg and graft outcomes is however not a uniform finding. This 
might be at least partially explained by the fact that circulating cells may not reflect 
intragraft events. Moreover, the redundancy and complexity of mechanisms of rejection 
underlies the difficulty in identifying biomarkers for prediction of graft outcome, and 
the induction of tolerance [258]. Also, potential local control mechanisms within the 
graft include not only several population of lymphocytes [88], but also mast cells [259] 
and monocytes [135]. Given this complexity, it is not surprising that no definite 
correlation between circulating Treg number and graft outcomes could be identified in 
our series. Indeed, at 2 years follow-up, non-alloimmune and/or non-inflammatory 
processes may well supervene to influence outcome, making associations even more 
difficult to detect [260]. In addition, a variety of individual factors, including sex, age 
and a range of gene polymorphisms potentially affect graft function and structure [260]. 
Notwithstanding, our results raise a concern about pro-tolerogenic strategies aimed at 
inducing donor-specific hyporesponsiveness through the promotion of Treg. Indeed, 
finding no positive trend between the number of circulating Treg and improved graft 
function or structure suggests that the role of these cells might not be so crucial in graft 
immune protection as previously believed, at least in human kidney transplantation. 
Notably, we found that Campath-IH treated patients on low-dose CsA as maintenance 
immunosuppression showed donor-specific hyporesponsiveness and that anergy was the 
main mechanism at the basis of their low reactivity against donor antigens. Although 
recent years have seen a surge of interest around Treg, anergy might in fact represent an 
alternative important mechanism to promote tolerance [261, 262]. Indeed, in renal 
transplant patients with stable graft function, anergy has already been reported as a way
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to promote hyporesponsiveness toward the donor [262]. It should be however taken into 
consideration that lymphocyte alloreactivity of all our patients was tested on ongoing 
maintenance immunosuppression. As anergy can be easily reverted by IL-2 addition, 
hyporesponsiveness toward donor cells in CsA patients might rely on maintenance 
therapy with an immunosuppressant that blocks IL-2 pathways [263]. Thus, CsA dose 
reduction or occurrence of inflammatory conditions such as infections, may result into 
an increased IL-2 production and thus revert the anergic state of these cells, eliciting an 
immune response against the graft.
Our findings challenge the hypothesis that Campath-IH is an intrinsic generator of 
Treg, as only SRL maintenance therapy was associated with the expansion of these 
cells. However, an intriguing finding of the present study was that maintenance 
immunosuppression with CsA was associated with the expansion of CD8+CD28’ T 
cells. Their negative expression of FOXP3 let us exclude they represented the same cell 
population isolated by Cortesini et al., which act by inducing endothelial and dendritic 
cells to express ILT-3 and ILT-4 inhibitory signals, thus making them tolerogenic [89]. 
Interestingly, a recent work by Trzonkowski et al. showed that, in renal transplant 
patients treated with Campath-IH, repopulating CD8+ T cells were mainly of 
immunosenescent CD8+CD28' phenotype and were able to suppress proliferation of 
CD4+ T cells [174]. The Authors hypothesized that expanded CD8+CD28' T cells might 
compete for 'immune space' with CD4+ T cells, suppressing their proliferation and 
therefore delaying CD4+ T cells recovery. Although we did not test immune function of 
CD8+CD28‘ cells from CsA-treated patients, our results suggest that these cells might 
have played a role also in our cohort of patients. Further studies are however needed to 
clarify this point.
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Another major contribution of the present study was finding that, when used at lower 
than conventional doses, CsA displays a relatively safe profile. Indeed, at the dosage 
employed in our protocol, it might provide enough immunosuppression to efficiently 
control both cellular and humoral allogeneic response, while exposing the kidney to 
minimal toxicity. Notably, also other well known adverse effects of CsA, including 
hypertension and glucose and lipid metabolism impairment, were relatively modest. 
Conversely, low-dose of SRL may have not been enough to control immune response, 
in line with the positive C4d staining in peritubular capillaries from patients in this 
treatment arm, which can be taken as a marker of humoral alloreactivity. On the other 
hand, even low doses of chronic SRL therapy might have negatively affected graft 
function, possibly even more than chronic use of calcineurin inhibitors. A growing body 
of evidence has suggested that SRL might indeed exert a nephrotoxic effect. Studies are 
available showing that SRL therapy is associated with the occurrence of proteinuria and 
this might be due to a direct toxic effect on podocytes [264].
Although calcineurin avoidance has been extensively claimed as a tool to improve renal 
graft outcomes, the largest randomized prospective trial performed so far, the 
SYMPHONY study, actually showed that low-dose CsA maintenance therapy provided 
better graft outcomes than low-dose SRL in kidney transplantation [265]. In this trial, 
1,645 renal transplant recipients were randomly assigned to receive standard-dose 
cyclosporine, mycophenolate mofetil, and corticosteroids, or daclizumab induction, 
mycophenolate mofetil, and corticosteroids in combination with low-dose cyclosporine, 
low-dose tacrolimus, or low-dose sirolimus. Patients on low-dose calcineurin inhibitors 
had the lowest rate of acute rejection, and a trend toward better graft survival and 
function[265]. This finding highlights that calcineurin inhibitors represent crucial
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molecules for immune suppression in transplantation, at least when non-depleting 
agents are used as induction therapy.
The beneficial effect of calcineurin inhibitors might be even more relevant in regimens 
including lymphocyte depletion. Indeed, after initial removal, lymphocytes undergoing 
homeostatic proliferation express markers of memory T cells. These cells have a low 
activation threshold, thus they may increase the risk of acute rejection. Importantly, in 
vitro experiments showed that CsA exert an inhibitory effect on these cells, which has 
not been shown for SRL [173]. Thus, maintenance immunosuppressive therapy with 
CsA might control alloimmune response better than SRL, especially in transplant 
patients undergoing induction therapy with lymphocyte depleting agents. This is in line 
with a retrospective analysis of the Organ Procurement and Transplantation 
Network/United Network for Organ Sharing (OPTN/UNOS) database, showing that, 
among Campath-IH treated patients, maintenance immunosuppression with calcineurin 
inhibitor-based immunosuppression may improve graft and rejection-free survival 
compared to calcineurin inhibitor-free regimens [137].
In conclusion, our study showed that: 1. Campath-IH is a safe and effective tool to 
prevent acute rejection with minimal doses of maintenance immunosuppression, in 
kidney transplant recipients; 2. maintenance immunosuppression with low-dose SRL 
and MMF is associated with the emergence of CD4+CD25+FOXP3+ Treg, but this is not 
paralleled by improved graft function or structure; 3. maintenance immunosuppression 
with low-dose CsA and MMF is associated with donor-specific hyporesponsiveness of 
peripheral leukocytes, and this is at least in part due to T cell anergy. This is associated 
with a trend to better graft function and structure.
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Our present findings suggest that lymphocyte depletion with Campath-IH might 
represent a useful strategy to minimize chronic immunosuppression in kidney 
transplantation, especially when CsA and MMF are used as maintenance drugs. The 
present results suggest that circulating Treg per se might be less relevant in transplant 
outcomes that previously thought. Further studies are however needed to clarify their 
impact in the clinical setting.
168
APPENDIX
GFR and RPF measurement by plasma clearance of non-radioactive iohexol and 
paraaminohippuric acid (PAH)
Procedures
On the morning of the study, a catheter is positioned in an antecubital vein for the 
injection of the marker substances, and another in the contralateral arm for subsequent 
blood sampling.
/
Catheter
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Catheter positioned in the antecubital vein
Catheters positioned in an antecubital vein for the injection o f the marker substances, and in the contralateral 
arm for blood sampling.
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After baseline blood sample collection for measurement of basal iohexol/PAH 
concentration (blank), 5 mL of Omnipaque containing 3.235 gr iohexol is slowly 
injected (2 minutes) into the injection catheter.
Drawing exactly 5 ml o f iohexol Syringe ready for 5 ml iohexol injection
Omnipaque solution (20 ml) can be used for more than one patient in the same day but 
not in different days.
The catheter is then washed with 10 mL normal saline solution.
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Washing the catheter with 10 ml saline
Note the exact time of injection (time 0) and use the same clock for timing throughout 
the procedure.
110 minutes later, a priming load of PAH solution at the dose of 8 mg/kg, adjusted for 
body weight in 5 kg increments, is injected in 1-2 minutes into the injection catheter, 
immediately followed by a timed constant infusion of 12 mg/min PAH with no 
adjustment for body weight, through a syringe-pump calibrated for precision of 0.04 
mL/h. Again note the exact time of PAH injection. After the 180 min blood sampling 
the constant infusion of PAH is stopped and the catheter removed.
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Injection o f the priming load o f PAH solution (dose = 8 mg/kg, in 1-2 minutes) adjusted for body 
weight in 5 kg increments
Constant infusion of 12 mg/min PAH solution (with no adjustment for body weight) through a syringe- 
pump
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For Iohexol and PAH determination, blood samples are collected at different timepoints 
according to the expected GFR (as creatinine clearance):
a) for GFR > 40 mL/min sampling at:
120.150.160.170.180, 210, 240 minutes;
b) for GFR < 40 mL/min sampling at:
120.150.160.170.180, 240, 300, 360, 420, and 480 minutes.
after iohexol injection.
Before any blood sampling, discharge a blood volume at least equivalent to the catheter 
volume (1.5 mL) in order to avoid blood dilution with saline.
Discharging a blood volume at least equivalent Blood sampling to the catheter volume before sampling
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Similarly, at the end of blood collection fill the entire catheter with saline solution.
4 ...:
Filling the catheter with saline solution at the end o f each blood collection
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Blood samples can remain at room temperature until the end of the procedure before 
plasma separation.
Blood samples (3 mL) are centrifuged at room temperature (3000 rpm for 10 minutes), 
the plasma collected and stored at -20 °C until assay.
Centrifuge 
at 3000 rpm 
for 10 min 
at room 
temperature
Collect
separated
plasma
jd
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Flow charts for GFR and RPF measurement
- for an expected GFR > 40 mL/min:
Iohexol
\
PAH constant infusion
PAH loading 
dose
i - - i — i - 1— i— i— i— i— i— i— i
Pre-dose 0 2
(blank
110 112 120 150 160 170 180 210 240 min
for an expected GFR < 4 0  mL/min:
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PAH constant 
infusion
Iohexol
PAH
loading
dose
0 2
Pre-dose 
(blank sample)
I I I I I I I I
110 112 120 150 160 170 180 240
min
300 360 420 480
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Critical points of the procedures
1. To inject the exact dose of iohexol and PAH.
2. To obtain a constant infusion of 12 mg/min PAH.
3. To ensure that all fluid is injected intravenously and that there is no subcutaneous 
leakage.
4. To note the exact times at which samples are taken.
5. To draw blood not diluted with saline.
Preparing samples for analysis of iohexol and PAH
1. Centrifuge each samples at 3000 rpm for 10 minutes.
2. Pipette plasma from each sample into a tube.
3. Label, freeze, and store at -20° C until shipment.
Note:
a) the model assumes exactly 3.235 g iohexol being injected. Should the injected dose 
be different from this, please report the dose actually injected in order to correct the 
formula used for calculating GFR.
b) the model assumes exactly 8 mg/kg PAH, (adjusted for body weight in 5 kg 
increments), being injected and a timed constant infusion of 12 mg/min PAH being 
infused. Should the injected dose and/or the infusion rate be different, please report
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the dose actually injected and/or the actual infusion speed in order to correct the 
formula used for calculating RPF.
c) the procedure implies all the markers are correctly injected, if subcutaneous leakage 
occurs, the procedure must be stopped and repeated a week apart.
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Methods to determine iohexol and PAH concentration in the plasma samples and 
calculation of GFR and RPF values
Iohexol plasma concentration is determined by high performance liquid 
chromatographic (HPLC) method. Iohexol clearance is first calculated according to a 
one-compartment model (CLi) by the formula:
CLi = injected dose of iohexol/AUC
where AUC is the area under the curve of the plasma concentration of iohexol. Then the 
value obtained is corrected according to Brochner-Mortensen, in order to estimate the 
corrected GFR (plasma clearance) by using the formula:
GFR=(0.990778x CLi)-(0.001218x CLi2)
GFR values is then normalized for body surface area and expressed as ml/min/1.73 sqm.
PAH concentration is measured by HPLC by using the same method for iohexol 
measurement. PAH clearance is calculated according to the formula:
RPF=Ro/CssP AH
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where Ro is the infusion rate; CssPAH is the PAH plasma concentration at the steady 
state (i.e. mean of PAH plasma concentrations measured at 150, 160, 170, 180 minutes 
from iohexol injection)
Renal plasma flow, estimated by plasma clearance of PAH, is then normalized by body 
surface area, and expressed as ml/min/1.73 sqm.
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LIST OF ABBREVIATIONS
6-MP: 6-mercaptopurine 
AUC: area under curve 
BM: bone marrow
CADI: chronic allograft damage index 
CAN: chronic allograft nephropathy 
CMV: cytomegalovirus 
CsA: cyclosporine
DIC: diffuse intravascular coagulation
DTH: delayed-type hypersensitivity
ELISPOT: enzyme-linked immunospot
GBM: glomerular basement membrane
GFR: glomerular filtration rate
GVDH: graft versus host disease
HLA: humal leukocyte antigen
HPLC: high-performance liquid chromatography
LDA: limiting dilution assay
MAP: mitogen activated protein
MHC: major histocompatibility complex
MLR: mixed lymphocyte reaction
MMF: mycophenolate mofetil
mTOR: mammalian target of rapamycine
NFAT: nuclear factor of activated cells
P AH :p-aminohippurate
RPF: renal plasma flow
SRL: sirolimus
TLI: total lymphoid irradiation
Treg: regulatory T cell
UNOS: United Network for Organ Sharing
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